

 **PALM INTRANET**K⁴
Day : Wednesday

Date: 8/9/2006

Time: 15:11:39

Inventor Information for 10/809637

Inventor Name	City	State/Country
FENG, JUN	CARLSBAD	CALIFORNIA
GWALTNEY, STEPHEN L.	SAN DIEGO	CALIFORNIA
KALDOR, STEPHEN W.	SAN DIEGO	CALIFORNIA
STAFFORD, JEFFREY A.	SAN DIEGO	CALIFORNIA
WALLACE, MICHAEL B.	SAN DIEGO	CALIFORNIA
ZHANG, ZHIYUAN	SAN DIEGO	CALIFORNIA

[Appln Info](#)[Contents](#)[Petition Info](#)[Atty/Agent Info](#)[Continuity/Reexam](#)[Foreign](#)Search Another: Application# [Search](#) or Patent# [Search](#)PCT / / [Search](#) or PG PUBS # [Search](#)Attorney Docket # [Search](#)Bar Code # [Search](#)

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L3	1630	544/292, 544/283, 544/284, 544/286	US-PGPUB; USPAT	OR	OFF	2006/08/09 15:07

containing 1 : 13 :



Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS


*Narrow
search dm-86*

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:38:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1745 TO ITERATE

100.0% PROCESSED 1745 ITERATIONS
SEARCH TIME: 00.00.01

7 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 32395 TO 37405
PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 13:38:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 34990 TO ITERATE

100.0% PROCESSED 34990 ITERATIONS
SEARCH TIME: 00.00.05

76 ANSWERS

L3 76 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

Habte

08/09/2006

	ENTRY	SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'CAPLUS' ENTERED AT 13:38:27 ON 09 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2006 VOL 145 ISS 7
FILE LAST UPDATED: 8 Aug 2006 (20060808/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 24 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER:

2006:142762 CAPLUS

DOCUMENT NUMBER:

144:233087

TITLE:

Preparation of fused pyrimidinones as chemokine CXCR3 receptor ligands.

INVENTOR(S):

Lin, Chu-Chung; Chen, Hong-Chuan; Lee, Kuang-Yuan;

PATENT ASSIGNER(S):

Huang, Ying-Huey; Fan, Yang-Ping; Xiang, Yibin

SOURCE:

Taigen Biotechnology, Taiwan

DOCUMENT TYPE:

U.S. Pat. Appl. Publ., 60 pp.

LANGUAGE:

CODEN: USXXCO

FAMILY ACC. NUM. COURT:

Patent

PATENT INFORMATION:

English

PATENT INFORMATION:

1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006036093	A1	20060316	US 2005-204792	20050816
WO 2006023381	A1	20060302	WO 2005-US28679	20050811
N: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PA, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SN, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, DJ, CF, CG, CI, CM, CA, GN, GM, GW, ML, MR, NE, SN, TD, TO, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPL. INFO.:

US 2004-601776P

P 20040816



OTHER SOURCE(S):

MARPAT 144:233087

GI

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS ON STN

(Continued)



AB Title compds. [I: A = aryl, heteroaryl; X = S, NR₁; L₁ = CR₁R₂, alkylene, heteroalkylene, null; L₂ = CR₁, null; L₃, L₄ = CO, SO₂, CO₂, COCH₂, SO₂CH₂, alkylene, heteroalkylene, etc.; L₃L₄N, L₁L₃N, L₁L₄N = atoms

to form 5-7 membered ring; R₁ = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; R₂ = R₁, etc.; R₂L₂ = null; R₃, R₄ = R₁, halo, cyano, amidino, guanidino, ureido, etc.; R₁, R₁, R₂, R₃ = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cyano, etc.), were prepared

Thus, title compound (II) was prepared in 7 steps from anthranilic acid, propionyl chloride, 4-ethoxyaniline, BocNHCH₂CH₂NH₂, 3,4-dichlorophenylacetic acid, and (Me₂S)2C:NQN. 138 I inhibited activation of CXCR3 using a Delfia GTP binding kit with IC₅₀ <1 μM.

IT' 876014-72-1P 876015-29-1P 876015-32-6P

876015-33-7P 876015-44-0P 876015-45-1P

876015-77-9P 876015-78-0P 876015-79-1P

876015-95-1P 876016-03-4P 876016-08-9P

876016-21-6P 876016-37-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of fused pyrimidinones as chemokine CXCR3 receptor ligands)

RN 876014-72-1 CAPLUS

CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3,4-dichloro-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS ON STN

(Continued)




RN 876015-29-1 CAPLUS

CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3,4-dichloro-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 876015-32-6 CAPLUS

CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3,4-dichloro-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 876015-33-7 CAPLUS

CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS ON STN

(Continued)



RN 876015-44-0 CAPLUS


CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 876015-45-1 CAPLUS

CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-N-[2-(4-morpholinyl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 876015-77-9 CAPLUS
 CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-(3-(dimethylamino)propyl)-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 876015-78-0 CAPLUS
 CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-N-(2-(1-methyl-2-pyrrolidinyl)ethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 876015-79-1 CAPLUS


L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 876016-08-9 CAPLUS
 CN Benzeneacetamide, N-[3-amino-1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3,4-dichloro-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 876016-21-6 CAPLUS
 CN Benzeneacetamide, N-[3-amino-1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 876016-37-4 CAPLUS
 CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-(2-aminoethyl)-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-N-[3-(1-pyrrolidinyl)propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 876015-95-1 CAPLUS
 CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-(3-pyridinylmethyl)-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 876016-03-4 CAPLUS
 CN Decanamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 876016-71-6P 876016-75-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of fused pyrimidinones as chemokine CXCR3 receptor ligands)

RN 876016-71-6 CAPLUS
 CN Carbamic acid, [(3R)-3-amino-3-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 876016-75-0 CAPLUS
 CN Benzeneacetamide, N-[(1R)-3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [A1, A4 = independently CH and derivs., N; Q = a bond, hetero/alkylene, CO, CH2CO, etc.; L = a bond, alkylene; X = CH2, SO2, CO; Ra = H, OH and derivs., halo, etc.; n = 0-4; R1 = hetero/aryl; R2 = H, halo, hetero/alkyl, etc.; or R2 may be combined with L to form a 5- to 8-membered ring containing 1-3 heteroatoms; R3 = absent, H, SRS, NHSO2R5, piperidin-4-yl, etc.; R3 may be combined with R2 to form a 4- to 8-membered ring containing 1-3 heteroatoms; R5 = hetero/alkyl, hetero/aryl; R4 = hetero/alkyl, hetero/aryl, etc.; and their pharmaceutically acceptable salts and prodrugs) were prepared as chemokine receptor CXCR3 modulators

(no data). Two biol. assays are given. Thus, reductive amination of 1-isopropylpiperidine-4-carboxaldehyde with 2-[(1R)-1-aminoethyl]-3-(4-ethoxyphenyl)-4(3H)-quinazolinone, and acylation of the amine intermediate with [4-fluoro-3-(trifluoromethyl)phenyl]acetic acid gave quinazolinone II. I are useful for the treatment of inflammatory and immune disorders and diseases, such as multiple sclerosis, rheumatoid arthritis, psoriasis, and inflammatory bowel disease (no data).

IT 873191-29-8P, [(1R)-2-Amino-2-[3-(4-ethoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]carbamate tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of fused pyrimidine derivs. as CXCR3 receptor modulators for prevention and treatment of inflammatory and immune disorders and diseases)

RN 873191-29-8 CAPLUS
CN Carbamic acid, [(2R)-2-amino-2-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Habe

L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:32072 CAPLUS
DOCUMENT NUMBER: 144:128993

TITLE: Preparation of fused pyrimidine derivatives as CXCR3 receptor modulators for prevention and treatment of inflammatory and immunoregulatory conditions
Pu, Zice; Johnson, Michael G.; Li, An-Rong; Marcus, Andrew P.; Medina, Julio C.; Bergeron, Philippe;

INVENTOR(S): Chen, Xiaoqi; Deignan, Jeffrey; Du, Xiaohui; Duquette, Jason


A.; Gustin, Darin; Mihalic, Jeffrey T.
Amgen Inc., USA
PCT Int. Appl., 80 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006004915	A1	20060112	WO 2005-US23251	20050628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, ML, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006069099	A1	20060330	US 2005-168005	20050627
PRIORITY APPL. INFO.:			US 2004-583901P	P 20040628


OTHER SOURCE(S): MARPAT 144:128993
GI

L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 473720-85-3 873191-38-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fused pyrimidine derivs. as CXCR3 receptor modulators for prevention and treatment of inflammatory and immune disorders and diseases)
RN 473720-85-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1R)-1-aminoethyl]-3-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 873191-38-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1R)-1-aminoethyl]-3-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5
THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

08/09/2006

L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1129696 CAPLUS
DOCUMENT NUMBER: 144:45525
TITLE: Methods for treating mast cell disorders
INVENTOR(S): Hayflick, Joel S.; Pefaur, Noah; Puri, Kamal D.;
Tino, William
PATENT ASSIGNEE(S): Icos Corporation, USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005110511	A1	20051222	WO 2005-US19558	20050604
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BM, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KE, MD, RU, TJ, TM, AT, BE, BO, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPL. INFO.: US 2004-576947P P 20040604

OTHER SOURCE(S): MARPAT 144:45525

AB The invention provides methods of inhibiting mast cell activity by administering a selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ). The invention also provides methods for treating or preventing a condition associated with undesirable mast cell activity in

an individual comprising administering an effective amount of a selective PI3Kδ inhibitor.


IT 871585-37-4 871585-74-9 871585-75-0
871585-80-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for treating mast cell disorders)

RN 871585-37-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-[amino[6-(dimethylamino)-9H-purin-9-yl]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-74-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[5-amino-1-[(1H-purin-6-ylamino)pentyl]-5-methyl-3-phenyl]- (9CI) (CA INDEX NAME)



RN 871585-75-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-[5-amino-1-[(2-amino-1H-purin-6-ylamino)pentyl]-5-methyl-3-phenyl]- (9CI) (CA INDEX NAME)



RN 871585-80-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-amino-1-[(2-amino-1H-purin-6-ylamino)butyl]-5-methyl-3-phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2005125953 CAPLUS

DOCUMENT NUMBER:

144:22759

TITLE:

Preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Fowler, Kerry W.; Huang, Danwen; Kesicki, Edward A.;
Ooi, Hua Chee; Oliver, Amy R.; Ruan, Fuqiang;

INVENTOR(S):

Treiberg, Jennifer

PATENT ASSIGNEE(S):

Icos Corporation, USA

SOURCE:

PCT Int. Appl., 247 pp.

DOCUMENT TYPE:

CODEN: PIXXD2

LANGUAGE:

Patent

FAMILY ACC. NUM. COUNT:

English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113556	A1	20051201	WO 2005-US16778	20050512
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BM, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2005113554	A2	20051201	WO 2005-US16661	20050512
WO 2005113554	A3	20060406		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BM, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2004-570784P

P 20040513


OTHER SOURCE(S):

MARPAT 144:22759

GI

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



AB Quinazolinone derivs. of formula I [X, Y = N, (substituted) CH; Z = NH, O;

R1-R3 = H, halo, alkyl; R4 = H, halo, OH, alkoxy, CN, acyl, etc.; R5 = alkyl, Ph, CH2C.tpbond.CH, etc.; R6 = H, halo, (substituted) NH2; R7 = alkyl, halo, CF3, etc.; ZR5 = alkylene) are prepared that inhibit PI3Ks activity. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compds. also are disclosed.

Thus,

II was prepared, and had EC50 value of 1.6 nM in human B lymphocyte assay.

IT 870281-25-7P 870281-26-8P 870281-32-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase δ)


RN 870281-25-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(1S)-5-amino-1-(1H-purin-6-ylamino)pentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 870281-26-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(1S)-5-amino-1-[(2-amino-1H-purin-6-yl)aminopentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-32-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(1S)-4-amino-1-[(2-amino-1H-purin-6-yl)aminobutyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




IT 870282-58-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase δ)

RN 870282-58-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(aminomethyl)-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



IT 870280-87-8P 870281-80-4P 870281-86-0P

870281-97-3P 870282-35-2P 870282-41-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase δ)

RN 870280-87-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(1S)-1-aminopropyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 870281-80-4 CAPLUS
 CN Carbamate acid, [(1S)-4-amino-1-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-86-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-aminopropyl]-5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870281-97-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-aminoethyl]-3-(3-hydroxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

ACCESSION NUMBER: 2004:857326 CAPLUS
 DOCUMENT NUMBER: 141:309639
 TITLE: Dipeptidyl peptidase inhibitors
 INVENTOR(S): Feng, Jun; Gwaltney, Stephen L.; Kaldor, Stephen W.; Stafford, Jeffrey A.; Wallace, Michael B.; Zhang, Zhiyuan
 PATENT ASSIGNEE(S): Syrrx, Inc., USA
 SOURCE: PCT Int. Appl., 244 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087053	A2	20041014	WO 2004-US9217	20040324
WO 2004087053	C2	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZH, ZW, AG, AL, AM, AN, AR, AU, AT, BE, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GR, GU, HE, IT, LJ, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2518465	AA	20041014	CA 2004-2518465	20040324
US 2004242568	A1	20041202	US 2004-809636	20040324
US 2004242566	A1	20041202	US 2004-809638	20040324
US 2004259870	A1	20041223	US 2004-809637	20040324
US 2005004117	A1	20050106	US 2004-809635	20040324
EP 1608317	A2	20051228	EP 2004-758366	20040324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LJ, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK PRIORITY APPLN. INFO.: US 2003-457785P P 20030325 WO 2004-US9217 W 20040324				

OTHER SOURCE(S): MARPAT 141:309639
 GI




AB Dipeptidyl peptidase IV inhibitors I [Q = CO, SO, SO2, C=NR5; R1 = ZR6; Z = moiety providing 1-6 atom separation between R6 and ring; R2 = (substituted)3-7-membered ring; R3, R4 = taken together form a (substituted)5-6-membered ring; R5 = H, (substituted)alkyl, cycloalkyl,


Habe

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 870282-35-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-amino-3-butynyl)-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 870282-41-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-5-chloro-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 etc.; R6 = (substituted)C1-7-cycloalkyl or aryl are disclosed. Thus, 2-[2-(3-aminopiperidin-1-yl)-6,7-dimethoxy-4-oxo-4H-quinazolin-3-ylmethyl]benzonitrile (I; R1 = 2-cyanophenylmethyl; R2 = 3-aminopiperidin-1-yl; R3, R4 = dimethoxyphenyl) was synthesized. This compd. exhibited enhanced stability in rat liver microsomes.
 IT 22126-97-2P 80096-35-1P 769157-99-5P
 769158-00-1P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (dipeptidyl peptidase inhibitors)
 RN 22126-97-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 80096-35-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 769157-99-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 769158-00-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-chlorophenyl)- (9CI) (CA INDEX NAME)

08/09/2006

L4 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:1006962 CAPLUS
 DOCUMENT NUMBER: 140:59652
 TITLE: Preparation of fused-ring pyrimidin-4(3H)-one derivatives as LXR modulators
 INVENTOR(S): Kaneko, Satoru; Watanabe, Tsuyoshi; Oda, Kozo; Mohan, Raju; Schweiger, Edwin J.; Martin, Richard
 PATENT ASSIGNER(S): Sankyo Company, Limited, Japan; X-CEPTOR Inc.
 SOURCE: PCT Int. Appl., 465 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106435	A1	20031224	WO 2003-JP7677	20030617
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003238157	A1	20031231	AU 2003-238157	20030617
PRIORITY APPLN. INFO.: US 2002-38962P P 20020618				
WO 2003-JP7677 W 20030617				

OTHER SOURCE(S): MARPAT 140:59652
 GI



AB The title compds. (I; A = aryl or heteroaryl; R1-R3 = H, OH, NO2, CN, etc.; or R1 and R2 together = alkylendioxy; R4, R5 = H, OH, halo, etc.; X = H, OH, halo, alkoxy, haloalkoxy; Y = (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl) which can modulate LXR function and as a result show excellent


L4 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 anti-arteriosclerotic and anti-inflammatory activity, were prepd. and formulated. Thus, reacting anthranilic acid with phenylacetic acid in

the presence of PPh3 in pyridine followed by addn. of 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoro-2-propanol afforded 76% 2-benzyl-3-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-4(3H)-quinazolinone. The compds. 1 showed excellent binding affinity against LXR (biol. data were given).

IT 637345-78-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused-ring pyrimidin-4(3H)-one derive. as LXR

modulators)
 RN 637345-78-9 CAPLUS
 CN 4(3H)-Quinazolinone.
 2-(aminophenylmethyl)-3-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L4 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:737738 CAPLUS
 DOCUMENT NUMBER: 139:261133
 TITLE: Quinazolinone amide compounds as modulators of nuclear receptors, particularly farnesoid X receptor (FXR) and/or orphan nuclear receptors, and their preparation, pharmaceutical compositions, and methods of use
 INVENTOR(S): Martin, Richard; Kahl, Jeffery Dean; Platt, Brenton
 PATENT ASSIGNER(S): X-CEPTOR Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 204 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076418	A1	20030918	WO 2003-US6793	20030304
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003228283	A1	20030922	AU 2003-228283	20030304
EP 1521746	A1	20050413	EP 2003-726031	20030304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: US 2002-363132P P 20020307				
WO 2003-US6793 W 20030304				

OTHER SOURCE(S): MARPAT 139:261133
 GI



L4 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Comps., pharmaceutical compds., and methods for modulating the activity of nuclear receptors are provided. In particular, amide-containing quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors. The disclosed compds. include 1 (n = 0-4; R1 = H, (un)substituted alk(en)enyl, (hetero)aryl, cycloalkyl(alkyl), (hetero)aralkyl, heterocyclyl(alkyl) (preceding groups designated as group A), OH or deriva., NH2 or deriva.; R2, R6 = (independently) group A, or R2R6 = (un)substituted alkylene; R4, R5 = (independently) group A, OH or deriva., NH2 or deriva., various acyl, sulfinyl, sulfonyl, or phosphoryl groups, etc.; or R4R5 (un)substituted alkylene, alkenylene, alkenylene(oxy/aza)alkenylene; or any of R2R5, R2R6, or R4R5 form 4- to 7-membered, (un)substituted heteroaryl or heterocyclyl group; R3 = (independently) halo, pseudohalo, group A, NH2 or deriva., OH or deriva., SH or deriva., various acyl, thioacyl, imidoyl, sulfinyl, or sulfonyl groups; or adjacent R3R3 = (un)substituted alkylene, alkenylene, alkenylenedioxy, thioalkenylenoxy, alkenylenedioxy; including stereoisomers, racemates, mixts., and pharmaceutically acceptable derivate; with one exception compound]. Over 300 specific compds. were prepared and claimed by name. Ten of the most preferred compds. are named. The compds. are useful for treating diseases and disorders selected from: hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, lipodystrophy, hyperglycemia, diabetes mellitus, dyslipidemia, atherosclerosis, gallstone disease, acne vulgaris, acneiform skin conditions, diabetes, Parkinson's disease, cancer, Alzheimer's disease, inflammation, immunol. disorders, lipid disorders, obesity, conditions characterized by a perturbed epidermal barrier function, hyperlipidemia, cholestasis, peripheral occlusive disease, ischemic stroke, obesity, disease states associated with elevated cholesterol levels, conditions of disturbed differentiation or excess proliferation of the epidermis or mucous membrane, and cardiovascular disorders. For instance, Me anthranilate was N-amidated with 2-chloropropionyl chloride (97%), followed by saponification of the ester (97%), and amidation/cyclocondensation of the resultant acid using p-anisidine and PCl3 (72%), to give 2-(1-(4-methoxyphenyl)-3-(4-methoxyphenyl)-3H-quinazolin-4-one. This intermediate chloride was amidated with methylamine in THF (99%), and the obtained secondary amine was sulfonylated with 4-tert-butylbenzenesulfonyl chloride and TEA in DCM (92%), to give preferred invention compound II.

In an FRET assay for binding to human FXR (ligand-binding domain, fused to glutathione-S-transferase), II had an EC50 of about 300 nM. In an FXR/ECREX7 co-transfection assay using African green monkey kidney cells, II had an efficacy of 190% relative to high control (chenodeoxycholic acid).

IT 602318-88-7P, 3-(4-Methoxyphenyl)-2-methylaminomethyl-3H-quinazolin-4-one 602318-95-6P, 2-Aminomethyl-3-(4-methoxyphenyl)-3H-quinazolin-4-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP


L4 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

(Preparation); RACT (Reactant or reagent); USES (Uses)

intermediate and drug candidate; prepn. of quinazolinone amides as farnesoid X and/or orphan nuclear receptor modulators)


RN 602318-88-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 602318-95-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

ACCESSION NUMBER: 2002:833514 CAPLUS

DOCUMENT NUMBER: 137:337912

TITLE: Preparation of purinylquinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta

INVENTOR(S): Sadhu, Chanchal; Dick, Ken; Treiberg, Jennifer; Sowell, C. Gregory; Kesicki, Edward A.; Oliver, Amy

PATENT ASSIGNEE(S): ICOS Corp., USA

SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of U.S. Ser. No. 841,341.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161014	A1	20021031	US 2001-27591	20011019
US 6667300	B2	20031223		
US 6518277	B1	20030211	US 2001-841341	20010424
CA 2463294	AA	20030501	CA 2002-2463294	20020827
WO 2003035075	A1	20030501	WO 2002-US27240	20020827
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MY, SD, SL, SZ, TG, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1438052	A1	20040721	EP 2002-757407	20020827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1606444	A	20050413	CN 2002-825687	20020827
JP 2005096235	T2	20050414	JP 2003-537642	20020827
ZA 2002008698	A	20031010	ZA 2002-8698	20021028
US 2003195211	A1	20031016	US 2003-337192	20030106
US 6800620	B2	20041005		
US 2004266780	A1	20041230	US 2003-697912	20031030
US 6949535	B2	20050927		
US 2005261317	A1	20051124	US 2005-110204	20050420
PRIORITY APPLN. INFO.:			US 2000-199655P	P 20000425
			US 2000-238057P	P 20001005
			US 2001-841341	A2 20010424
			US 2001-27591	A 20011019
			WO 2002-US27240	M 20020827
			US 2003-697912	A1 20031030

OTHER SOURCE(S): MARPAT 137:337912

GI

L4 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB A method of disrupting leukocyte function comprises administration of title compds. [1; X = C(Rb)2, CH2CHRb, CH:CRb; Rb = H, alkyl, heteroalkyl, aryl, heteroaryl, aralkyl, etc.; Y = null, S, SO, SO2, NH, O, CO, CO2, NHCOCH2S; R, R1 = H, alkyl, aryl, heteroaryl, halo, etc.; R2 = H, (substituted) alkyl, cycloalkyl, heterocycloalkyl, alkenecycloalkyl, alkenyl, alkenecycloalkyl, aryl, heteroaryl, etc.; A = (substituted) mono- or bicyclic ring system containing 22 N atoms and in which 21 ring is aromatic]. Thus, dose-dependent decrease in histamine release from basophils when stimulated with anti-IgE was 100% at 1,000 nM, with an EC50 of about 25 nM for I (Y = S, R = 5-Me, R1 = H, R2 = 2-ClC6H4, R3 = H; S connected to 6-position of purine ring; preparation given).


IT 371244-07-4P, 4(3H)-Quinazolinone, 2-(aminomethyl)-5-methyl-3-(2-methylphenyl)- 371244-08-5P, 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-chlorophenyl)-5-fluoro- 371244-09-6P, 4(3H)-Quinazolinone, 2-(1-aminoethyl)-5-methyl-3-(2-methylphenyl)-

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of purinylquinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta)

RN 371244-07-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-(aminomethyl)-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371244-08-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 371244-09-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-5-methyl-3-(2-methylphenyl)- (9CI)
(CA INDEX NAME)



L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
US 2002-231895 A1 20020829

OTHER SOURCE(S): MARPAT 137:337907
GI



AB Title compds. I [wherein X = a bond, CO, CR5R6, CR5, SO, SO2, or N; Z =

a bond, H, O, S, NR17, or CR7; with the proviso that X and Z are not both a bond; L = CO-alkylene or (hetero)alkylene; Q = (hetero)alkylene, CO, OCO, NR8CO, CH2CO, CH2SO, or CH2SO2; or NLO = heterocyclyl; R1 and R2 = independently H, (hetero)alkyl, or (hetero)aryl; or CR1R2 = (hetero)cyclyl; or CNR2L = heterocyclyl; R3 = OH, alkoxy, NH2, (di)alkylamino, heteroalkyl, heterocyclyl, acylaminoamidino, guanidino, ureido, CN, heteroaryl, carbamoyl, or carboxy; R4 = (hetero)alkyl, (hetero)aryl, etc.; R5 and R6 = independently H, (hetero)alkyl, or (hetero)aryl; or CR5R6 = a ring; R7 and R8 = independently H, (hetero)alkyl, or (hetero)aryl; Y1 and Y2 = independently N, O, S, or NR13; Y3 = N or C, wherein C shares a double bond with either Z or Y4; Y4 = NR14, CR14, N, NR14CR15R16; R12 = H, halo, OH, NH2, (di)alkylamino, (hetero)alkyl, or (hetero)aryl, with provisos; R13 = H, (hetero)alkyl, (hetero)aryl, etc.; R14 = (hetero)alkyl, (hetero)aryl, etc.; R15 and R16

= independently H or (hetero)alkyl; R17 = H, (hetero)alkyl, (hetero)aryl, etc.; with provisos were prepared as chemokine receptor modulators, in particular CXCR3 antagonists. For example, anthranilic acid was acylated with propionyl chloride and the amide cyclized using acetic anhydride to give 2-ethylbenzo[d][1,3]oxazine-4-one. Treatment with 4-fluoroaniline, followed by ethylene glycol and NaOH afforded 2-ethyl-3-(4-fluorophenyl)-3H-quinazolin-4-one. Bromination and stepwise addition of 1-amino-2-methoxyethane and decanoyl chloride produced the decanoic acid (quinazolinylethyl)(methoxyethyl)amide II. Approx. one third of the 101 invention compds. tested in a CXCR3 binding assay displayed activity with

Habte

L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2002:813938 CAPLUS
DOCUMENT NUMBER: 137:337907
TITLE: Preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions
INVENTOR(S): Medina, Julio C.; Johnson, Michael G.; Li, An-Rong; Liu, Jiwen; Huang, Alan Xi; Zhu, Liusheng; Marcus, Andrew P.
PATENT ASSIGNEE(S): Tularik Inc., USA
SOURCE: PCT Int. Appl., 205 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083143	A1	20021024	WO 2001-US47850	20011211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
CA 2431553	AA	20021024	CA 2001-2431553	20011211
US 2002169159	A1	20021114	US 2001-15532	20011211
US 6964967	B2	20051115		
EP 1343505	A1	20030917	EP 2001-273533	20011211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004536796	T2	20041209	JP 2002-580947	20011211
CN 1575177	A	20050202	CN 2001-822596	20011211
BR 2001016096	A	20051018	BR 2001-16096	20011211
US 2003069234	A1	20030410	US 2002-164690	20020606
US 6794379	B2	20040921		
US 2003055054	A1	20030320	US 2002-231895	20020829
US 7053215	B2	20060530		
ZA 2003004342	A	20050509	ZA 2003-4342	20030603
NO 2003002612	A	20030805	NO 2003-2612	20030610
US 2005075333	A1	20050407	US 2004-946935	20040921
US 7067662	B2	20060627		
US 2006116388	A1	20060601	US 2006-332054	20060113
PRIORITY APPLN. INFO.:			US 2000-255241P	P 20001211
			US 2001-296499P	P 20010606
			US 2001-15532	A1 20011211
			WO 2001-US47850	W 20011211
			US 2002-164690	A1 20020606


L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IC50 values of < 1 μM. I are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis, and type I diabetes (no data).
IT 473720-85-3P 473720-87-5P 473720-88-6P
473721-09-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate, preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions)

RN 473720-85-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1R)-1-aminoethyl]-3-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473720-87-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-3-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 473720-88-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-3-(4-iodophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)


08/09/2006

L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 473721-09-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-3-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

FORMAT


L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:798224 CAPLUS
 DOCUMENT NUMBER: 135:357937
 TITLE: Quinazolinone derivatives as inhibitors of human phosphatidylinositol 3-kinase delta
 INVENTOR(S): Sadhu, Chanchal; Dick, Ken; Freiberg, Jennifer; Sowell, C. Gregory; Kesicki, Edward A.; Oliver, Amy
 PATENT ASSIGNEE(S): Icos Corporation, USA
 SOURCE: PCT Int. Appl., 278 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081346	A2	20011101	WO 2001-US13315	20010424
WO 2001081346	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2406278	AA	20011101	CA 2001-2406278	20010424
EP 1278748	A2	20010129	EP 2001-928855	20010424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010371	A	20010617	BR 2001-10371	20010424
JP 2003531209	T2	20031021	JP 2001-578436	20010424
NZ 522076	A	20050826	NZ 2001-522076	20010424
NO 2002005104	A	20021210	NO 2002-5104	20021028
ZA 2002008698	A	20031010	ZA 2002-8698	20021028
PRIORITY APPL. INFO.:			US 2000-199655P	P 20000425
			US 2000-238057P	P 20001005
			WO 2001-US13315	W 20010424

OTHER SOURCE(S): MARPAT 135:357937
 GI

L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K δ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K δ plays a role in leukocyte function are claimed. Preferably, the methods employ active agents that selectively inhibit PI3K δ , while not significantly inhibiting activity of other PI3K isoforms. Comps. are provided that inhibit PI3K δ activity, including comps. that selectively inhibit PI3K δ activity. The comps. claimed are all quinazolin-4-one derivs., including I (Y = null, S, NH; R = H, halo, OH, OMe, Me, CF₃; R₁

H, OMe, halo; R₁ together with C-6 and C-7 of quinazolinone ring define a 5- or 6-membered aromatic ring optionally containing ≥ 1 O, N or S; R₂ = Cl-6 alkyl, Ph, halophenyl, alkylphenyl, biphenyl, PhCH₂, pyridinyl, 4-methylpiperazinyl, CO₂Et, morpholinyl; R₃ = NH₂, halo, Cl-3 alkyl, S(Cl-3 alkyl), OH, NH(Cl-3 alkyl), N(Cl-3 alkyl)₂, NH(Cl-3 alkyl)enophenyl; q = 1, 2 and pharmaceutically acceptable salts and solvates thereof. Methods of using PI3K δ inhibitory comps. to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K δ inhibitory comps. to inhibit PI3K δ -mediated processes in vitro and in vivo. Thus, in an example, dose-dependent decrease in histamine release from basophils when stimulated with anti-IgE was 100% at 1.000 nM,

with an EC₅₀ of about 25 nM for I (Y = S, R = 5-Me, R₁ = H, R₂ = 2-ClC₆H₄).

R₃ = H; S connected to 6-position of purine ring; preparation given).

IT 371244-07-4P 371244-08-5P 371244-09-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and substitution reaction of, with chloropurine derivs.)

RN 371244-07-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-(aminomethyl)-5-methyl-3-(2-methylphenyl)- (9CI)

(CA INDEX NAME)


L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 371244-08-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371244-09-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:208250 CAPLUS
 DOCUMENT NUMBER: 134:252352
 TITLE: Preparation of 3-aryl-2-aryluroidalkylquinazolin-4-ones and related compounds as mediators of hedgehog signaling pathways.
 INVENTOR(S): Baxter, Anthony David; Boyd, Edward Andrew; Guichert, Oivin M.; Price, Stephen; Rubin, Lee D.
 PATENT ASSIGNEE(S): Curis, Inc., USA
 SOURCE: PCT Int. Appl., 177 pp.
 CODEN: PIXX22
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019800	A2	20010322	WO 2000-US25461	20000915
WO 2001019800	A3	20011206		
WO 2001019800	C2	20021003		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, ES, FI, GB, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, ML, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385736	EA	20010322	CA 2000-2385736	20000915
EP 1216234	A2	20020426	EP 2000-963551	20000915
EP 1216234	B1	20041229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509414	T2	20030311	JP 2001-523360	20000915
US 6545005	B1	20030408	US 2000-663835	20000915
AT 286033	E	20050115	AT 2000-963551	20000915
EP 1516876	A1	20050323	EP 2004-28252	20000915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AU 780846	B2	20050421	AU 2000-74948	20000915
ES 2234662	T3	20050701	ES 2000-963551	20000915
US 2005080138	A1	20050414	US 2004-953601	20040929
AU 2005220214	A1	20051103	AU 2005-220214	20051006
PRIORITY APPLN. INFO.:				
			US 1999-154526P	P 19990916
			US 1999-159412P	P 19991014
			US 1999-162899P	P 19991101
			AU 2000-74948	A 20000915
			EP 2000-963551	A3 20000915
			US 2000-663835	A2 20000915


L4 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:552517 CAPLUS
 DOCUMENT NUMBER: 131:310612
 TITLE: Novel quinazolinones from 2-cyanomethyl-3-phenyl-4(3H)quinazolinone
 AUTHOR(S): El-Feky, S. A.
 CORPORATE SOURCE: Dept. of Organic Pharmaceutical Chemistry, Faculty of Pharmacy, Zagazig Univ., Zagazig, Egypt
 SOURCE: Bollettino Chimico Farmaceutico (1998), 137(7), 286-289
 CODEN: BCFPAI; ISSN: 0006-6648
 SOCIETA EDITORIALE Farmaceutica
 PUBLISHER: Journal
 DOCUMENT TYPE: English
 LANGUAGE: English
 GI




AB The title compound was converted to several other quinazolinones, e.g., I, II, III, and IV. The new compounds were characterized by elemental analyses, ¹H-NMR and IR spectra, and alternative syntheses in certain cases.
 IT 220460-17-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and conversion to oxadiazole derivative)
 RN 220460-17-3 CAPLUS
 CN 2-Quinazolineethanimidamide, N-(benzoyloxy)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 WO 2000-US25461 W 20000915
 US 2000-687800 B2 20001013
 US 2000-711343 B2 20001109
 US 2000-724277 A1 20001128


OTHER SOURCE(S): MARPAT 134:252352
 AB R1LX1Y1Z1LK2Y2Z2LR2 (R1, R2 = H, alkyl, (substituted) aryl, aralkyl, heteroaryl, heteroarylethyl; L = null, alkyl, alkenyl, alkynyl, (CH2)nO(CH2)p, etc.; n, p = 0-10; X1, X2 = NR8, O, S, Se, N:R8, ON:CH, heterocyclyl, bond, etc.; Y1, Y2 = CO, CS, SO2, SO, C(N:R8), heteroaryl, bond, etc.; Z1, Z2 = NR8, O, S, Se, N:R8, ON:CH, heterocyclyl, bond, etc.; R8 = H, alkyl, (substituted) aryl, aralkyl, heteroaryl, heteroarylethyl, etc.), were prepared. Thus, triphosgene in EtOAc was added to 4-nitro-3-trifluoromethylaniline in EtOAc followed by stirring and reflux. The mixture was concentrated, dissolved in CHCl3, and treated with 3-(4-fluorophenyl)-2-(1-methylaminoethyl)-4-oxo-3,4-dihydroquinazolin-2-ylidene to give 978 1-(1-(3-(4-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-ylidene)-3-(3-trifluoromethyl-4-nitrophenyl)-1-methylurea. The latter inhibited sonic hedgehog-induced Gli transcription activity with IC50 <5 μM.
 IT 330796-23-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 3-aryl-2-aryluroidalkylquinazolin-4-ones and related compounds as mediators of hedgehog signaling pathways)
 RN 330796-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 220460-11-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclization of)
 RN 220460-11-7 CAPLUS
 CN 2-Quinazolineethanimidamide, N-(acetyloxy)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




IT 220460-09-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, acetylation, and conversion to oxadiazole derivative)
 RN 220460-09-3 CAPLUS
 CN 2-Quinazolineethanimidamide, N-(benzoyloxy)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:800426 CAPLUS
 DOCUMENT NUMBER: 130:168315
 TITLE: Novel quinazolinones from
 2-cyanomethyl-3-phenyl-4(3H)-quinazolinone
 AUTHOR(S): El-Peky, Said A.
 CORPORATE SOURCE: Dep. organic Pharmaceutical Chemistry, Faculty Pharmacy, Zagazig University, Zagazig, Egypt
 SOURCE: Chinese Pharmaceutical Journal (Taipei) (1998), 50(5), 305-312
 CODEN: CPHJEP; ISSN: 1016-1015
 PUBLISHER: Pharmaceutical Society of Republic of China
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB 2-[[[(4-Chlorophenyl)thio] (cyano)methylene]-3-phenyl-1,2,3,4-tetrahydroquinazolin-4-one, 2-amino-4-phenylpyrazolo[1,5-a]quinazolin-5(4H)-one, and 2-[[5-methyl- or phenyl-1,2,4-oxadiazol-3-yl]methyl]-3-phenyl-4(3H)-quinazolinone were prepared from
 2-(cyanomethyl)-3-phenyl-4(3H)-quinazolinone via its α -bromo and amide oxime derivs. The new compds. were characterized by elemental anal., ¹H NMR, IR, and alternative synthesis in some cases.
 IT 220460-09-3P 220460-11-7P 220460-17-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Preparation of phenylquinazolinones from (cyanomethyl)phenylquinazolinone)
 RN 220460-09-3 CAPLUS
 CN 2-Quinazolineethanimidamide, 3,4-dihydro-N-hydroxy-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 220460-11-7 CAPLUS
 CN 2-Quinazolineethanimidamide, N-(acetyloxy)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:352629 CAPLUS
 DOCUMENT NUMBER: 129:27954
 TITLE: Quinazolinone derivatives as cholecystokinin (CCK) ligands
 INVENTOR(S): Padia, Janak Khimchand
 PATENT ASSIGNEE(S): Warner-Lambert Co., USA
 SOURCE: U.S., 23 pp., Cont.-in-part of U.S. Ser. No. 287,454.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5756502	A	19980526	US 1995-500436	19950710
US 5869665	A	19990209	US 1997-826843	19970408
PRIORITY APPLN. INFO.:			US 1994-287454	A2 19940808
			US 1995-500436	A3 19950710

OTHER SOURCE(S): CASREACT 129:27954; MARPAT 129:27954
 GI




AB The title compds. [I; W, X, Y, Z = CR3, CR4, CR5, CR6, N, etc.; M = O, S; B = bond or (un)substituted alkylene; A = RINCO(CH2)n, CONR11(CH2)n, etc.;

n = 0, 1; R1, R2 = C1-6 alkyl, (un)substituted aryl, etc.; R3-R6 = H, OH, alkoxy, etc.; R11 = H, lower alkyl] are prepared I with good binding affinity for the CCK-A and CCK-B receptors are useful agents to suppress appetite, reduce gastric acid secretion, and the like. Thus, 2-(aminomethyl)-3-[3-(methylethoxy)phenyl]-4(3H)-quinazolinone (preparation given) was reacted with 3-methylphenyl isocyanate to give 50% the title compound (II), which showed CCK-A and CCK-B receptor binding affinities


(K1) of 1637 and 879 nm resp.
 IT 205064-38-6P 207978-52-7P

Habe

L4 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220460-17-3 CAPLUS
 CN 2-Quinazolineethanimidamide, N-(benzoyloxy)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Quinazolinone derivs. as cholecystokinin (CCK) ligands)
 RN 205064-38-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-[3-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 207978-52-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-aminoethyl)-3-[3-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:169718 CAPLUS

DOCUMENT NUMBER: 128:238969

TITLE: Novel Nonpeptide CCK-B Antagonists: Design and Development of Quinazolinone Derivatives as Potent, Selective, and Orally Active CCK-B Antagonists

AUTHOR(S): Padia, Janak K.; Field, Mark; Hinton, Joanna; Ken, Pablo, Julius; Pinnock, Rob; Roth, Bruce D.; Singh, Lakhbir; Suman-Chauhan, Nirmala; Trivedi, Bharat K.; Webdale, Louise

CORPORATE SOURCE: Departments of Chemistry and of Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Ann Arbor, MI, 48105, USA

SOURCE: Journal of Medicinal Chemistry (1998), 41(7), 1042-1049


CODEN: JMCHAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society


DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I



II

AB Urea-linked quinazolinones (I; R = (un)substituted Ph, cyclohexyl; R1 = (un)substituted Ph, 3-pyridyl, 1-naphthyl) were prepared as selective orally active CCK-B antagonists. Thus, thioxoquinazolinones II (prepared from anthranilic acid and the requisite isothiocyanate) were treated with hydrazine gave the 2-hydrazino compds. which were then treated with an isocyanate to give I. Representative compds. of this series were tested in the functional assay, i.e., guinea pig stomach strip assay, and showed pure antagonist profiles. I [R = 3-(tert-butoxycarbonyl)phenyl, R1 = 3-isopropoxyphenyl] and I [R = 3-cyanophenyl, R1 = 3-(dimethylamino)phenyl] (III) were orally active in the elevated rat

X-maze test and showed dose-dependent anxiolytic-like action. These compds. were

also evaluated for their pharmacokinetic profile. The absolute oral bioavailability of III was 22% in rats.

IT 205064-38-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of urea-linked quinazolinones as selective CCK-B receptor antagonists)

RN 205064-38-6 CAPLUS

L4 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:510992 CAPLUS

DOCUMENT NUMBER: 117:110992

TITLE: Electroreduction of some potential antimicrobial thiosemicarbazide derivatives of quinazolin-4(3H)-one

AUTHOR(S): Ismail, Mohamed I.

CORPORATE SOURCE: Fac. Sci., Univ. Ain Shams, Cairo, Egypt

SOURCE: Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999) (1992), (4), 585-9

CODEN: JCPKSH; ISSN: 0300-9580

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 117:110992

AB Polarographic data for a series of 3-phenyl-2-substituted thiosemicarbazide derivatives of quinazolin-4(3H)-ones (with antimicrobial activity), in 50% ethanolic aqueous buffers covering a wide range of pH


are reported and discussed. A mechanism interpreting the electrode process, in both acidic and alkaline media, is proposed and confirmed via the identification of CPE products, Hammett's σ -E1/2 relation and pKa determination

IT 22126-97-2P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, by electroredn. of formylphenylquinazolinone thiosemicarbazide)


RN 22126-97-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(3-(1-methylethoxy)phenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

GI

L4 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1986:497416 CAPLUS

DOCUMENT NUMBER: 105:97416

TITLE: Synthesis and biological activities of certain derivatives of 3-aryl-4(3H)-quinazolinones. Part II

AUTHOR(S): Rao, A. Devender; Shankar, C. Ravi; Reddy, P.

CORPORATE SOURCE: Bhagavan; Reddy, V. Malli

SOURCE: Coll. Pharm. Sci., Kakatiya Univ., Warangal, 506 009, India

Journal of the Indian Chemical Society (1985), 62(3), 214-7


CODEN: JICSAH; ISSN: 0019-4522

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 105:97416

GI



AB 3-Arylquinazolinones I [R = H, Br; R1 = 4-MeC6H4, 2-MeC6H4, 4-O2NC6H4, 2-O2NC6H4; R2 = NMe2, NET2, N(CH2CH2OH)2, piperidino, morpholino, 4-AcNHC6H4SO2, etc.] were prepared from I (R2 = Cl), which were obtained

by cyclocondensation of N-chloroacetylthranilic acids with R1NH2 in the presence of PCl3. I are antifungal agents, I (R = H, R1 = 4-O2NC6H4, R2 =


4-AcNHC6H4SO2) giving total control of Curvularia lunata and Fusarium oxysporum at 800 µg/mL.

IT 80096-33-9P 103952-91-6P 103952-92-7P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and condensation of, with acetamidobenzenesulfonyl chloride)

RN 80096-33-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 103952-91-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-(aminomethyl)-6,8-dibromo-3-(4-methylphenyl)- (9CI)


L4 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)




RN 103952-92-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 103952-93-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HBr



L4 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1983:72038 CAPLUS
DOCUMENT NUMBER: 98:72038
TITLE: Studies on side-chain bromination and oxidation of 6-bromo-2-methyl-3-phenyl-4(3H)-quinazolinone and related compounds
AUTHOR(S): El-Sherief, H. A. H.; El-Naggar, G. M.; Mahmoud, A. M.; Aref, H.; Abdel-Hamied, K.
CORPORATE SOURCE: Fac. Sci., Assiut Univ., Assiut, Egypt
SOURCE: Bulletin of the Faculty of Science, Assiut University (1982), 11(1), 49-60
CODEN: BSAUDW; ISSN: 0366-4740
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB Bromination of the quinazolinone I (R = Me) gave I (R = CH₂Br, CHBr₂). I (R = CH₂Br) reacted with nucleophiles to give I (R = CH₂NHMe, piperidinomethyl, morpholinomethyl, CH₂SCo₂H, CH₂SCo₂Me, CH₂SCo₂CH₂CO₂H, CH₂SPH, CH₂SCo₂HMe-2). I (R = Me) was oxidized to I (R = CHO) which was converted to various anils. I (R = CH:CHPh, CH:CHCo₂HMe-4) were brominated to I (R = CHBrCHBrPh, CHBrCHBrCo₂HMe-4). The latter compound was treated with nucleophiles to give I (R = CHBrCHBrCo₂HMe-4; R₁ = OMe, OEt, NH₂, OAc).

IT 84546-37-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
RN 84546-37-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-(2-amino-1-bromo-2-(4-methoxyphenyl)ethyl)-6-bromo-3-phenyl-, monohydrobromide (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1982:6679 CAPLUS
DOCUMENT NUMBER: 96:6679
TITLE: Quinazolinones. 2. Syntheses and some reactions of 2-azidomethyl-3-aryl-4-quinazolinones
AUTHOR(S): Domanig, Rainer
CORPORATE SOURCE: Inst. Org. Pharm. Chem., Univ. Innsbruck, Innsbruck, A-6020, Austria
SOURCE: Monatshefte fuer Chemie (1981), 112(10), 1195-202
CODEN: MOCHB7; ISSN: 0026-9247
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 96:6679
GI




AB Starting with the chloromethyl compds. I (R = Cl; R₁ = H, 2-Me, 2-MeO, 2-NO₂, 3-MeO, 3,5-(MeO)₂, 4-Cl, 5-NO₂), the new 2-azidomethyl-3-aryl-4-quinazolinones I (R = N₃) were prepared, some of which were reduced to the corresponding amines I (R = NH₂) by H₂S in good yield. As a first example of the capability of the azides to undergo 1,3-dipolar cycloaddn., II (R₁ = 2-Me, 3-MeO, 4-Cl) were prepared by reacting I (R = N₃) with MeOCC.tpbond.CCO₂Me.
IT 22126-97-2P 80096-33-9P 80096-34-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
RN 22126-97-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 80096-33-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 80096-34-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 80096-35-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1974:463563 CAPLUS
DOCUMENT NUMBER: 81:63563
TITLE: Chemistry of heterocycles. LVII. Synthesis and transformation of
4H-3,1-benzoxazin-4-one-2-carboxylic acid amides
AUTHOR(S): Petyunin, P. A.; Bulgakov, V. A.; Petyunin, G. P.
CORPORATE SOURCE: Khar'k. Farm. Inst., Kharkov, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1974), (5), 609-12
CODEN: KGSSAQ; ISSN: 0132-6244
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.


AB Benzoxazinecarboxamides I (R = H, C1-7 alkyl, CH₂:CHCH₂, PhCH₂) were obtained in 40-87% yields by cyclization of o-HO₂CC₆H₄NHCOCONHR in boiling Ac₂O for 10 min. Quinazolinocarboxamides II (R = Me, H; R₁ = H, C1-5 alkyl, CH₂CH₂Cl, CH₂CO₂Et, Ph, o-MeC₆H₄, o-ClC₆H₄, o-, m-, p-MeOC₆H₄, o-, m-, p-HO₂CC₆H₄, cyclohexyl, p-H₂NSO₂C₆H₄, 2-pyridyl, 3-quinolyl) were obtained in 53-93% yields by amination of I with R₁NH₂.

IT 53115-39-2P 53115-40-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 53115-39-2 CAPLUS
CN 2-Quinazolinocarboxamide, 3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 53115-40-5 CAPLUS
CN Benzoic acid, 4-[2-(aminocarbonyl)-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1981:175028 CAPLUS
DOCUMENT NUMBER: 94:175028
TITLE: Reactions of 2,3-disubstituted 4(3H)-quinazolinones and related compounds
AUTHOR(S): Badr, M. Z. A.; El-Naggar, G. M.; El-Sherief, H. A.
CORPORATE SOURCE: Fac. Sci., Assiut Univ., Assiut, Egypt
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1980), 19B(10), 925-6
CODEN: IJSEDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 94:175028
GI




AB The arylidenequinazolines I (R₁ = bond, R₂ = p-MeO, H, m-NO₂, p-NO₂) were brominated with Br₂ to give I (R = R₁ = Br). I (R = R₁ = Br, R₂ = p-MeO) underwent substitution reactions to give I (R = Br, R₁ = AcO, MeO, EtO; R = R₁ = H₂N, piperidino, morpholino, PhO, PhS; R₂ = p-MeO). I (R₁ = bond, R₂ = p-MeO) was also obtained as an elimination product.

IT 77143-54-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 77143-54-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1,2-diamino-2-(4-methoxyphenyl)ethyl]-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 1973:16128 CAPLUS
DOCUMENT NUMBER: 78:16128
TITLE: 4-Quinazolinones. II. 2-(Aminomethyl)-3-aryl-4-quinazolinones
AUTHOR(S): Kozhevnikov, Yu. V.; Pilat, N. V.
CORPORATE SOURCE: USSR
SOURCE: Tr. Perm. Sel.-Khoz. Inst. (1971), No. 79, 66-72
From: Ref. Zh., Khim. 1972, Abstr. No. 92h404
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB The appropriate 3-(substituted phenyl)-2-(chloromethyl)quinazolinone, K phthalimide, and DMF refluxed 1 hr gave the following I (R = phthalimido) (R₁ and % yield given): H, 80.6; o-Me, 42.7; p-Me, 85.5; p-MeO, 65.3; m-Br, 60; p-Br, 75.8; and o-Cl, 53.6. These refluxed with N₂H₄·H₂O in alc., then with 6N HCl gave the following I.HCl (R = NH₂) (R₁ and % yield given): H, 40.6; o-Me, 30.3; p-Me (Ia), 50.8; p-MeO, 45.6; m-Br, 42; p-Br, 57.4; and o-Cl, 39.5. Ia heated with ClCH₂COCl in HOAc gave 58.5% II (R₂ = Cl), which refluxed 2 hr with Et₂NH in PhMe gave 62% II (R₁ = Et₂N). Similarly prepared II were (R₂ and % yield given): morpholino, 60.8; piperidino, 72.3; phenylpiperazino, 63.7; p-tolylpiperazino, 64.5; and o-tolylpiperazino, 56.8.
IT 22126-93-8P 39070-42-3P 39070-43-4P
39070-44-5P 39070-45-6P 39070-46-7P
39070-47-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22126-93-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl-, monohydrochloride (8CI, 9CI) (CA INDEX NAME)



● HCl


RN 39070-42-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 39070-43-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-methylphenyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 39070-44-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-methoxyphenyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 39070-45-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(3-bromophenyl)-,
 monohydrochloride
 (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 39070-46-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-bromophenyl)-,
 monohydrochloride
 (9CI) (CA INDEX NAME)




● HCl

RN 39070-47-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-chlorophenyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1971:76386 CAPLUS
 DOCUMENT NUMBER: 74:76386
 TITLE: Heterocyclic chemistry. LI. Reaction of ethoxalylanthranil with amines
 AUTHOR(S): Petyunin, P. A.; Chernykh, V. P.; Petyunin, G. P.; Kozhevnikov, Yu. V.
 CORPORATE SOURCE: Khar'k. Pharm. Inst., Kharkov, USSR
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1970), (11), 1575-8
 CODEN: KGSSAQ; ISSN: 0132-6244
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI For diagram(s), see printed CA Issue.
 AB The title compound (I, Z = O) reacted with 28 aromatic amines (RNH2) in DMF, yielding the corresponding I (Z = NR). The latter underwent amidation with NH3, H2H4, and R1C6H4NH2 (R1 = H, 3-, 4-Br, 3-Me, 4-MeO), and saponification in the usual manner.
 IT 10689-32-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 10689-32-8 CAPLUS
 CN 2-Quinazolinecarboxamide, 3,4-dihydro-4-oxo-3-(p-sulfamoylphenyl)- (8CI) (CA INDEX NAME)




L4 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1969:87715 CAPLUS
 DOCUMENT NUMBER: 70:87715
 TITLE: 4-Quinazolones. II. Synthesis of some imidazo[1,5-a]quinazolin-5(4H)ones
 AUTHOR(S): Singh, Buddha D.; Chaudhury, D. N.
 CORPORATE SOURCE: Bihar Univ., Muzaffarpur, India
 SOURCE: Journal of the Indian Chemical Society (1969), 46(1), 21-5
 CODEN: JICSAH; ISSN: 0019-4522
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The synthesis of 4-phenylimidazo[1,5-a]quinazolin-5(4H)-one and its 1-substituted analogs is described.
 IT 22126-93-8P 22126-97-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 22126-93-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl-, monohydrochloride (8CI, 9CI) (CA INDEX NAME)



● HCl

RN 22126-97-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:21:12 ON 09 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8

DICTIONARY FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10809637gh.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N

G2 Ak,C,S,N,CH2,A

Structure attributes must be viewed using STN Express query preparation.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL


2

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N

G2 Ak,C,S,N,CH2,A

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:41:35 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 33621 TO ITERATE

5.9% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 661461 TO 683379
PROJECTED ANSWERS: 852 TO 1836

L2 4 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 10:41:41 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 673691 TO ITERATE

100.0% PROCESSED 673691 ITERATIONS
SEARCH TIME: 00.00.13

1134 ANSWERS

L3 1134 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE
ENTRY
166.94

TOTAL
SESSION
167.15

FILE 'CAPLUS' ENTERED AT 10:41:59 ON 08 AUG 2006

Habte

08/08/2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Aug 2006 VOL 145 ISS 7
FILE LAST UPDATED: 7 Aug 2006 (20060807/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 72 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:142762 CAPLUS

DOCUMENT NUMBER: 144:233087

TITLE: Preparation of fused pyrimidinones as chemokine CXCR3 receptor ligands.

INVENTOR(S): Lin, Chu-Chung; Chen, Hong-Chuan; Lee, Kuang-Yuan; Huang, Ying-Huey; Fan, Yang-Ping; Xiang, Yibin

PATENT ASSIGNEE(S): Taigen Biotechnology, Taiwan

SOURCE: U.S. Pat. Appl. Publ., 60 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006036093	A1	20060216	US 2005-204792	20050816
WO 2006023381	A1	20060302	WO 2005-US28679	20050811
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPL. INFO.: US 2004-601776P P 20040816

OTHER SOURCE(S): MARPAT 144:233087

GI

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. [I: A = aryl, heteroaryl; X = S, NR₁; L₁ = CR₁R₂, alkylene, heteroalkylene, null; L₂ = CR₁, null; L₃, L₄ = CO, SO₂, CO₂, COCH₂, SO₂CH₂, alkylene, heteroalkylene, etc.; L₃L₄N, L₁L₃N, L₁L₄N = atoms to form 6-7 membered ring; R₁ = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; R₂ = R₁, etc.; R₂L₂ = null; R₃, R₄ = R₁, halo, cyano, amidino, guanidino, ureido, etc.; R₁, R₂, R₃, R₄ = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cyano, etc.], were prepared. Thus, title compound (II) was prepared in 7 steps from anthranilic acid, propionyl chloride, 4-ethoxyaniline, BocNHCH₂CH₂NH₂, 3,4-dichlorophenylacetic acid, and (Me₂S)C₂N₂. 138 I inhibited activation of CXCR3 using a Delfia GTP binding kit with IC₅₀ <1 μM.

IT 876015-89-3P 876015-91-7P 876016-09-0P
876016-11-4P 876016-12-5P 876016-13-6P
876016-14-7P 876016-15-8P 876016-16-9P
876016-17-0P 876016-18-1P 876016-22-7P
876016-23-8P 876016-24-9P 876016-25-0P
876016-26-1P 876016-27-2P 876016-28-3P
876016-30-7P 876016-31-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of fused pyrimidinones as chemokine CXCR3 receptor ligands)

RN 876015-89-3 CAPLUS


CN Benzeneacetamide, N-[3-[(1-acetyl-4-piperidinyl)amino]-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-N-[2-(4-morpholinyl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 876015-91-7 CAPLUS


CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-(4-piperidinylamino)propyl]-3-fluoro-N-[2-(4-morpholinyl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 876016-09-0 CAPLUS


CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(tetrahydro-2H-thiopyran-4-yl)amino]propyl]-3-fluoro-N-[2-(4-morpholinyl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 876016-11-4 CAPLUS


CN Benzeneacetamide, N-[3-[(1-acetyl-4-piperidinyl)amino]-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-N-[3-pyridinylmethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 876016-12-5 CAPLUS


CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-(4-piperidinylamino)propyl]-3-fluoro-N-[3-pyridinylmethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 876016-13-6 CAPLUS
 CN Benzeneacetamide, 3,4-dichloro-N-[2-(dimethylamino)ethyl]-N-[3-[(1-ethyl-4-piperidinyl)amino]-1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 876016-15-9 CAPLUS
 CN Benzeneacetamide, 3,4-dichloro-N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-(4-piperidinylamino)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 876016-16-9 CAPLUS
 CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-3-fluoro-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Habe


L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 876016-14-7 CAPLUS
 CN Benzeneacetamide, 3,4-dichloro-N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(tetrahydro-2H-thiopyran-4-yl)amino]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 876016-17-0 CAPLUS
 CN Benzeneacetamide, 3,4-dichloro-N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(1-ethyl-4-piperidinyl)amino]propyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



08/08/2006


L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 876016-18-1 CAPLUS
 CN Benzeneacetamide, 3,4-dichloro-N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-(4-piperidinylamino)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 876016-23-8 CAPLUS
 CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-3-fluoro-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[[1-(1-methylethyl)-4-piperidinyl]amino]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 876016-22-7 CAPLUS
 CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-N-[3-[[1-ethyl-4-piperidinyl]amino]-1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 876016-24-9 CAPLUS
 CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-3-fluoro-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[[tetrahydro-2H-pyran-4-yl]amino]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 876016-25-0 CAPLUS


08/08/2006

Habte

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-3-fluoro-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(tetrahydro-2H-thiopyran-4-yl)amino]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A

RN 876016-26-1 CAPLUS
 CN Benzeneacetamide, N-[3-[(1-acetyl-4-piperidinyl)amino]-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 876016-27-2 CAPLUS
 CN Benzeneacetamide, N-[3-(dimethylamino)propyl]-N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[[1-(1-methylethyl)-4-piperidinyl]amino]propyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A




PAGE 2-A

RN 876016-28-3 CAPLUS
 CN Benzeneacetamide, N-[3-(dimethylamino)propyl]-N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 876016-30-7 CAPLUS
 CN Benzeneacetamide, N-[3-[(1-ethyl-4-piperidinyl)amino]-1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 876016-31-8 CAPLUS
 CN Benzeneacetamide, 3-fluoro-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[[1-(1-methylethyl)-4-piperidinyl]amino]propyl]-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 2 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

24 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2006
 ACCESSION NUMBER: 2006:32072 CAPLUS
 DOCUMENT NUMBER: 144:128993

DOCUMENT NUMBER: 144:128993
TITLE: Preparatio

DOCUMENT NUMBER: 144128993
TITLE: Preparation of fused pyrimidine derivatives as CXCR3 receptor modulators for prevention and treatment of inflammatory and immunoregulatory conditions
INVENTOR(S): Fu, Zice; Johnson, Michael G.; Li, An-Rong; Marcus, Andrew P.; Medina, Julio C.; Bergeron, Philippe; Chen, Xiaopu; Deignan, Jeffrey; Du, Xiaohui; Duquette, Jason A.; Gustin, Darin; Mihalic, Jeffrey T.

PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 80 pp.

SOURCE: FCI INC. Appl., 66 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

DOCUMENT TYPE: Patent
LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200604915	A1	20060112	WO 2005-US23251	20050628
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, EE, EG, ES, FI, GB, GE, GH, GM, HN, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, SM, SY, TZ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RV:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, RU, IE, IS, IT, LU, MC, NL, NO, PT, RO, SG, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TZ, TM			
US 2006069099	A1	20060310	US 2005-168005	20050627
PRIORITY APPLN. INFO.:			US 2004-583901P	P 20040628
OTHER SOURCE(S):	HARPAT	144:128993		

L4 ANSWER 2 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [Al, A4 = independently CH and derivs., N; Q = a bond, heteroalkylene, CO, CH2CO, etc.; L = a bond, alkylene; X = CH2, SO2, CO; Ra = H, OH and derivs., halo, etc.; n = 0-4; R1 = heteroalkyl; R2 = H, halo, heteroalkyl, etc.; or R2 may be combined with L to form a 5- to 8-membered ring containing 1-3 heteroatoms; R3 = absent, H, SR5, NHSO2R5, piperidin-4-yl, etc.; R3 may be combined with R2 to form a 4- to 8-membered ring containing 1-3 heteroatoms; R5 = heteroalkyl, heteroaryl;

R4 = hetero/aralkyl, hetero/aralkyl, etc.) and their pharmacologically acceptable salts and prodrugs were prepared as chemokine receptor (CKCR) modulators (no data). Two biol. assays are given. Thus, two novel 1-*N*-[1-(4-fluorophenyl)-1-hydroxyethylidene]hydrazide (I) (*N*-(1R,2S)-aminoethoxy)-3-(4-ethoxyphenyl)-4-[3(R)-quinazolinone], and acylation of the amine intermediate with [4-fluoro-3-(trifluoromethyl)phenyl]acetic acid gave quinazolinone II. I. are useful for the treatment of inflammatory and immune disorders (inflammation, diseases, rheumatoid arthritis, psoriasis, and inflammatory bowel disease (no data)).

IT 873191-60-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of fused pyrimidine derivs. as CXCR3
receptor
modulators for prevention and treatment of inflammatory and immune
disorders and diseases)


```

      disorders and diseases)
RN      873191-60-7  CAPLUS
CN      Benzeneacetamide, N-({(1R)-1-[3-(4-cyanophenyl)-3,4-dihydro-4-oxo-2-
      quinazolinyl]ethyl}-4-fluoro-N-(tetrahydro-2H-thiopyran-4-yl)-3-
      (trifluoromethyl)- (9CI) (CA INDEX NAME)

```

Absolute stereochemistry.

L4 ANSWER 2 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1329696 CAPLUS
DOCUMENT NUMBER: 144:45525
TITLE: Methods for treating mast cell disorders
INVENTOR(S): Haylick, Joel S.; Pefaur, Noah; Puri, Kamal D.; Tino, William
PATENT ASSIGNEE(S): Icos Corporation, USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005120511	A1	20051222	WO 2005-US19558	20050604
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
AW, BH, BM, BN, BR, BS, BT, BV, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

PRIORITY APPL. INFO.: US 2004-576947P P 20040604
OTHER SOURCE(S): MARPAT 144:45525

AB The invention provides methods of inhibiting mast cell activity by administering a selective inhibitor of phosphoinositide 3-kinase delta (PI3K). The invention also provides methods for treating or preventing a condition associated with undesirable mast cell activity in an individual comprising administering an effective amount of a selective PI3K inhibitor.


IT 371243-12-8 371243-13-9 371243-14-0
371243-15-1 371243-17-3 371243-22-0
371243-23-1 474012-90-3 474012-93-6
474012-96-9 474012-98-1 474013-01-9
845527-57-3 845527-58-4 845527-59-5
845527-60-8 845527-61-9 845527-62-0
845527-63-1 845527-64-2 845527-65-3
845527-66-4 845527-67-5 845527-68-6
845527-69-7 845527-70-0 845527-71-1
845527-72-2 845527-73-3 845527-74-4
870282-36-3 870282-37-4 871585-40-9
871585-41-0 871585-42-1 871585-43-2
871585-44-3 871585-45-4 871585-46-5
871585-47-6 871585-48-7 871585-49-8
871585-50-1 871585-51-2 871585-52-3
871585-53-4 871585-54-5 871585-55-6
871585-56-7 871585-57-8 871585-58-9
871585-59-0 871585-60-3 871585-62-5
871585-63-6 871585-64-7 871585-65-8

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

871585-66-9 871585-67-0 871585-68-1
871585-69-2 871585-70-5 871585-71-6
871585-72-7 871585-73-8 871585-74-9
871585-75-0 871585-76-1 871585-77-2
871585-78-3 871585-79-4 871585-80-7
871585-81-8 871585-82-9 871585-83-0
871585-84-1 871585-85-2 871585-86-3
871585-87-4 871585-88-5 871585-89-6
871585-90-9 871585-91-0 871585-92-1
871585-93-2 871585-94-3 871585-95-4
871585-96-5 871585-97-6 871585-98-7
871585-99-8 871586-00-4 871586-01-5
871586-02-6 871586-03-7 871586-04-8
871586-05-9 871586-06-0 871586-07-1
871586-08-2 871586-09-3 871586-10-6
871586-11-7 871586-12-8 871586-13-9
871586-14-0 871586-15-1 871586-16-2
871586-17-3 871586-18-4 871586-19-5
871586-20-8 871586-21-9 871586-22-0
871586-23-1 871586-24-2 871586-25-3
871586-26-4 871586-27-5 871586-28-6
871586-29-7 871586-30-0 871586-31-1 87158
6-32-2 871586-33-3 871586-34-4
871586-35-5 871586-36-6 871586-37-7
871586-38-8 871586-39-9 871586-40-2
871586-41-3 871586-42-4 871586-43-5
871586-44-6 871586-45-7 871586-46-8
871586-47-9


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for treating mast cell disorders)

RN 371243-12-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-13-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 371243-14-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-15-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 371243-17-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-22-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-23-1 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474012-90-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474012-93-6 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 474013-01-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-57-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-58-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

Habe

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474012-96-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474012-98-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-59-5 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-60-8 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




08/08/2006

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 845527-61-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-62-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-63-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-66-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-67-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-68-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-64-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,3-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-65-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-69-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-[(2-diethylamino)ethyl]methylamino]phenyl]-5-methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-70-0 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-fluorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




08/08/2006


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 845527-71-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-72-2 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-chlorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-73-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 871585-40-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 871585-41-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-42-1 CAPLUS
 Habte


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-74-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 870282-36-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]-3-butyryl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871585-43-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871585-44-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-45-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871585-46-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-50-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871585-51-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]-2-(phenylmethoxy)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-52-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[2-(phenylmethoxy)-1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-47-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 871585-48-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-49-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-53-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]-2-(phenylmethoxy)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-54-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-fluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871585-55-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(4-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-56-7 CAPLUS
 CN 4-(3H)-Quinazolinone, 3-(4-fluorophenyl)-2-[(2-fluoro-1H-purin-6-yl)amino]ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 871585-57-8 CAPLUS
 CN 4-(3H)-Quinazolinone, 3-(4-fluorophenyl)-5-methyl-2-[1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871585-58-9 CAPLUS
 CN 4-(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-62-5 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-[(2-hydroxy-1-(1H-purin-6-ylamino)ethyl)-5-methyl-3-phenyl]- (9CI) (CA INDEX NAME)




RN 871585-63-6 CAPLUS
 CN 4-(3H)-Quinazolinone, 5-methyl-3-phenyl-2-(phenyl(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl)- (9CI) (CA INDEX NAME)




RN 871585-64-7 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]phenylmethyl-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-59-0 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871585-60-3 CAPLUS
 CN 4-(3H)-Quinazolinone, 3-(3-fluorophenyl)-5-methyl-2-[1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-65-8 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-[[[(2-fluoro-1H-purin-6-yl)amino]phenylmethyl]-5-methyl-3-phenyl]- (9CI) (CA INDEX NAME)




RN 871585-66-9 CAPLUS
 CN 4-(3H)-Quinazolinone, 5-methyl-3-phenyl-2-(phenyl(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl)- (9CI) (CA INDEX NAME)




RN 871585-67-0 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-68-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-69-2 CAPLUS
 CN Carbamic acid, [5-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)-5-(1H-purin-6-ylamino)pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-73-8 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 871585-74-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[5-amino-1-(1H-purin-6-ylamino)pentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-75-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[5-amino-1-[(2-amino-1H-purin-6-yl)amino]pentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 871585-70-5 CAPLUS
 CN Carbamic acid, [5-[(2-amino-1H-purin-6-yl)amino]-5-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 871585-71-6 CAPLUS
 CN Carbamic acid, [4-[(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)-4-(1H-purin-6-ylamino)butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 871585-72-7 CAPLUS
 CN Carbamic acid, [4-[(2-amino-1H-purin-6-yl)amino]-4-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-76-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-dimethylphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871585-77-2 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(2,6-dimethylphenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




08/08/2006


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 871585-78-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-(4-morpholinylmethyl)-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871585-79-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-(4-morpholinylmethyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-80-7 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[4-amino-1-[(2-amino-1H-purin-6-yl)amino]butyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 871585-84-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 871585-85-2 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-chlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871585-86-3 CAPLUS

Habte


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-81-8 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-6-fluoro-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-82-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[2-(1,1-dimethylethoxy)-1-(1H-purin-6-ylamino)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-83-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-(3-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]-2-hydroxyethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-87-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 871585-88-5 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-89-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-90-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-93-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2,6-dichlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871585-94-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




Hatte

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-91-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-3-(2,6-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871585-92-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3,5-dichlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 871585-95-4 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)



RN 871585-96-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-chloro-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-97-6 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)butyl]- (9CI) (CA INDEX NAME)




RN 871585-98-7 CAPLUS

08/08/2006


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]butyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-99-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3,5-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-00-4 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-[3-(4-morpholinylmethyl)phenyl]-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-03-7 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-2-[1-[(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 871586-04-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(5-fluoro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871586-05-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




Habte


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871586-01-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-[3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 871586-02-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(5-bromo-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ylamino)propyl]- (9CI) (CA INDEX NAME)



RN 871586-07-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-08-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-09-3 CAPLUS

08/08/2006


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4 (3H)-Quinazolinone, 2-[1-[(5-bromo-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-3-(3-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-10-6 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(3-fluorophenyl)-5-methyl-2-[1-[(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 871586-11-7 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 871586-15-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(3-fluorophenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-16-2 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(2,6-difluorophenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871586-12-8 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 871586-13-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 6,7-difluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-14-0 CAPLUS


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871586-17-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-phenyl-2-[3,3,3-trifluoro-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 871586-18-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(3-hydroxyphenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-19-5 CAPLUS

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 3-(3-methoxyphenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 871586-20-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-[2-(dimethylamino)ethoxy]phenyl]-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-21-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[3-(cyclopropylmethoxy)phenyl]-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 871586-24-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-25-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-[3-(cyclopropylmethoxy)phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-26-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-[3-(2-propynyloxy)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871586-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-[3-(2-propynyloxy)phenyl]-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-hydroxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871586-27-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-ethynylphenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-28-6 CAPLUS
 CN Benzonitrile, 3-[5-methyl-4-oxo-2-[1-(1H-purin-6-ylamino)ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 871586-29-7 CAPLUS
 CN Benzamide, 3-[5-methyl-4-oxo-2-[1-(1H-purin-6-ylamino)ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871586-30-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[(3-acetylphenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-31-1 CAPLUS
 CN Acetamide, 2-[3-[5-methyl-4-oxo-2-[1-(1H-purin-6-ylamino)ethyl]-3(4H)-quinazolinyl]phenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871586-34-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[(3-methoxy-2-[1-(1H-purin-6-ylamino)ethyl]-3-(4H)-quinazolinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 871586-35-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[(3-(2-methoxyethoxy)phenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-36-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-ethynylphenyl)-5-methyl- (9CI) (CA INDEX NAME)

Habe

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871586-32-2 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]-3-[3-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 871586-33-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[3-(2-methoxyethoxy)phenyl]-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871586-37-7 CAPLUS
 CN Benzonitrile, 3-[2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 871586-38-8 CAPLUS
 CN Benzonitrile, 3-[2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871586-39-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-[3-(4-morpholinyl)phenyl]-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-40-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-((2-amino-1H-purin-6-yl)amino)ethyl]-5-methyl-3-[3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 871586-43-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-((2-amino-1H-purin-6-yl)amino)propyl]-5-chloro-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 871586-44-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-((2-amino-1H-purin-6-yl)amino)ethyl]-5-chloro-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 871586-45-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-6-fluoro-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871586-41-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-((2-amino-1H-purin-6-yl)amino)ethyl]-3-[3-(2-methoxyethoxy)phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-42-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-((2-amino-1H-purin-6-yl)amino)ethyl]-3-[3-(2-dimethoxyethoxy)phenyl]-5-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871586-46-8 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2,6-difluorophenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)



RN 871586-47-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-((2-amino-1H-purin-6-yl)amino)propyl]-5-chloro-3-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1313884 CAPLUS
DOCUMENT NUMBER: 144:32213
TITLE: Methods using phosphoinositide 3-kinase δ inhibitors for treating and/or preventing aberrant proliferation of hematopoietic cells
INVENTOR(S): Hayflick, Joel S.; Bouscary, Didier; Lacombe, Catherine; Mayeux, Patrick
PATENT ASSIGNEE(S): Icos Corporation, USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117889	A1	20051215	WO 2004-US37860	20041112
W: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, XG, KZ, MD, RU, TJ, TH, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006106038	A1	20060518	US 2005-137901	20050525
PRIORITY APPLN. INFO.:			US 2004-574481P	P 20040525
			US 2004-578683P	P 20040609

OTHER SOURCE(S): MARPAT 144:32213
AB The invention discloses methods for treating and/or preventing aberrant proliferation of hematopoietic cells. More particularly, the invention discloses methods for treating and/or preventing aberrant proliferation of hematopoietic cells comprising selectively inhibiting phosphoinositide 3-kinase δ (PI3K δ) activity in hematopoietic cells. The methods may be used to treat any indication involving aberrant proliferation of hematopoietic cells.
IT 371243-12-8 371243-13-9 371243-14-0
371243-15-1 371243-17-3 371243-22-0
371243-23-1 474012-90-3 474012-93-6
474012-96-9 474012-98-1 474013-01-9
845527-52-8 845527-58-4 845527-59-5
845527-60-8 845527-61-9 845527-62-0
845527-63-1 845527-64-2 845527-65-3
845527-66-4 845527-67-5 845527-68-6
845527-69-7 845527-70-0 845527-71-1
845527-72-2 845527-73-3 845527-74-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphoinositide 3-kinase δ inhibitors for treating and/or preventing aberrant proliferation of hematopoietic cells)
RN 371243-12-8 CAPLUS

L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 4(3H)-Quinazolinone, 5-methyl-3-((2-methylphenyl)-2-((1H-purin-6-ylamino)methyl))- (9CI) (CA INDEX NAME)




RN 371243-13-9 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-((2-chlorophenyl)-5-fluoro-2-((1H-purin-6-ylamino)methyl))- (9CI) (CA INDEX NAME)




RN 371243-14-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-(((2-amino-1H-purin-6-yl)amino)methyl)-5-methyl-3-((2-methylphenyl))- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-15-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-(((2-amino-1H-purin-6-yl)amino)methyl)-3-((2-chlorophenyl))-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-(((2-fluoro-1H-purin-6-yl)amino)methyl)-5-methyl-3-((2-methylphenyl))- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 371243-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 474012-98-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474013-01-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-52-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474012-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 474012-96-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-58-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-59-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-60-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-61-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-62-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-65-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-66-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-67-5 CAPLUS

Habte

L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-63-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-64-2 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(2,3-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4 (3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-68-6 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 845527-69-7 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-[2-[(2-(diethylamino)ethyl)methylamino]phenyl]-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-70-0 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-fluorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-71-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-74-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-72-2 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-chlorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-73-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2005:1262655 CAPLUS
 DOCUMENT NUMBER: 144:612
 TITLE: Phosphoinositide 3-kinase δ selective inhibitors for inhibiting angiogenesis
 INVENTOR(S): Hallahan, Dennis; Hayflick, Joel S.; Sadhu, Chanchal
 PATENT ASSIGNEE(S): Vanderbilt University, USA; Icos Corporation
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005112935	A1	20051201	WO 2004-US29561	20040909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, D2, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006079538	A1	20060413	US 2005-129006	20050512
PRIORITY APPLN. INFO.: US 2004-570688P P 20040513 OTHER SOURCE(S): MARPAT 144:612				
AB The invention discloses methods for inhibiting angiogenesis. The methods comprise selectively inhibiting phosphoinositide 3-kinase delta (PI3K δ) activity in endothelial cells. The methods may comprise administration of one or more cytotoxic therapies including but not limited to radiation, chemotherapeutic agents, photodynamic therapies, radiofrequency ablation, anti-angiogenic agents, and combinations thereof. Inhibitors of the invention include quinazolin-4-one derivs.				
IT 371243-12-8 371243-13-9 371243-14-0 371243-15-1 371243-17-3 371243-22-0 371243-23-1 474012-90-3 474012-93-6 474012-96-9 474012-98-1 474013-01-9 845527-52-8 845527-53-9 845527-54-0 845527-57-3 845527-58-4 845527-59-5 845527-60-8 845527-61-9 845527-62-0 845527-63-1 845527-64-2 845527-65-3 845527-66-4 845527-67-5 845527-68-6 845527-69-7 845527-70-0 845527-71-1 845527-72-2 845527-73-3 845527-74-4 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (phosphoinositide 3-kinase δ inhibitors for angiogenesis inhibition)				
RN 371243-12-8 CAPLUS CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)				

L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-13-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-14-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-15-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 371243-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 474012-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 474012-96-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




08/08/2006


L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 474012-98-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474013-01-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-52-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-58-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-59-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-53-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-dichlorophenyl)-5-methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-54-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-fluorophenyl)-2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 845527-60-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-61-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-62-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-63-1 CAPLUS
CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-64-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2,3-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-67-5 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-68-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[(2-amino-1H-purin-6-yl)amino]methyl]-3-(3,5-difluorophenyl)-5-methyl]- (9CI) (CA INDEX NAME)




RN 845527-69-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-[[2-(diethylamino)ethyl]methylamino]phenyl]-5-Habte

L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-65-3 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-66-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-70-0 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(2-fluorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-71-1 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-72-2 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-chlorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)



RN 845527-73-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 20051259353 CAPLUS
 DOCUMENT NUMBER: 144:22759
 TITLE: Preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
 INVENTOR(S): Fowler, Kerry W.; Huang, Danwen; Kesicki, Edward A.; Ooi, Hua Chee; Oliver, Amy R.; Ruan, Fuqiang; Treiberg, Jennifer
 PATENT ASSIGNEE(S): Icos Corporation, USA
 SOURCE: PCT Int. Appl., 247 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113556	A1	20051201	WO 2005-US16778	20050512
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2005113554	A2	20051201	WO 2005-US16661	20050512
WO 2005113554	A3	20060406		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2004-570784P P 20040513
 OTHER SOURCE(S): MARPAT 144:22759
 G1

L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 845527-74-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Quinazolinone derivs. of formula I [X, Y = N, (substituted) CH; Z = NH, O; R1-R3 = H, halo, alkyl; R4 = H, halo, OH, alkoxy, CN, acyl, etc.; R5 = alkyl, Ph, CH2C.tpbond.CH, etc.; R6 = H, halo, (substituted) NH2; R7 = alkyl, halo, CF3, etc.; ZR5 = alkylene] are prepared that inhibit PI3K activity. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compds. also are disclosed. Thus, II was prepared, and had EC50 value of 1.6 nM in human B lymphocyte assay.
 IT 870280-98-1P 870281-20-2P 870281-21-3P 870281-23-5P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase δ)
 RN 870280-98-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1R)-2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-20-2 CAPLUS
 CN Carbanic acid, [(5S)-5-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)-5-(1H-purin-6-ylamino)pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 870281-21-3 CAPLUS
CN Carbanic acid, [(5S)-5-[(2-amino-1H-purin-6-yl)amino]-5-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)pentyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 870281-23-5 CAPLUS
CN Carbanic acid, [(4S)-4-[(2-amino-1H-purin-6-yl)amino]-4-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)butyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

870282-26-1P 870282-27-2P 870282-29-4P
870282-30-7P 870282-31-8P 870282-32-9P
870282-36-3P 870282-37-4P 870282-42-1P
870282-43-2P 870282-44-3P 870282-45-4P
870282-46-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase 5)


RN 870280-85-6 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870280-88-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870280-89-0 CAPLUS

Habte

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 870280-85-6P 870280-88-9P 870280-89-0P
870280-90-3P 870280-91-4P 870280-92-5P
870280-93-6P 870280-94-7P 870280-95-8P
870280-96-9P 870280-97-0P 870280-99-2P
870281-01-9P 870281-02-0P 870281-03-1P
870281-04-2P 870281-05-3P 870281-06-4P
870281-07-5P 870281-08-6P 870281-09-7P
870281-10-0P 870281-12-2P 870281-13-3P
870281-14-4P 870281-15-5P 870281-16-6P
870281-17-7P 870281-18-8P 870281-19-9P
870281-22-4P 870281-24-6P 870281-25-7P
870281-26-8P 870281-27-9P 870281-28-0P
870281-30-4P 870281-31-5P 870281-32-6P
870281-34-8P 870281-36-0P 870281-38-2P
870281-40-6P 870281-42-8P 870281-43-9P
870281-44-0P 870281-45-1P 870281-46-2P
870281-47-3P 870281-48-4P 870281-49-5P
870281-50-8P 870281-51-9P 870281-52-0P
870281-53-1P 870281-54-2P 870281-55-3P
870281-56-4P 870281-57-5P 870281-58-6P
870281-59-7P 870281-61-1P 870281-62-2P
870281-63-3P 870281-64-4P 870281-65-5P
870281-66-6P 870281-67-7P 870281-68-8P
870281-69-9P 870281-70-2P 870281-71-3P
870281-72-4P 870281-73-5P 870281-74-6P
870281-75-7P 870281-76-8P 870281-77-9P
870281-78-0P 870281-79-1P 870281-82-6P
870281-88-2P 870281-89-3P 870281-90-6P
870281-91-7P 870281-92-8P 870281-93-9P
870281-94-0P 870282-00-1P 870282-01-2P
870282-02-3P 870282-03-4P 870282-04-5P
870282-06-7P 870282-07-8P 870282-08-9P
870282-09-0P 870282-12-5P 870282-14-7P
870282-16-9P 870282-17-0P 870282-18-1P
870282-19-2P 870282-20-5P 870282-22-7P
870282-23-8P 870282-24-9P 870282-25-0P

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870280-90-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870280-91-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-2-[(1S)-1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870280-92-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[(1S)-1-((1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870280-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870280-96-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1S)-1-((1H-purin-6-ylamino)ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870280-97-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870280-94-7 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1S)-1-((1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)propyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870280-95-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870280-99-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1R)-1-[(2-amino-1H-purin-6-yl)amino]-2-(phenylmethoxy)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-01-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1R)-2-(phenylmethoxy)-1-((1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-02-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1R)-1-[(2-fluoro-1H-purin-6-yl)amino]-2-(phenylmethoxy)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-03-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-fluorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-06-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-fluorophenyl)-5-methyl-2-[(1S)-1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-07-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1S)-1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-04-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(4-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-05-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-fluorophenyl)-5-methyl-2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-08-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-fluorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-09-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-10-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-fluorophenyl)-5-methyl-2-[(1S)-1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-12-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1R)-2-hydroxy-1-(1H-purin-6-ylamino)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-15-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2S)-[(2-fluoro-1H-purin-6-yl)amino]phenylmethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-16-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1S)-phenyl(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-13-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(S)-phenyl(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-14-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(S)-[(2-amino-1H-purin-6-yl)amino]phenylmethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-17-7 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-18-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-19-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-22-4 CAPLUS
 CN Carbamic acid, [(4S)-4-[(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)-4-(1H-purin-6-ylamino)butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-24-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-25-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-5-amino-1-(1H-purin-6-ylamino)pentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-26-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-5-amino-1-[(2-amino-1H-purin-6-yl)amino]pentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-27-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-dimethylphenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-28-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-dimethylphenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-30-4 CAPLUS
 CN 4(3H)-Quinazolinone, 5-(4-morpholinylmethyl)-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-31-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-(4-morpholinylmethyl)-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-32-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-4-amino-1-[(2-amino-1H-purin-6-yl)amino]butyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-38-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1R)-2-(1,1-dimethylethoxy)-1-(1H-purin-6-ylamino)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-40-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(3-methylphenyl)-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-34-8 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-36-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-6-fluoro-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-42-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-43-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-44-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-chlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-45-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1R)-1-[(2-amino-1H-purin-6-yl)amino]-2-hydroxyethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-46-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-47-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-48-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-49-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(3-fluorophenyl)-2-[(1S)-1-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-50-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-51-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[(1S)-1-[(1H-purin-6-ylamino)ethyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-52-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-53-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-3-(2,6-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-54-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-dichlorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-55-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-dichlorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-56-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-57-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-58-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-chloro-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-59-7 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-61-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]butyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-62-2 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3,5-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-65-5 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(1S)-1-[(5-bromo-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-66-6 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-2-[(1S)-1-[(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-63-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-[3-(4-morpholinylmethyl)phenyl]-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-64-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-[3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-67-7 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(1S)-1-[(5-fluoro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-68-8 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(1R)-2-hydroxy-1-(1H-purin-6-ylamino)ethyl]-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-69-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-70-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-73-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-fluorophenyl)-5-methyl-2-[(1S)-1-[(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-74-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-71-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-72-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(5-bromo-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-3-(3-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-75-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-76-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-77-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6,7-difluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-78-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-88-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-89-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-2-[(1S)-1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-79-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-4-(diethylamino)-1-(1H-purin-6-ylamino)butyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-82-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-90-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-fluorophenyl)-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-91-7 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-92-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-93-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1S)-3,3,3-trifluoro-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-94-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-hydroxyphenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-00-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-methoxyphenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-01-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[3-(2-(dimethylamino)ethoxy)phenyl]-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-02-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[3-(cyclopropylmethoxy)phenyl]-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-03-4 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-[3-(2-propynyloxy)phenyl]-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-04-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-hydroxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-06-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-07-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-[3-(cyclopropylmethoxy)phenyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-08-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-[3-(2-propynyloxy)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-09-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-ethynylphenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-12-5 CAPLUS
 CN Benzonitrile, 3-[5-methyl-4-oxo-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-14-7 CAPLUS
 CN Benzanide, 3-[5-methyl-4-oxo-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-16-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-acetylphenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-17-0 CAPLUS
 CN Acetamide, 2-[3-[5-methyl-4-oxo-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]-3(4H)-quinazolinyl]phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-18-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-2-[(1S)-1-[(1H-purin-6-ylamino)ethyl]-3-[3-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-19-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[3-(2-methoxyethoxy)phenyl]-5-methyl-2-[(1S)-1-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-20-5 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-2-[(1S)-1-[(1H-purin-6-ylamino)ethyl]-3-[3-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-22-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[3-(dimethylamino)propoxy]phenyl]-5-methyl-2-[(1S)-1-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-23-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-[3-(3-ethynylphenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-24-9 CAPLUS
 CN Benzonitrile, 3-[2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-25-0 CAPLUS
 CN Benzamide, 3-[2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-26-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-acetylphenyl)-2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-27-2 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-[3-(4-morpholinyl)phenyl]-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 870282-29-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-[3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-32-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)-3-butynyl]- (9CI) (CA INDEX NAME)




RN 870282-36-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]-3-butynyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 870282-37-4 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-30-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-[3-(2-methoxyethoxy)phenyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-31-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-[3-(2-dimethylaminoethoxy)phenyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-42-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-chloro-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-43-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


08/08/2006

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-44-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-6-fluoro-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-45-4 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2,6-difluorophenyl)-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-55-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1R)-2-(1,1-dimethylethoxy)-1-(1H-purin-6-ylamino)ethyl]-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 870281-98-4P 870281-99-5P 870282-05-6P
 870282-10-3P 870282-11-4P 870282-13-6P
 870282-15-8P 870282-28-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase 5)
 RN 870281-98-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-hydroxyphenyl)-5-methyl-2-[(1S)-1-[[2-(trimethylsilyl)ethoxy]methyl]-9H-purin-6-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-46-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-chloro-3-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 870282-21-6 870282-55-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase 5)
 RN 870282-21-6 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-(3-hydroxyphenyl)-2-[(1S)-1-[[2-(trimethylsilyl)ethoxy]methyl]-9H-purin-6-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-99-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-methoxyphenyl)-5-methyl-2-[(1S)-1-[[2-(trimethylsilyl)ethoxy]methyl]-9H-purin-6-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-05-6 CAPLUS
 CN Imidodicarbonic acid, [6-[[[(1S)-1-[3,4-dihydro-3-(3-hydroxyphenyl)-5-methyl-4-oxo-2-quinazolinyl]ethyl]amino]-9-[[2-(trimethylsilyl)ethoxy]methyl]-9H-purin-2-yl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-10-3 CAPLUS

CN Methanesulfonic acid, trifluoro-, 3-[5-methyl-4-oxo-2-[(1S)-1-[[9-[[2-(trimethylsilyl)ethoxy]methyl]-9H-purin-6-yl]amino]ethyl]-3(4H)-quinazolinyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-11-4 CAPLUS

CN 4(3H)-Quinazolinone, 5-methyl-2-[(1S)-1-[[9-[[2-(trimethylsilyl)ethoxy]methyl]-9H-purin-6-yl]amino]ethyl]-3-[[2-(trimethylsilyl)ethynyl]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 870282-28-3 CAPLUS

CN 4(3H)-Quinazolinone, 5-methyl-3-[3-(4-morpholinyl)phenyl]-2-[(1S)-1-[[9-[[2-(trimethylsilyl)ethoxy]methyl]-9H-purin-6-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.

RN 870282-13-6 CAPLUS

CN Benzonitrile, 3-[5-methyl-4-oxo-2-[(1S)-1-[[9-[[2-(trimethylsilyl)ethoxy]methyl]-9H-purin-6-yl]amino]ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870282-15-8 CAPLUS

CN Benzamide, 3-[5-methyl-4-oxo-2-[(1S)-1-[[9-[[2-(trimethylsilyl)ethoxy]methyl]-9H-purin-6-yl]amino]ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1124613 CAPLUS

DOCUMENT NUMBER: 144:22885

TITLE: Synthesis and microbiological evaluation of N'-3-(4-(4-chlorophenyl)thiazol-2-yl)quinazolin-4(3H)-ones

AUTHOR(S): Pattan, S. R.; Reddy, V. V. K.; Pattan, J. S.; Venkataramana, N. V.; Prajapati, P. N.; Bhat, A. R.; Hemashettar, B. M.

CORPORATE SOURCE: Dept. of Medicinal Chemistry, K.L.E.S's College of Pharmacy, Belgaum, 590 010, India

SOURCE: Indian Journal of Heterocyclic Chemistry (2005), 15(1), 79-80

CODEN: IJCHEI; ISSN: 0971-1627

PUBLISHER: Prof. R. S. Varma

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:22885

AB N'-3-(4-(4-Chlorophenyl)thiazol-2-yl)-2-aminomethylquinazolin-4(3H)-ones were synthesized. The prepared compds. were screened for the antimicrobial activity. Some of them showed promising antifungal and antibacterial activity.

IT 870539-32-5P 870539-33-6P 870539-34-7P

870539-35-8P 870539-36-9P 870539-37-0P

870539-39-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL

(Biological study); PREP (Preparation)


(preparation and microbiol. evaluation of

(chlorophenyl)thiazolylquinazolin-

4(3H)-ones)

RN 870539-32-5 CAPLUS


CN 4(3H)-Quinazolinone, 2-[[4-(4-chlorophenyl)amino]methyl]-3-[4-(4-chlorophenyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870539-33-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[4-(4-chlorophenyl)-2-thiazolyl]-2-[[4-(4-fluorophenyl)amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870539-34-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)-2-thiazolyl]-2-[[4-(4-nitrophenyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 870539-35-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)-2-thiazolyl]-2-[[4-(4-methoxyphenyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 870539-36-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)-2-thiazolyl]-2-[[4-(4-methoxyphenyl)amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870539-37-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)-2-thiazolyl]-2-[[4-(4-pyridinylamino)amino]methyl]- (9CI) (CA INDEX NAME)



RN 870539-39-2 CAPLUS
 CN Benzoic acid, 4-[[[3-[[4-(4-chlorophenyl)-2-thiazolyl]-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:960102 CAPLUS
 DOCUMENT NUMBER: 143:248418
 TITLE: Preparation of heterocycle-substituted acetic acid esters or acetanilides
 INVENTOR(S): Sugino, Motoaki; Iwamoto, Ryohei; Katakura, Toshie; Sugita, Shuichi
 PATENT ASSIGNEE(S): Konica Minolta Photo Imaging, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp. CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005232041	A2	20050902	JP 2004-41049	20040218
PRIORITY APPLN. INFO.:			JP 2004-41049	20040218
OTHER SOURCE(S):				
GI				




AB The esters or acetanilides I (A = OR₁, NHAr; R₂ = alkyl, aryl, heterocyclyl; Q₁ = 5-7-membered ring-forming nonmetallic atom, group; R₁ = alkyl, aryl; Ar = aryl; L₁ = H, substituent), useful as intermediates for yellow photog. couplers, etc., are prepared by reacting I (R₂ = H; A, Q₁, R₁, L₁ = same as above) with R₂X (R₂ = alkyl, aryl, heterocyclyl; X = halo, OSO₂R₃; R₃ = alkyl, aryl). Thus, BuI was added dropwise to a mixture of MeCN, benzopyrimidinylacetate II (R₂ = H), and Et₃N, previously stirred at 40° for 1 h, over 1 h and the reaction mixture was further refluxed for 4 h to give 93% II (R₂ = Bu).

IT 863318-29-0P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of heterocycle-substituted acetate esters or acetanilides by introducing alkyl, aryl, or heterocyclyl to N with halides or sulfonates)

Habe

L4 ANSWER 8 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 863318-29-0 CAPLUS
 CN Benzoic acid, 4-chloro-3-[[[3,4-dihydro-4-oxo-3-(2-pyridinyl)-2-quinazolinyl]-1H-imidazol-1-ylacetyl]amino]-, dodecyl ester (9CI) (CA INDEX NAME)



08/08/2006

L4 ANSWER 9 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:822709 CAPLUS

DOCUMENT NUMBER: 143:238608

TITLE: Silver halide color photographic material and area gradation image-forming method

INVENTOR(S): Tanaka, Shigeo; Ishidai, Hiroshi

PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.

SOURCE: Jpn. Kokai Tokkyo Koho, 97 pp.

CODEN: JPOKAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005221902	A2	20050818	JP 2004-31458	20040209
PRIORITY APPLN. INFO.:			JP 2004-31458	20040209
OTHER SOURCE(S):	MARPAT	143:238608		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed is a Ag halide color photog. material which comprises on a support 21 yellow coupler-containing Ag halide emulsion layer, 21 magenta coupler-containing Ag halide emulsion layer, and 21 cyan coupler-containing Ag halide emulsion layer and has a AgCl content 295 mol% in the all Ag halide emulsion layers, wherein the yellow, magenta, and cyan couplers are represented by I (B, R = substituent; Z = atomic group forming 6-7-membered ring; and A = leaving group), II (R11,12 = substituent; Y1 = leaving group), and III (R1 = H, substituent; R2 = substituent; m = integer; Z = nonmetallic atomic group forming N-containing 5-membered ring; and X1 = leaving group), resp. Further, 21 of said Ag halide emulsion contains a metal complex having Group V-X element central metal and nitroso or thionitrosyl ligand and a sp. inorg. S compound, and is sensitized by Au chalcogenide. Also disclosed is a process using a developer comprising an aromatic primary amine compound, a hydroxylamine derivative, and a compound represented by IV (R11,12 = H, substituent; R13,14 = H, alkyl, etc.; R15,16 = substituent; Rw = substituent; and M = H, alkali metal, alkali earth metal, etc.).


IT 840524-02-9

RL: NUU (Other use, unclassified); USES (Uses)
(silver halide color photog. material and area gradation image-forming method)

RN 840524-02-9 CAPLUS

CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 10 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:673090 CAPLUS

DOCUMENT NUMBER: 143:166655

TITLE: Phosphoinositide 3-kinase ̢-selective inhibitors

INVENTOR(S): Watta, Stephanie W.; Northcott, Carrie A.

PATENT ASSIGNEE(S): Michigan State University, USA

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PEXKX2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005067901	A2	20050728	WO 2005-US677	20050107
WO 2005067901	A3	20051201		
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, BF, CG, CI, CM, GN, GQ, GW, HL, HR, NE, SN, TD, TG			
US 2005239809	A1	20051027	US 2005-31477	20050107
PRIORITY APPLN. INFO.:			US 2004-535412P	P 20040108
			US 2004-547107P	P 20040224
			US 2004-548620P	P 20040227

OTHER SOURCE(S): MARPAT 143:166655

GI



AB The present invention is based on the discovery that the ̢ isoform of phosphoinositide 3-kinase (PI-3-K) plays a role in arterial spontaneous tone, and specifically the p110̢ subunit in the mesenteric resistance arteries. The data emphasize the critical importance of the

Habe

L4 ANSWER 10 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

p110̢ subunit of PI-3-K to the development of hypertension and hypertension-related conditions by showing that it is localized to the vascular smooth muscle cells, up-regulated in both activity and expression, and pharmacol. responsive to specific inhibitors as evidence by changes in spontaneous tone. Thus, compds. that selectively inhibit phosphoinositide 3-kinase (PI-3-K) p110̢ expression activity can be used to treat hypertension and hypertension-related disorders. Inhibitors of expression include ribozymes, antisense oligonucleotides, and siRNA, while inhibitors of activity may include aptamers and small mols. In particular, 2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (I) is provided as a selective PI-3-K̢ inhibitor for the treatment of hypertension.

IT 371243-12-8 371243-13-9 371243-14-0

371243-15-1 371243-17-3 371243-22-0

371243-23-1 474012-90-3 474012-93-6

474012-96-9 474012-98-1 474013-01-9


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phosphoinositide 3-kinase ̢-selective inhibitors for treating

and preventing hypertension and hypertension-related disorders)

RN 371243-12-9 CAPLUS

CN 4(3H)-Quinazolinone, 5-methyl-3-[(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-13-9 CAPLUS


CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 10 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-14-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-amino-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)]- (9CI) (CA INDEX NAME)




RN 371243-15-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-amino-1H-purin-6-yl)amino]methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)]- (9CI) (CA INDEX NAME)




RN 371243-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)]- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 474012-96-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-98-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



08/08/2006


L4 ANSWER 10 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 474013-01-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:302468 CAPLUS
 DOCUMENT NUMBER: 142:382086
 TITLE: Silver halide photographic paper showing improved color reproducibility, storage stability, color fading balance, and fast processability
 INVENTOR(S): Sugita, Shuichi; Sugino, Motoaki; Iwamoto, Ryohei
 PATENT ASSIGNEE(S): Konica Minolta Photo Imaging, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 92 pp.
 CODEN: JKXKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005091679	A2	20050407	JP 2003-324246	20030917
PRIORITY APPLN. INFO.:			JP 2003-324246	20030917
OTHER SOURCE(S):		MARPAT 142:382086		

 GI




AB The title photog. paper comprises at least a red-sensitive Ag halide emulsion layer, a green-sensitive Ag halide emulsion layer, and a red-sensitive Ag halide emulsion layer on a support, wherein the blue-sensitive Ag halide emulsion layer contains a yellow coupler represented by I (R1 = substituent; X1 = aryl, heterocyclyl; Z1 = atoms for forming 6-membered ring) and the green-sensitive Ag halide emulsion layer contains a magenta coupler represented by II (Y11 = H, halo, alkyl, aryl, cycloalkyl, heterocyclyl, alkoxy, aryloxy; R11, R13 = substituent; L11 = -NR14-, -O-, R12, R14 = alkyl, cycloalkyl, alkenyl, heterocyclyl, aryl; m11 = 1, 2; n11 = 0-4; X11 = H, group capable of leaving upon reaction with color development agent oxide). The photog. paper may contain the above yellow coupler in the red-sensitive Ag halide emulsion layer and a specified cyan coupler in the red-sensitive Ag halide layer. The above coupler combinations improved the color reproduction as well as the

L4 ANSWER 11 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 other photog. properties.
 IT 468730-13-4 849336-68-1
 RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
 (yellow coupler in red-sensitive Ag halide emulsion layer of photog. paper showing improved color reproducibility, storage stability, color fading balance, and fast processability)
 RN 468730-13-4 CAPLUS
 CN Benzoic acid, 3-[[3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl] (5,5-dimethyl-2,4-dioxo-3-oxazolidinyl)acetyl]amino]-4-methoxy-, tetradecyl ester (9CI) (CA INDEX NAME)




RN 849336-68-1 CAPLUS
 CN 2-Quinazolineacetamide, N-[2-chloro-5-[(dioctylamino)sulfonyl]phenyl]-3,4-dihydro-4-oxo-3-phenyl-1H-1,2,4-triazol-1-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:302464 CAPLUS
 DOCUMENT NUMBER: 142:382083
 TITLE: Silver halide photographic paper containing specific surfactant and specific photographic yellow coupler
 INVENTOR(S): Nakamura, Takeshi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 53 pp.
 CODEN: JKXKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005091649	A2	20050407	JP 2003-323808	20030917
PRIORITY APPLN. INFO.:			JP 2003-323808	20030917
OTHER SOURCE(S):		MARPAT 142:382083		

 GI



AB The title film has light-sensitive layers containing photog. emulsions on a support, wherein surfactant R-(CF2)m-CH2CH2-Y-L1-COOX (R = H, F; m = integer 3-16; Y = S, SO2, SO, O; L1 = 2-valent C23 compound; X = H, cation) and wherein yellow coupler I (R = substituent; Z = 6- or 7-membered ring residue; R' = substituent; n = integer 0-4; X = H, hydrogen; A = H, leaving group). The photog. paper shows good storageability and provides images of good storageability.
 IT 840524-02-9
 RL: TEM (Technical or engineered material use); USES (Uses)
 (yellow coupler in silver halide photog. paper)
 RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 13 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:286870 CAPLUS
DOCUMENT NUMBER: 143:26556

TITLE: Synthetic studies on 3-arylquinazolin-4-ones: intramolecular nucleophilic aromatic substitution reaction of 2-carboxamido-3-arylquinazolin-4-ones and its application to the synthesis of secondary aryl amines

AUTHOR(S): Fuwa, Haruhiko; Kobayashi, Toshitake; Tokitoh, Takashi; Torii, Yukiko; Natsugari, Hideaki
CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan
SOURCE: Tetrahedron (2005), 61(17), 4297-4312
CODEN: TETRAH; ISSN: 0040-4020


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:26556


GI




AB 2-Carboxamido-3-arylquinazolin-4-ones were prepared via acylation of aromatic amines, cyclodehydration, transesterification, and amidation. A novel intramolecular nucleophilic aromatic substitution (SNAr) reaction of 2-carboxamido-3-arylquinazolin-4-ones, a potentially useful scaffold in the field of medicinal chemical, is described. E.g., treatment of 2-carboxamido-3-arylquinazolin-4-ones I (X = 4- CF_3 , 4- CO_2Me , 4-CN, etc.; R = CH_2Ph , Ph, Bu) with NaH in DMF gave migrated products II. The synthetic utility of the SNAr reaction as a tool for the synthesis of secondary aryl amines, including diaryl amines, is also demonstrated. Thus, reaction of the 2-ethoxycarbonyl-3-arylquinazolin-4-ones and primary amines in the presence of a base induced a cascade process comprised of amide formation, intramolecular SNAr reaction, and cleavage of the resultant tertiary amide to yield (in one-pot) secondary aryl amines.

IT 830324-73-7P 830324-74-8P 830324-75-9P
830324-83-9P 830324-87-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intramolecular nucleophilic aromatic substitution (SNAr) reaction of 2-carboxamido-3-arylquinazolin-4-ones)
RN 830324-73-7 CAPLUS
CN 2-Quinazolinecarboxamide, 3-(2-chloro-3-pyridinyl)-3,4-dihydro-4-oxo-N-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 830324-74-8 CAPLUS
CN 2-Quinazolinecarboxamide, 3-(2-chloro-3-pyridinyl)-3,4-dihydro-N-(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 830324-75-9 CAPLUS
CN 2-Quinazolinecarboxamide, 3-(2-chloro-3-pyridinyl)-3,4-dihydro-4-oxo-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)



RN 830324-83-9 CAPLUS
CN 2-Quinazolinecarboxamide, 3,4-dihydro-4-oxo-N-phenyl-3-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




Habe

L4 ANSWER 13 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 830324-87-3 CAPLUS

CN Benzoic acid, 2-[4-oxo-2-[(phenylamino)carbonyl]-3(4H)-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


08/08/2006

L4 ANSWER 14 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:281059 CAPLUS
 DOCUMENT NUMBER: 142:345089
 TITLE: Color photographic films showing fine color reproduction and excellent light resistance
 INVENTOR(S): Iwamoto, Ryohei; Sugino, Motoaki; Sugita, Shuichi
 PATENT ASSIGNEE(S): Konica Minolta Photo Imaging, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 116 pp.
 CODEN: JKOXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005084074	A2	20050331	JP 2003-312415	20030904
PRIORITY APPL. INFO.			JP 2003-312415	20030904
OTHER SOURCE(S):		MARPAT 142:345089		


GI



AB The films have blue-, green-, and red-sensitive emulsion layers on supports and contain yellow couplers I (R = substituent; X = aryl, heterocycle; Z = 6-membered azacycle; L = H or group leaving upon reaction with oxidized developers) and 21 of HOC6H3-n1 (o'-R11)R12n1 (R10, R11 = alkyl; R12 = alkyl, NHR13, SR13 (R13 = monovalent organic group)).
 CO2R14 (R14 = H, monovalent organic group; n1 = 0-3), II (R21 = H, OH, oxy radical, SO2R27, SO2R27 (R27 = alkyl, aryl), alk(en)yl, alkynyl, COR28 (R28 = H, monovalent organic group); R22-R24 = alkyl; R25, R26 = H, OCOR29 (R29 = monovalent organic group); n2 = 0-4), C6OR31R32R33R34R35R36 (R31 = alkyl, trialkylsilyl; R32-R36 = H, alkyl(oxy), etc.), C6(OH)R41R42R43R44 (R41-R44 = H, alkyl(oxy), etc.), III (R53 = aryl, heterocycle; Z54, Z55 = Cl-3 alkylene satisfying total C number 3-6; n5 = 1, 2), or prescribed high-b.p. solvents (Markushes given) in one or more of the blue-sensitive layers.
 IT 848650-81-7
 RL: TEM (Technical or engineered material use); USES (Uses)
 (blue-sensitive emulsion layers; color photog. films containing sp. yellow

L4 ANSWER 14 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

couplers and dye fixers and showing good color reprod. and lightfastness)
 RN 848650-81-7 CAPLUS
 CN 2-Quinazolineacetamide, N-[5-[[2-(2,5-bis(1,1-dimethylpropyl)phenoxy)-1-oxohexyl]amino]-2-methoxyphenyl]-6,8-dichloro-a-[2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:258905 CAPLUS
 DOCUMENT NUMBER: 142:345078
 TITLE: Silver halide color photographic material showing excellent pressure-resistance, sticking-resistance, and color fading-resistance for color proof application
 INVENTOR(S): Nakamura, Takeshi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 70 pp.
 CODEN: JKOXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005077961	A2	20050324	JP 2003-310811	20030903
PRIORITY APPL. INFO.			JP 2003-310811	20030903
OTHER SOURCE(S):		MARPAT 142:345078		

GI



AB The title color photog. material contains a surface active agent represented by I [R1, R2 = alkyl; R3-5 = H, substituent; X1, X2 = connection group, single bond; M+ = cationic group; Y- = anion; m = 0, 1] or R(CF2)mCH2CH2YLn+ (R1) (R2) (R3).X- [R = H, F; m = 3-16; Y = S, SO2, SO, O; L = divalent group having 24 carbons; R1-3 = H, alkyl; X- = anion] and a yellow coupler represented by II [R = substituent; Z = atoms for forming N-containing 6- or 7-membered ring; R' = substituent; n = 0-4;
 X = H, substituent; A = H, group capable of leaving upon coupling with oxidized color development agent] in a photog. emulsion layer.
 IT 848408-90-2
 RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
 (yellow coupler in silver halide color photog. material showing excellent pressure-resistance, sticking-resistance, and color fading-resistance for color proof application)
 RN 848408-90-2 CAPLUS
 CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-[4-(dodecylloxy)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 16 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:235530 CAPLUS
 DOCUMENT NUMBER: 142:306367
 TITLE: Silver halide photographic paper showing improved yellow color reproducibility and image formation method from digital image data for color proof
 INVENTOR(S): Tanaka, Shigeo; Ishidai, Hiroshi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 99 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005070685	A2	20050317	JP 2003-303814	20030828

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 142:306367
 GI



AB The title photog. paper contains a yellow coupler represented by I [B, R = substituent; Z = atoms for forming N-containing 6- or 7-member ring; A = H, group capable of leaving upon coupling with oxidized color development agent] and a high boiling organic solvent(s) selected from RaOC(CH₂)_mCOORb [Ra, Rb = C₄-10-alkyl; m = 2-10], R₁OC(CH₂)_nCOOR₂ [R₁, R₂ = C₄-10-alkyl; n = 2-10], R₃OC(CH₂)_pCOOR₄ [R₃, R₄ = C₃-24-alkyl; p = 2-10], C(Rg)(Rh)(Ri)OH [Rg = alkyl, alkenyl; Rh, Ri = H, alkyl, alkenyl], X-[(CH₂)_qOCOR]_r [X = 5- to 7-member saturated hydrocarbon ring; Rj = C₄-16-alkyl; q = 0-2; r = 1-3], Rk-OCH₂-CH(OH)-Rm [Rk = aliphatic, aromatic; Rm = H, aliphatic], R₁OC(R₂-COO(-R₃-COO-R₂-COO))R₄ [R₁, R₄ = alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl; R₂, R₃ = alkylene, alkenylene, cycloalkylene; s = 1-20], and R₅O-R₆-(OOC-R₇-COO-R₆-)COR₈ [R₆, R₇ = alkylene, alkenylene, cycloalkylene; R₅, R₈ = acyl, phosphonyl; t = 1-20] in a photosensitive emulsion layer(s).
 IT 840524-02-9
 RI: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
 (yellow coupler; silver halide photog. paper showing improved yellow color reproducibility and image formation method from digital image data for color proof)
 RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX


L4 ANSWER 16 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 17 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:235516 CAPLUS
 DOCUMENT NUMBER: 142:325823
 TITLE: Silver halide color photographic material containing yellow coupler
 INVENTOR(S): Okuyama, Masato
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 42 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005070576	A2	20050317	JP 2003-302270	20030827

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 142:325823
 GI



AB Disclosed is a Ag color photog. material comprising a yellow photosensitive Ag halide emulsion layer, a magenta photosensitive Ag halide emulsion layer, and a cyan photosensitive Ag halide emulsion layer on a reflective support, wherein a dye-forming coupler in the yellow photosensitive Ag halide emulsion layer is represented by I (R = substituent; Z = atomic group forming ring; R' = substituent; n = 0-4; X = H, substituent; and A = leaving group), said coupler is dispersed in a hydrophilic colloid solution after dissolving in a high- or low-b.p. solvent, and said soluble contains a low-b.p. solvent 2-10%.
 IT 840524-02-9
 RI: NUU (Other use, unclassified); USES (Uses)
 (silver halide color photog. material containing yellow coupler)
 RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 17 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 18 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:216177 CAPLUS
 DOCUMENT NUMBER: 142:306362
 TITLE: Silver halide color photographic paper showing excellent yellow color reproducibility suitable for digital color proof and its manufacture
 INVENTOR(S): Aoki, Atsushi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 48 pp.
 CODEN: JQXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005062585	A2	20050310	JP 2003-294128	20030818
PRIORITY APPLN. INFO.:			JP 2003-294128	20030818
OTHER SOURCE(S):		MARPAT 142:306362		

GI



AB The title color photog. paper contains a yellow coupler represented by I [R = substituent; Z = atoms for forming 6- or 7-member ring; R' = substituent; n = 0-4; X = H, substituent; A = H, group capable of leaving upon coupling with oxidized color development agent] and a high boiling solvent represented by R21-(O)p-PO((O)r-R23)-(O)q-R22 [R21-23 = aliphatic, aromatic; p, q, r = 0, 1] in a photog. emulsion layer.
 IT 840524-02-9
 RL: DEV (Device component use); USES (Uses)
 (yellow coupler; silver halide color photog. paper showing excellent yellow color reproducibility suitable for digital color proof and its manufacture)
 RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 19 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:216166 CAPLUS
 DOCUMENT NUMBER: 142:306361
 TITLE: Color photographic paper
 INVENTOR(S): Nakamura, Takeshi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 48 pp.
 CODEN: JQXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005062498	A2	20050310	JP 2003-292835	20030813
PRIORITY APPLN. INFO.:			JP 2003-292835	20030813
OTHER SOURCE(S):		MARPAT 142:306361		

GI



AB The title photog. paper has light-sensitive layers containing photog. emulsion on a reflective support, wherein surfactant Ra-COON(Rb)-L-D(Ra = C2-6 alkylene; Rb = H, alkyl, aryl; D = -SO3M, -COOM; M = H, metal cation) is added in the photog. paper and wherein photog. coupler I (Z = 6-7-membered ring residue; R' = substituent; n = integer 0-4; X = H, substituent; A = H, leaving group) is added in at least one of light-sensitive layers. The photog. paper shows good pressure-resistance and good image storageability.
 IT 840524-02-9
 RL: TEM (Technical or engineered material use); USES (Uses)
 (photog. couplers in color photog. paper)
 RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 20 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:209982 CAPLUS
 DOCUMENT NUMBER: 142:287748
 TITLE: Silver halide color photographic paper showing improved storage stability suitable for digital color proof and image formation method using the same
 INVENTOR(S): Tanabe, Junichi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 49 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005062586	A2	20050310	JP 2003-294129	20030818
PRIORITY APPLN. INFO.:			JP 2003-294129	20030818
OTHER SOURCE(S):		MARPAT 142:287748		

 GI




AB The title color photog. paper contains a yellow coupler represented by I
 [R = substituent; Z = atoms for forming 6- or 7-member ring; R' = substituent; n = 0-4; X = H, substituent; A = H, group capable of leaving upon coupling with oxidized color development agent] and a photog. emulsion stabilizer(s) selected from R11-SO2S-M11, R21-SO2-M21, and R31-S-S-R32 [R11, R21 = aliphatic, aromatic, heterocyclic; M11, M21 = cation; R31, R32 = aliphatic, aromatic; R31 joining together with R32 may form ring] in
 a photog. emulsion layer.
 IT 840524-02-9
 RL: DEV (Device component use); USES (Uses)
 (yellow coupler; silver halide color photog. paper showing improved storage stability suitable for digital color proof and image formation method using the same)
 RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[(4-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:160815 CAPLUS
 DOCUMENT NUMBER: 142:233323
 TITLE: Methods of inhibiting immune responses stimulated by an endogenous factor by administering phosphoinositide 3-kinase δ selective inhibitors
 INVENTOR(S): Douangpanya, Jason; Hayflick, Joel S.; Puri, Kamal D.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 27 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043239	A1	20050224	US 2004-918803	20040813
PRIORITY APPLN. INFO.:			US 2003-495370P	P 20030814
OTHER SOURCE(S):		MARPAT 142:233323	US 2004-540090P	P 20040128

AB The present invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting undesirable immune responses without inhibiting desired immune responses. In one embodiment, the invention provides methods of inhibiting an endogenous immune response stimulated by at least one endogenous factor without substantially inhibiting an exogenous immune response stimulated by at least one exogenous factor comprising administering an amount of a phosphoinositide 3-kinase δ (PI3K δ) selective inhibitor effective to inhibit the endogenous immune response stimulated by endogenous factor without substantially inhibiting the exogenous immune response stimulated by the at least one exogenous factor.
 IT 371243-12-8 371243-13-9 371243-14-0
 371243-15-1 371243-17-3 371243-22-0
 371243-23-1 474012-90-3 474012-93-6
 474012-96-9 474012-98-1 474012-01-9
 845527-52-8 845527-53-9 845527-54-0
 845527-57-3 845527-58-4 845527-59-5
 845527-60-8 845527-61-9 845527-62-0
 845527-63-1 845527-64-2 845527-65-3
 845527-66-4 845527-67-5 845527-68-6
 845527-69-7 845527-70-0 845527-71-1
 845527-73-3 845527-74-4 845618-66-8
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as PI3K δ selective inhibitor; phosphoinositide 3-kinase δ selective inhibitors for inhibiting immune responses stimulated by endogenous factor)
 RN 371243-12-8 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 20 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-13-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-14-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-amino-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 371243-15-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino)methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino)methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 474012-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 474012-96-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474012-98-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 474013-01-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-52-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




08/08/2006


L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 845527-53-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-dichlorophenyl)-5-methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-54-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-fluorophenyl)-2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 845527-57-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-61-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-62-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-58-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-59-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-60-8 CAPLUS


L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-63-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-64-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,3-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-65-3 CAPLUS

08/08/2006

L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-66-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-67-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-70-0 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-fluorophenyl)-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-71-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-2-[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-68-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 845527-69-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-[(2-diethylamino)ethyl]methylamino]phenyl]-5-methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 845527-73-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-74-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 845618-66-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-2-[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of leukocyte accumulation response to inflammatory mediator by inhibiting phosphoinositide 3-kinase and signal transduction of vascular endothelium to treat inflammatory conditions)
 RN 371243-12-8 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-((2-methylphenyl)amino)methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)



RN 371243-13-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-((2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-14-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-amino-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:158543 CAPLUS
 DOCUMENT NUMBER: 142:233321
 TITLE: Methods of inhibiting leukocyte accumulation
 INVENTOR(S): Diacovo, Thomas G.; Hayflick, Joel S.; Puri, Kamal D.
 PATENT ASSIGNEE(S): Icos Corporation, USA; Washington University
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016349	A1	20050224	WO 2004-US26834	20040813
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005054614	A1	20050310	US 2004-918825	20040813
PRIORITY APPLN. INFO.:			US 2003-495370P	P 20030814
			US 2004-540036P	P 20040128

OTHER SOURCE(S): MARPAT 142:233321
 AB The invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting leukocyte accumulation comprising selectively inhibiting phosphoinositide 3-kinase delta (PI3Kδ) activity in vascular endothelial cells. The adhesivity induced in these cells can result in temporary adhesion between the leukocytes and the endothelial cells, typically referred to as leukocyte tethering. Leukocyte tethering is generally mediated by interactions between selectin receptors including but not limited to E-selectin and P-selectin on endothelial cells and corresponding ligands present on leukocytes. The disclosed methods may be used to treat individuals having an inflammatory condition where leukocytes are accumulating at the site of insult or inflamed tissue. The disclosed methods may affect inflammatory conditions mediated by one or more components of the PI3K/Akt signal transduction pathway of endothelial cells.
 IT 371243-12-8 371243-13-9 371243-14-0
 371243-15-1 371243-17-3 371243-22-0
 371243-23-1 474012-90-3 474012-93-6
 474012-96-9 474012-98-1 474013-01-9
 845527-52-8 845527-53-9 845527-54-0
 845527-57-3 845527-58-4 845527-59-5
 845527-60-8 845527-61-9 845527-62-0
 845527-63-1 845527-64-2 845527-65-3
 845527-66-4 845527-67-5 845527-68-6
 845527-69-7 845527-70-0 845527-71-1
 845527-72-2 845527-73-3 845527-74-4


L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-15-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-amino-1H-purin-6-yl)amino]methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 371243-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 474012-98-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474013-01-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-52-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474012-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 474012-96-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-53-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-dichlorophenyl)-5-methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-54-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-fluorophenyl)-2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 845527-57-3 CAPLUS

08/08/2006

L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-58-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-59-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-60-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-61-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-62-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-63-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-64-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,3-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-65-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 845527-66-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-67-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


Habte

08/08/2006

L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(9CI) (CA INDEX NAME)




RN 845527-68-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[2-amino-1H-purin-6-yl]amino]methyl]-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 845527-69-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-[[2-(diethylamino)ethyl]methylamino]phenyl]-5-methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-72-2 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(2-chlorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-73-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-74-4 CAPLUS

Habte

L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-70-0 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(2-fluorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)



RN 845527-71-1 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 4(3H)-Quinazolinone, 2-[[2-amino-1H-purin-6-yl]amino]ethyl]-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


08/08/2006

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:158542 CAPLUS
 DOCUMENT NUMBER: 142:254586
 TITLE: Method using a phosphoinositide 3-kinase B inhibitor for inhibiting immune responses stimulated by an endogenous factor
 INVENTOR(S): Douangpanya, Jason; Hayflick, Joel S.; Puri, Kamal D.
 PATENT ASSIGNEE(S): Icos Corporation, USA
 SOURCE: PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016348	A1	20050224	WO 2004-US26436	20040813
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RV: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		US 2003-495370P P 20030814 US 2004-540090P P 20040128		

OTHER SOURCE(S): MARPAT 142:254586
 AB The invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting undesirable immune responses without inhibiting desired immune responses. In one embodiment, the invention provides methods for inhibiting an endogenous immune response stimulated by at least one endogenous factor without substantially inhibiting an exogenous immune response stimulated by at least one exogenous factor comprising administering an amount of a phosphoinositide 3-kinase B (PI3KB) selective inhibitor effective to inhibit the endogenous immune response stimulated by endogenous factor without substantially inhibiting the exogenous immune response stimulated by the at least one exogenous factor.
 IT 371243-12-8 371243-13-9 371243-14-0
 371243-15-1 371243-17-3 371243-22-0
 371243-23-1 474012-90-3 474012-93-6
 474012-96-9 474012-98-1 474013-01-9
 845527-52-8 845527-53-9 845527-54-0
 845527-57-3 845527-58-4 845527-59-5
 845527-60-8 845527-61-9 845527-62-0
 845527-63-1 845527-64-2 845527-65-3
 845527-66-4 845527-67-5 845527-68-6
 845527-69-7 845527-70-0 845527-71-1
 845527-72-2 845527-73-3 845527-74-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (phosphoinositide 3-kinase inhibitor for inhibiting immune responses stimulated by endogenous factor)
 RN 371243-12-8 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-13-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-14-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-15-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 371243-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474012-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 474012-96-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-52-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-53-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-dichlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-54-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-fluorophenyl)-2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]- (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474012-98-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474013-01-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-57-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-58-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-59-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-60-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-61-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 4(3H)-Quinazolinone, 3-(2,3-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-65-3 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-66-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-62-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-63-1 CAPLUS
CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-64-2 CAPLUS


L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-67-5 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-68-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[2-amino-1H-purin-6-yl]amino]methyl]-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 845527-69-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-[[2-(diethylamino)ethyl]methylamino]phenyl]-5- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-70-0 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(2-fluorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-71-1 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-74-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-((2-amino-1H-purin-6-yl)amino)ethyl]-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT:


3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-72-2 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(2-chlorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-73-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:140199 CAPLUS
DOCUMENT NUMBER: 142:228609
TITLE: Silver halide color photographic material containing specific yellow coupler
INVENTOR(S): Muramatsu, Yasuhiko
PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
SOURCE: Jpn. Kokai Tokkyo Koho, 42 pp.
CODEN: JKOXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
JP 2005043530 A2 20050217 JP 2003-201442 20030725
PRIORITY APPLN. INFO.: JP 2003-201442 20030725
OTHER SOURCE(S): MARPAT 142:228609
GI




I




II

AB The material with short-side length 2400 mm has each 21 yellow, magenta, and cyan color-forming light-sensitive emulsion layer on a reflecting support, in which the yellow color-forming light-sensitive layer contains a coupler I or II (R = substituent; Z = atoms required to form N-containing 6- or 7-membered ring with C=O; N; R' = substituent; n = 0-4; X = H, substituent; A = H, group to be released when coupled with color developer oxidation product). The material shows improved storage stability after development, and is useful for color proof.
IT 839711-63-6 839711-66-9
RL: TDM (Technical or engineered material use); USES (Uses)
yellow coupler) (silver halide color photog. material containing pyrimidinone derivative)
RN 839711-63-6 CAPLUS
CN 2-Quinazolinoneacetamide, N-[5-[[2-[2,5-bis(1,1-dimethylpropyl)phenoxy]-1-oxooctyl]amino]-2-(1-methylethoxy)phenyl]-3-cyclohexyl-a-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)-3,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 24 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 839711-66-9 CAPLUS
 CN Benzoic acid, 4-[2-[[5-chloro-2-(dodecyloxy)phenyl]amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




Habte

L4 ANSWER 25 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:138433 CAPLUS
 DOCUMENT NUMBER: 142:228608
 TITLE: Silver halide photographic emulsion containing metal complex and yellow coupler
 INVENTOR(S): Tanaka, Shigeo; Ishida, Hiroshi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 91 pp.
 CODEN: JIOCAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005043529	A2	20050217	JP 2003-201441	20030725
PRIORITY APPLN. INFO.:			JP 2003-201441	20030725
OTHER SOURCE(S):			MARPAT 142:228608	



AB The material has 21 emulsion layer with AgCl 295 mol%, containing (a) an emulsion containing an Ir complex and a metal complex having a central metal of group VB to VIII elements except Ir in a periodic table and a nitrosyl or thionitrosyl ligand and (b) the yellow coupler I (B, R = substituent; Z = atoms required to form N-containing 6- or 7-membered ring with NC=N; A = H, group to be released when coupled with color developer oxidation product). The material prevents sensitivity change in storage under high-temperature conditions.

IT 840524-02-9
 RL: TEM (Technical or engineered material use); USES (Uses)
 (yellow coupler; silver halide photog. emulsion containing metal complex and yellow coupler)

RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[[2-(4-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 26 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1062614 CAPLUS
 DOCUMENT NUMBER: 142:155910
 TITLE: Intramolecular nucleophilic aromatic substitution reaction of 2-carboxamido-3-arylquinazolin-4-ones and its application to the synthesis of secondary aryl amines
 AUTHOR(S): Fuwa, Haruhiko; Kobayashi, Toshitake; Tokitoh, Takashi; Torii, Yukiko; Natsugari, Hideaki
 CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, 113-0033, Japan
 SOURCE: Synlett (2004), (14), 2497-2500
 CODEN: SYNLET; ISSN: 0936-5214
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:155910


AB A novel intramol. nucleophilic aromatic substitution reaction of 2-carboxamido-3-arylquinazolin-4-one derivs. induced by base treatment and its application to the expeditious synthesis of secondary aryl amines, including diaryl amines, are described.

IT 830324-73-7 830324-74-8 830324-75-9 830324-83-9 830324-87-3 830324-88-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis of secondary aryl amines and diaryl amines via intramol. nucleophilic aromatic substitution reaction of 2-carboxamido-3-arylquinazolin-4-one derivs.)

RN 830324-73-7 CAPLUS
 CN 2-Quinazolinecarboxamide, 3-(2-chloro-3-pyridinyl)-3,4-dihydro-N-(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 830324-74-8 CAPLUS
 CN 2-Quinazolinecarboxamide, 3-(2-chloro-3-pyridinyl)-3,4-dihydro-N-(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 830324-75-9 CAPLUS

08/08/2006


L4 ANSWER 26 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Quinazolinecarboxamide, 3-(2-chloro-3-pyridinyl)-3,4-dihydro-4-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 830324-83-9 CAPLUS
 CN 2-Quinazolinecarboxamide, 3,4-dihydro-4-oxo-N-phenyl-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 830324-87-3 CAPLUS
 CN Benzoic acid, 2-[4-oxo-2-[(phenylamino)carbonyl]-3(4H)-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 830324-88-4 CAPLUS
 CN Benzoic acid, 2-[4-oxo-2-[[3-(trifluoromethyl)phenyl]amino]carbonyl]-3(4H)-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:902341 CAPLUS

DOCUMENT NUMBER: 141:379919

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092123	A2	20041028	WO 2004-US11187	20040412
WO 2004092123	A3	20050519		
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRIORITY APPLN. INFO.:

US 2003-461727P P 20030410
 US 2003-469286P P 20030509
 US 2003-485678P P 20030709

OTHER SOURCE(S):

MARPAT 141:379919


GI



AB Title compds. e.g. [I; R1 = (substituted) alkyl, alkoxy; R2 = H, halo; R3 = H, CHO, Ac, (substituted) alkyl; R4 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, alkylamino, Ph, heteroaryl], were prepared. Thus, 4-bromo-2-fluoro-N-(5-methylthiazol-2-yl)benzenesulfonamide, 4-fluorobenzenesulfonic acid, Pd(PPh3)4, and K2CO3 were stirred in PhMe/Me2CHOH/H2O to give 15. 2,4'-difluoro-N-(5-methylthiazol-2-yl)-1,1'-biphenyl-4-sulfonamide. In a screen for inhibition of *Candida albicans*.

Habte

L4 ANSWER 26 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT:

22

THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

logarithmic phase growth, title compds. showed IC50's of as low as 0.0005 μM.

IT 313067-40-2


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of (iso)thiazole benzenesulfonamides and other heterocycles

as inhibitors of fungal invasion)

RN 313067-40-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(phenylamino)methyl]-3-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



08/08/2006

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:767291 CAPLUS

DOCUMENT NUMBER: 141:325173

TITLE: Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methylpiperazinyl)-containing derivatives
 AUTHOR(S): Watkins, William J.; Lemoine, Remy C.; Chong, Lee; Cho, Aesop; Renau, Thomas E.; Kuo, Bonnie; Wong, Vickie; Ludvikow, Maria; Garizi, Negar; Iqbal, Nadeem; Barnard, John; Jankowska, Renata; Singh, Rajeshwar; Madsen, Deidre; Lolans, Karen; Lomovskaya, Olga; Oza, Uma; Dudley, Michael N.

CORPORATE SOURCE: Essential Therapeutics, Inc., Mountain View, CA, 94043, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(20), 5133-5137

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:325173

AB Structure-activity relationships of a novel series of fungal efflux pump inhibitors with respect to potentiation of the activity of fluconazole against strains of *Candida albicans* and *Candida glabrata* over-expressing ABC-type efflux pumps are systematically explored.

IT 562835-78-3P 562835-83-0P 562835-84-1P

562835-85-2P 562835-87-4P 562835-90-9P

562835-91-0P 562835-92-1P 562835-94-3P

562836-06-0P 562836-07-1P 562836-26-4P

626245-88-3P 770746-52-6P 770746-53-7P


770746-54-8P 770746-55-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(in vitro structure-activity relationships of (N-methylpiperazinyl)-containing derivs. of quinazolinone, fungal efflux pump inhibitors)

RN 562835-78-3 CAPLUS

CN Urea, N'-(3-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)





L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562835-87-4 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-90-9 CAPLUS

CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 562835-83-0 CAPLUS

CN Urea, N'-(2-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 562835-84-1 CAPLUS


CN Urea, N'-(4-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 562835-85-2 CAPLUS


CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562835-91-0 CAPLUS


CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 562835-92-1 CAPLUS

CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562835-94-3 CAPLUS
 CN Carbamic acid, [1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl](2,4-dimethoxyphenyl)-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)




RN 562836-06-0 CAPLUS
 CN Benzamide, 4-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 770746-52-6 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 770746-53-7 CAPLUS
 CN Urea, N'-(3-cyanophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 770746-54-8 CAPLUS
 CN Urea, N'-2-benzothiazolyl-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562836-07-1 CAPLUS
 CN Benzamide, 2-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562836-26-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 626245-88-3 CAPLUS
 CN Urea, N'-(6-chloro-3-pyridazinyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 770746-55-9 CAPLUS
 CN Benzenesulfonamide, 4-chloro-N-[[[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl](2,4-dimethoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




IT 626245-93-0 626245-96-3 626246-00-2
 626246-07-9 626246-13-7 626246-16-0
 626246-22-8 626246-28-4 626246-31-9
 626246-43-3 626246-48-8 626246-51-3
 626246-54-6 626246-56-8 626246-64-8
 633307-22-9 770746-58-2 770746-59-3
 770746-60-6 770746-61-7 770746-62-8
 770746-63-9 770746-64-0 770746-65-1
 770746-66-2 770746-67-3 770746-68-4
 770746-69-5 770746-70-8 770746-73-1
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in vitro structure-activity relationships of (N-methylpiperazinyl)-containing derivs. of quinazolinone, fungal efflux pump inhibitors)
 RN 626245-93-0 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626245-96-3 CAPLUS
 CN Urea, N-[1-([3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl)-N'-(4-fluorophenyl)-N-(3,4,5-trimethoxyphenyl)]- (9CI)
 (CA INDEX NAME)




RN 626246-00-2 CAPLUS
 CN Urea, N-(2,4-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N'-(4-fluorophenyl)-N-(2,4-dimethoxyphenyl)- (9CI)
 (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-07-9 CAPLUS
 CN Urea, N-[1-[6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
 (CA INDEX NAME)




RN 626246-13-7 CAPLUS
 CN Urea, N-[1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
 (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-16-0 CAPLUS
 CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-[6-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI)
 (CA INDEX NAME)




RN 626246-22-8 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-6-methyl-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
 (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-28-4 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-6-(1-oxopropoxy)-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
 (CA INDEX NAME)




RN 626246-31-9 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-6-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
 (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-43-3 CAPLUS
CN Urea, N-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-48-8 CAPLUS
CN Urea, N-[1-[7-cyano-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-56-8 CAPLUS
CN Urea, N-[1-[3,4-dihydro-8-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-64-8 CAPLUS
CN Urea, N-[1-[3,4-dihydro-6-hydroxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-51-3 CAPLUS
CN 7-Quinazolinecarboxylic acid, 2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 626246-54-6 CAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N-[(1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633307-22-9 CAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N-[(1S)-1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 770746-58-2 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 770746-59-3 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 770746-60-6 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 770746-61-7 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 770746-64-0 CAPLUS
CN Urea, N-[2,4-bis(cyclopropylmethoxy)phenyl]-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 770746-65-1 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxy-3-pyridinyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 770746-62-8 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(3,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 770746-63-9 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 770746-66-2 CAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-[5-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 770746-67-3 CAPLUS
CN Acetamide, 2-[[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-6-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 770746-68-4 CAPLUS
 CN Methanesulfonamide, N-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 770746-69-5 CAPLUS
 CN Acetamide, N-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 770746-70-8 CAPLUS
 CN 7-Quinazolinecarboxylic acid, 2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 849751-99-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2,4-difluorophenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 849752-46-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(1R)-1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 770746-73-1 CAPLUS
 CN Urea, N'-(2,4-dimethoxyphenyl)-N-[(1R)-1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 633305-75-6P 849751-99-1P 849752-46-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (in vitro structure-activity relationships of (N-methylpiperazinyl)-containing derivs. of quinazolinone, fungal efflux pump inhibitors)
 RN 633305-75-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(1S)-1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 29 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:767290 CAPLUS
 DOCUMENT NUMBER: 141:325172
 TITLE: Quinazolinone-based fungal efflux pump inhibitors. Part 1: Discovery of an (N-methylpiperazine)-containing derivative with activity in clinically relevant Candida spp.
 AUTHOR(S): Lemoine, Remy C.; Glinka, Tomasz W.; Watkins, William J.; Cho, Aesop; Yang, Jessie; Iqbal, Nadeem; Singh, Rajeshwar; Madsen, Deidre; Lolans, Karen; Lomovskaya, Olga; Oza, Umar; Dudley, Michael N.
 CORPORATE SOURCE: Essential Therapeutics, Inc., Mountain View, CA, 94043, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(20), 5127-5131
 CODEN: BMCLEB; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:325172
 AB The discovery of a series of quinazolinone-based fungal efflux pump inhibitors by high-throughput screening for potentiation of fluconazole in C. albicans is described. Attempts to improve the aqueous solubility of screening hits led to the discovery of an analog with greatly improved phys. properties and activity against clin.-relevant Candida spp.
 IT 562835-78-3P 770743-57-2P 770743-58-3P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (N-methylpiperazine)-containing quinazolinone derivative, efflux pump inhibitors in clin. relevant Candida spp.)
 RN 562835-78-3 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-[(1R)-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 770743-57-2 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-[(1R)-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 29 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 770743-58-3 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-([1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]-1-methylethyl]-N-(2,4-dimethoxyphenyl)-(9CI) (CA INDEX NAME)



RN 770743-59-4 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-([1S]-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl)-N-(2,4-dimethoxyphenyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 29 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633305-74-5 CAPLUS
 CN Benzenesulfonamide, N-([1S]-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl)-N-(2,4-dimethoxyphenyl)-2,4-dinitro-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633305-75-6 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-([1S]-1-[(2,4-dimethoxyphenyl)amino]ethyl)-3-(4-methyl-1-piperazinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
 Habte


L4 ANSWER 29 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 770743-60-7
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (N-methylpiperazine-containing quinazolinone derivative, efflux pump inhibitors in clin. relevant Candida spp.)

RN 770743-60-7 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-([1R]-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl)-N-(2,4-dimethoxyphenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 562836-26-4P 633305-74-5P 633305-75-6P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (N-methylpiperazine-containing quinazolinone derivative, efflux pump inhibitors in clin. relevant Candida spp.)
 RN 562836-26-4 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-([1S]-1-[(2,4-dimethoxyphenyl)amino]ethyl)-3-(4-methyl-1-piperazinyl)-(9CI) (CA INDEX NAME)

L4 ANSWER 29 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

08/08/2006

L4 ANSWER 30 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:609430 CAPLUS
 DOCUMENT NUMBER: 141:164773
 TITLE: Processing of silver halide color photographic material containing yellow coupler and color imaging method to improve yellow color reproducibility
 INVENTOR(S): Ishida, Hiroshi; Tanaka, Shigeo
 PATENT ASSIGNEE(S): Konica Minolta MG K. K., Japan; Konica Minolta Photo Imaging K. K.
 SOURCE: Jpn. Kokai Tokkyo Koho, 91 pp.
 CODEN: JKOXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004212936	A2	20040729	JP 2003-291105	20030811
JP 2004246316	A2	20040902	JP 2003-201438	20030725
PRIORITY APPLN. INFO.: OTHER SOURCE(S):	MARPAT 141:164773		JP 2002-368028	A 20021219




AB A silver halide color photog. material containing a yellow coupler represented by R1m-G-NH-O-R2 (R1 = aliphatic, aromatic, heterocyclyl, alkoxy, aryloxy, amino; m = 1, 2; R2 = coupling group; G = -CO-, -CNR3-, -PO-, -SO-, -SO2-, R3 = R2) is processed by a processing solution containing a compound represented by 1 (R11, R12 = H, substituent; R13, R14 = H, alkyl, aryl; R15, R16 = -(C(A)2)f-Og-(C(A)2)h-Oi-(C(A)2)j-Ok-H; Rv = H, -(C(A)2)f-Og-(C(A)2)h-Oi-(C(A)2)j-Ok-H, -CH2CHG2SO3M; M = H, alkali metal; alkaline earth metal, ammonium pyridinium; A = H, hydroxyl, hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl; f, h, j = 1, 2; g, i, k = 0, 1). The color photog. material is especially suitable for color proof applications.
 IT 728032-91-5 728032-92-6

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:971729 CAPLUS
 DOCUMENT NUMBER: 140:27843
 TITLE: Preparation of quinazolinylmethyl ureas as fungal efflux pump inhibitors
 INVENTOR(S): Watkins, Will J.; Lemoine, Remy; Cho, Aesop; Palme, Monica
 PATENT ASSIGNEE(S): Essential Therapeutics, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 62 pp., Cont.-in-part of U.S. Pat. Appl. 2003 220,338.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003229097	A1	20031211	US 2002-334755	20021230
US 6689782	B2	20040210		
US 6596723	B1	20030722	US 2001-906864	20010716
US 2003220338	A1	20031127	US 2002-243074	20020912
WO 2004024140	A1	20040325	WO 2003-US5184	20030221

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003215343 A1 20040430 AU 2003-215343 A2 20030221
 PRIORITY APPLN. INFO.:
 US 2001-906864 A2 20010716
 US 2002-243074 A2 20020912
 US 2002-334755 A 20021230
 WO 2003-US5184 W 20030221


OTHER SOURCE(S): MARPAT 140:27843
 GI



L4 ANSWER 30 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RL: DEV (Device component use); USES (Uses)
 (yellow coupler; processing of silver halide color photog. material contg. yellow coupler and color imaging method to improve yellow color reproducibility)
 RN 728032-91-5 CAPLUS
 CN Benzoic acid, 3-[[[3-[[[3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl] (5,5-dimethyl-2,4-dioxo-3-oxazolidinyl)acetyl]amino]-4-(1-methylethoxy)phenyl]sulfonyl]amino]-4-(1-methylethoxy)-, tetradecyl ester (9CI) (CA INDEX NAME)




RN 728032-92-6 CAPLUS
 CN 2-Quinazolineacetamide, α-chloro-N-[5-chloro-2-(octadecyloxy)phenyl]-3,4-dihydro-4-oxo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AB The title compds. [I; A1 = C, N (provided that when A1 = N, R5 does not exist); R2, R3 = H, halo, alkoxy; R4, R6 = H, halo, alkoxy, OCF3, OCH2(cycloalkyl); R5 = [1,2,3]triazol-2-yl; R7, R8 = H, halo, CN, alkoxy, OCH2F, OCF3, or taken together form OCH2O; R1 = alkyl, cycloalkyl, CH2(alkyl), etc.; R21 = H, alkyl] and, particularly I wherein the compound is in 5 absolute configuration at the starred carbon, that are efflux pump inhibitors and therefore are useful as potentiators of anti-fungal agents for the treatment of infections caused by fungi that employ an efflux pump resistance mechanism, were claimed. The general methods for the synthesis of the racemic and the enantiomerically enhanced compds. I are given. E.g., a 5-step synthesis of I [A1 = C; R1 = Me; R2, R3, R5, R8, R21 = H; R4, R6 = OMe; R7 = CN] (starting from anthranilic acid and propionic anhydride), was presented. The activity of the compds. I in combination with an antifungal agent (fluconazole) were assessed using a checkerboard assay and the broth microdilution protocol. Data presented in tables show potentiation of anti-fungal, as manifested by a reduction in the MIC of the anti-fungal, in the presence, as contrasted to the absence, of an efflux pump inhibitor I. The compds. I, most of which are shown to have little or no intrinsic anti-fungal activity, are tested at concns. of 4-32 μg/mL. Pharmaceutical composition comprising the compound I and an antifungal agent is claimed.
 IT 633305-97-2P 633306-05-5P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of quinazolinylmethyl ureas as fungal efflux pump inhibitors)
 RN 633305-97-2 CAPLUS
 CN Piperazine, 1-[(2-aminocyclopentyl)carbonyl]-4-[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)



RN 633306-05-5 CAPLUS
 CN Piperazine, 1-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 633305-78-9P 633305-79-0P 633305-80-3P
 633305-81-4P 633305-82-5P 633305-83-6P
 633305-84-7P 633305-86-9P 633305-87-0P
 633305-88-1P 633305-89-2P 633305-90-5P
 633305-91-6P 633305-92-7P 633305-93-8P
 633305-94-9P 633305-95-0P 633305-96-1P
 633305-98-3P 633305-99-4P 633306-00-0P
 633306-01-1P 633306-03-3P 633306-04-4P
 633306-06-6P 633306-07-7P 633306-08-8P
 633306-10-2P 633306-11-3P 633306-12-4P
 633306-13-5P 633306-14-6P 633306-15-7P
 633306-16-8P 633306-17-9P 633306-18-0P
 633306-19-1P 633306-20-4P 633306-21-5P
 633306-22-6P 633306-23-7P 633306-24-8P
 633306-25-9P 633306-26-0P 633306-27-1P
 633306-28-2P 633306-29-3P 633306-30-6P
 633306-31-7P 633306-32-8P 633306-33-9P
 633306-34-0P 633306-35-1P 633306-36-2P
 633306-37-3P 633306-38-4P 633306-39-5P
 633306-40-8P 633306-41-9P 633306-42-0P
 633306-43-1P 633306-44-2P 633306-45-3P
 633306-46-4P 633306-47-5P 633306-48-6P
 633306-49-7P 633306-50-0P 633306-52-2P
 633306-53-3P 633306-54-4P 633306-55-5P
 633306-56-6P 633306-57-7P 633306-58-8P
 633306-59-9P 633306-60-2P 633306-61-3P
 633306-62-4P 633306-63-5P 633306-64-6P
 633306-65-7P 633306-66-8P 633306-67-9P
 633306-68-0P 633306-69-1P 633306-70-4P
 633306-71-5P 633306-72-6P 633306-73-7P
 633306-74-8P 633306-75-9P 633306-76-0P
 633306-77-1P 633306-78-2P 633306-79-3P
 633306-80-6P 633306-81-7P 633306-82-8P
 633306-83-9P 633306-84-0P 633306-85-1P
 633306-86-2P 633306-87-3P 633306-88-4P
 633306-89-5P 633306-90-8P 633306-91-9P
 633306-92-0P 633306-93-1P 633306-94-2P

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

633306-95-3P 633306-96-4P 633306-97-5P
 633306-98-6P 633306-99-7P 633307-00-3P
 633307-01-4P 633307-02-5P 633307-03-6P
 633307-04-7P 633307-05-8P 633307-06-9P
 633307-07-0P 633307-08-1P 633307-09-2P
 633307-10-5P 633307-11-6P 633307-12-7P
 633307-13-8P 633307-14-9P 633307-15-0P
 633307-16-1P 633307-17-2P 633307-18-3P
 633307-19-4P 633307-20-7P 633307-21-8P
 633307-22-9P 633307-24-1P 633307-26-3P
 633307-28-5P 633307-30-9P 633307-32-1P
 633307-34-3P 633307-36-5P 633307-38-7P
 633307-39-8P 633307-40-1P 633307-41-2P
 633307-42-3P 633307-43-4P 633307-44-5P
 633307-45-6P 633307-46-7P 633307-47-8P
 633307-48-9P 633307-49-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of quinazolinylmethyl ureas as fungal efflux pump inhibitors)
 RN 633305-78-9 CAPLUS
 CN Urea, N'-(4-cyanophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 633305-79-0 CAPLUS


CN Urea, N'-(4-(difluoromethoxy)phenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633305-80-3 CAPLUS

CN Urea, N'-(3-chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 633305-81-4 CAPLUS


CN Urea, N'-(4-chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 633305-82-5 CAPLUS

CN Urea, N'-(4-cyanophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 633305-83-6 CAPLUS


CN Urea, N'-(4-(difluoromethoxy)phenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 633305-84-7 CAPLUS

CN Urea, N'-(1,3-benzodioxol-5-yl)-N-(2,4-dimethoxyphenyl)-N-[1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633305-86-9 CAPLUS
CN Urea, N'-[3-chlorophenyl]-N-[1-[6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 633305-87-0 CAPLUS
CN Urea, N'-[1-[6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(3-fluorophenyl)- (9CI)
(CA INDEX NAME)


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633305-90-5 CAPLUS
CN Urea, N'-[1-[6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-(difluoromethoxy)phenyl)-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 633305-91-6 CAPLUS
CN Urea, N'-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-(difluoromethoxy)phenyl)-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 633305-92-7 CAPLUS

Habte

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633305-88-1 CAPLUS
CN Urea, N'-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(3-chlorophenyl)-N-(2,4-dimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 633305-89-2 CAPLUS
CN Urea, N'-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(3-fluorophenyl)- (9CI)
(CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Urea, N'-(4-cyanophenyl)-N-[1-[6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 633305-93-8 CAPLUS
CN Urea, N'-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-cyanophenyl)-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 633305-94-9 CAPLUS
CN Urea, N'-1,3-benzodioxol-5-yl-N-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI)
(CA INDEX NAME)

08/08/2006

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633305-95-0 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-4-oxo-3-[4-(1,3,4-thiadiazol-2-yl)-1-piperazinyl]-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 633305-96-1 CAPLUS
 CN Urea, N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)-N-[1-[3-(4-formyl-1-piperazinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-00-0 CAPLUS
 CN Carbamic acid, [1-[[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 633306-01-1 CAPLUS
 CN Carbamic acid, [(3R)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633305-98-3 CAPLUS
 CN Carbamic acid, [2-[[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]cyclopentyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 633305-99-4 CAPLUS
 CN Piperazine, 1-[[[(3S)-3-amino-1-pyrrolidinyl]carbonyl]-4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-03-3 CAPLUS
 CN Carbamic acid, [(3R)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-04-4 CAPLUS
 CN Carbamic acid, [(3S)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-06-6 CAPLUS

CN Piperazine, 1-[7-chloro-2-[[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-07-7 CAPLUS

CN Piperazine, 1-[2-[[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-08-8 CAPLUS


CN Piperazine, 1-[(3-aminopyrazinyl)carbonyl]-4-[2-[[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 633306-10-2 CAPLUS


CN Piperazine, 1-[2-[[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(2-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-11-3 CAPLUS

CN Piperazine, 1-[2-[[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(2-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 633306-12-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[4-[2-[[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-13-5 CAPLUS

CN Piperazine, 1-[[[(2S)-1-cyclopropyl-2-pyrrolidinyl]carbonyl]-4-[2-[[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-14-6 CAPLUS


CN Piperazine, 1-[2-[[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[[[(2S)-1-methyl-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-15-7 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(tetrahydro-2-furanyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 633306-16-8 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(3-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-19-1 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[[1-[(dimethylamino)sulfonyl]-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633306-20-4 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(5-methyl-3-isoxazolyl)carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-17-9 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 633306-18-0 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[[1-(methylsulfonyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-21-5 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(3-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 633306-22-6 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(3-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-23-7 CAPLUS
 CN Piperazine, 1-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4S,5R)-5-methyl-2-oxo-4-oxazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-24-8 CAPLUS
 CN Piperazine, 1-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4S,5R)-5-methyl-2-oxo-4-oxazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-27-1 CAPLUS
 CN Piperazine, 1-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 633306-28-2 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-25-9 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(5S)-5-oxo-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 633306-26-0 CAPLUS
 CN Piperazine, 1-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-29-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-30-6 CAPLUS
 CN Acetamide, N-[(1S,2R)-1-[(4-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-31-7 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-{[6-chloro-2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-32-8 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-{[7-chloro-2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-35-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-{[2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-36-2 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-{[6-chloro-2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-33-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-{[6-chloro-2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-34-0 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-{[2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino}ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-37-3 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-{[7-chloro-2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-38-4 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[(4-{[2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino}ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-39-5 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-40-8 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S,3R)-3-hydroxy-2-[(methylsulfonyl)amino]-1-oxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-43-1 CAPLUS
 CN Carbamic acid, [(1S)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-3-(methylsulfonyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-44-2 CAPLUS
 CN Acetamide, N-[(1S)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-3-(methylsulfonyl)propyl]-2,2-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-41-9 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-42-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-3-(methylsulfonyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-45-3 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-(hydroxymethyl)-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-46-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-47-5 CAPLUS
 CN Piperazine, 1-[(2S)-2-amino-1-oxobutyl]-4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-48-6 CAPLUS
 CN Piperazine, 1-[(2S)-2-amino-1-oxobutyl]-4-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-52-2 CAPLUS
 CN Piperazine, 1-[(2S)-2-amino-1-oxobutyl]-4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-53-3 CAPLUS
 CN Carbamic acid, [(1S)-1-[(4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-49-7 CAPLUS
 CN Piperazine, 1-[(2S)-2-amino-1-oxobutyl]-4-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-50-0 CAPLUS
 CN Piperazine, 1-[(2S)-2-amino-1-oxobutyl]-4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-54-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[(4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]propyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-55-5 CAPLUS
 CN Carbamic acid, [(1S)-1-[(4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-56-6 CAPLUS

CN Carbamic acid, [(1S)-1-[[4-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-57-7 CAPLUS

CN Carbamic acid, [(1S)-1-[[4-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-60-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-61-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-methylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-58-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-59-9 CAPLUS

CN Carbamic acid, [(1S)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-62-4 CAPLUS

CN Carbamic acid, [(1S)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-methylpropyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-63-5 CAPLUS

CN Carbamic acid, [(1S)-1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-methylpropyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-64-6 CAPLUS
 CN Carbamic acid, [(1R)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-65-7 CAPLUS
 CN Carbamic acid, [(1R)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-68-0 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-69-1 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-66-8 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-67-9 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-70-4 CAPLUS
 CN Piperazine, 1-[(2S)-2-amino-1-oxopropyl]-4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-71-5 CAPLUS
 CN Piperazine, 1-[(2S)-2-amino-1-oxopropyl]-4-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-72-6 CAPLUS

CN Piperazine, 1-[(2S)-2-amino-1-oxopropyl]-4-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-73-7 CAPLUS

CN Piperazine, 1-[(2S)-2-amino-1-oxopropyl]-4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-74-8 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-75-9 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-76-0 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6-methoxy-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-77-1 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-78-2 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-79-3 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-80-6 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-81-7 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[2-(dimethylamino)-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-84-0 CAPLUS
 CN Piperazine, 1-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylacetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-85-1 CAPLUS
 CN Piperazine, 1-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylacetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-82-8 CAPLUS
 CN Piperazine, 1-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2R)-2-pyrrolidinylacetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 633306-83-9 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylacetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-86-2 CAPLUS
 CN Piperazine, 1-[2-amino-4-thiazolyl]acetyl]-4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 633306-87-3 CAPLUS
 CN Carbamic acid, [3-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-3-oxopropyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-88-4 CAPLUS
 CN Carbamic acid, [3-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-3-oxopropyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 633306-89-5 CAPLUS
 CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-2-oxoethyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-90-8 CAPLUS
 CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-2-oxoethyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 633306-91-9 CAPLUS
 CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-2-oxoethyl]methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-92-0 CAPLUS
 CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-2-oxoethyl]methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 633306-93-1 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[[[(methylsulfonyl)amino]acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-94-2 CAPLUS
 CN Piperazine, 1-(2-amino-2-methyl-1-oxopropyl)-4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 633306-95-3 CAPLUS
 CN Piperazine, 1-(2-amino-2-methyl-1-oxopropyl)-4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-96-4 CAPLUS
 CN Piperazine, 1-(2-amino-2-methyl-1-oxopropyl)-4-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 633306-97-5 CAPLUS
 CN Piperazine, 1-(2-amino-2-methyl-1-oxopropyl)-4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-98-6 CAPLUS
 CN Piperazine, 1-(2-amino-2-methyl-1-oxopropyl)-4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 633306-99-7 CAPLUS
 CN Carbacic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633307-00-3 CAPLUS
 CN Carbacic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 633307-01-4 CAPLUS
 CN Carbacic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633307-02-5 CAPLUS
 CN Carbacic acid, [2-[4-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 633307-03-6 CAPLUS
 CN Carbacic acid, [2-[4-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 633307-04-7 CAPLUS
 CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 633307-05-8 CAPLUS
 CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 633307-06-9 CAPLUS
 CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 633307-07-0 CAPLUS
 CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 633307-08-1 CAPLUS
 CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 633307-09-2 CAPLUS
 CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 633307-10-5 CAPLUS
 CN Carbamic acid, [1-[[4-[2-[1-[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 633307-11-6 CAPLUS
 CN Carbamic acid, [1-[[4-[2-[1-[(2,4-bis(cyclopropylmethoxy)phenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A


RN 633307-12-7 CAPLUS
 CN Piperazine, 1-[(3-amino-1-pyrrolidinyl)carbonyl]-4-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 633307-15-0 CAPLUS
 CN Piperazine, 1-[(2S)-2-amino-1-oxopropyl]-4-[2-[1-[(2,4-bis(cyclopropylmethoxy)phenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 633307-16-1 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-bis(cyclopropylmethoxy)phenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-17-2 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[2-[1-[(4-fluorophenyl)amino]carbonyl][3-(2H-1,2,3-triazol-2-yl)phenyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-

Habe

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 633307-13-8 CAPLUS
 CN Piperazine, 1-[2-[1-[[[2-(cyclopropylmethoxy)phenyl][[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-14-9 CAPLUS
 CN Piperazine, 1-[2-[1-[[[4-(cyclopropylmethoxy)phenyl][[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-18-3 CAPLUS
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[2-[1-[(4-fluoro-2-methoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 633307-19-4 CAPLUS
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[2-[1-[[[4-fluorophenyl]amino]carbonyl][2-(trifluoromethoxy)phenyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633307-20-7 CAPLUS
 CN Piperazine, 1-(cyclopropylmethyl)-4-[[2-[[2-(cyclopropylmethoxy)phenyl]amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 633307-21-8 CAPLUS
 CN Piperazine, 1-(cyclopropylmethyl)-4-[[2-[[2-(2-ethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633307-26-3 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[4-[[2-[[2-(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633307-28-5 CAPLUS
 CN Piperazine, 1-[7-chloro-2-[[15]-1-[[2,4-dimethoxyphenyl]amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[[2-(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633307-22-9 CAPLUS
 CN Urea, N-[[2,4-dimethoxyphenyl]-N-[[15]-1-[[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633307-24-1 CAPLUS
 CN Urea, N-[[15]-1-[[3,4-dihydro-4-oxo-3-[[4-(1,3,4-thiadiazol-2-yl)-1-piperazinyl]-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633307-30-9 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[6-chloro-2-[[15]-1-[[2,4-dimethoxyphenyl]amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633307-32-1 CAPLUS
 CN Carbamic acid, [(1S,2R)-1-[[4-[[7-chloro-2-[[15]-1-[[2,4-dimethoxyphenyl]amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633307-34-3 CAPLUS

CN Carbamic acid, [(1S,2R)-1-[[4-[2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-36-5 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633307-40-1 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[6-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-41-2 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633307-38-7 CAPLUS

CN Piperazine, 1-[(2S)-2-amino-1-oxopropyl]-4-[7-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-39-8 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633307-42-3 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[7-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-43-4 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633307-44-5 CAPLUS

CN Carbamic acid, [2-[[4-[[2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-45-6 CAPLUS

CN Piperazine, 1-(2-amino-2-methyl-1-oxopropyl)-4-[6-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633307-46-7 CAPLUS

CN Carbamic acid, [2-[[4-[[2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-47-8 CAPLUS

CN Carbamic acid, [2-[[4-[[7-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633307-48-9 CAPLUS

CN Carbamic acid, [2-[[4-[[2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-49-0 CAPLUS

CN Carbamic acid, [2-[[4-[[2-[(1S)-1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 562835-90-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazolinylmethyl ureas as fungal efflux pump inhibitors)

RN 562835-90-9 CAPLUS

CN Urea, N-[1-[[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




IT 562836-26-4P 626245-65-6P 633305-74-5P

633305-75-6P 633305-76-7P 633305-77-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolinylmethyl ureas as fungal efflux pump inhibitors)


RN 562836-26-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626245-65-6 CAPLUS
 CN Urea, N-[(1S)-1-[3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 633305-74-5 CAPLUS
 CN Benzenesulfonamide, N-[(1S)-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-2,4-dinitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633305-75-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633305-76-7 CAPLUS
 CN Urea, N-[(1S)-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633305-77-8 CAPLUS
 CN Urea, N-[(1S)-1-[3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:930975 CAPLUS
 DOCUMENT NUMBER: 139:395945
 TITLE: Preparation of quinazolinylmethyl urea derivatives as fungal efflux pump inhibitors
 INVENTOR(S): Watkins, Will J.; Lemoine, Remy; Cho, Aesop; Palme, Monica
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 109 pp., Cont.-in-part of U.S. Ser. No. 906,864.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003220338	A1	20031127	US 2002-243074	20020912
US 6596723	B1	20030722	US 2001-906864	20010716
US 2003229097	A1	20031211	US 2002-334755	20021230
US 6689782	B2	20040210		
WO 2004024140	A1	20040325	WO 2003-US5184	20030221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003215343	A1	20040430	AU 2003-215343	20030221
PRIORITY APPLN. INFO.:				
			US 2001-906864	A2 20010716
			US 2002-243074	A2 20020912
			US 2002-334755	A 20021230
			WO 2003-US5184	W 20030221

OTHER SOURCE(S): MARPAT 139:395945
 GI


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB This invention relates to compds. of formula I [A1-A6 = C, N; R1 = H, alkyl, cycloalkyl, CH2-cycloalkyl, etc.; R2 = alkyl; R3-R12 = H, alkyl, CF3, alkoxy, halo, OH, CN, etc.] that are efflux pump inhibitors and therefore are useful as potentiators of anti-fungal agents for the treatment of infections caused by fungi that employ an efflux pump resistance mechanism. Thus, II was prepared and showed a reduced MIC value against *Candida albicans* in the presence of fluconazole.

IT 562835-78-3P 626245-65-6P 626245-72-5P
626245-77-0P 626245-79-2P 626247-18-5P
RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazolinylmethyl urea derivs. as fungal efflux pump inhibitors)
RN 562835-78-3 CAPLUS
CN Urea, N'-[3-chlorophenyl]-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626245-65-6 CAPLUS
CN Urea, N'-[1-[3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626245-72-5 CAPLUS
CN 1-Piperazinebutanoic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626245-77-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 626245-79-2 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626247-18-5 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 626245-51-0P 626245-67-8P 626245-68-9P
626245-69-0P 626245-70-3P 626245-74-7P
626245-81-6P 626245-83-8P 626245-85-0P
626245-88-3P 626245-90-7P 626245-93-0P
626245-96-3P 626246-00-2P 626246-04-6P
626246-07-9P 626246-10-4P 626246-13-7P
626246-16-0P 626246-17-1P 626246-19-3P
626246-22-8P 626246-25-1P 626246-28-4P
626246-31-9P 626246-34-2P 626246-37-5P
626246-40-0P 626246-43-3P 626246-45-5P
626246-48-8P 626246-51-3P 626246-54-6P
626246-56-8P 626246-60-4P 626246-64-8P
626246-67-1P 626246-69-3P 626246-71-7P
626246-72-8P 626246-74-0P 626246-75-1P
626246-76-2P 626246-81-9P 626246-84-2P
626246-89-7P 626246-91-1P 626246-92-2P
626246-93-3P 626246-94-4P 626246-95-5P


Habe

08/08/2006


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

626246-97-7P 626246-99-9P 626247-01-6P
 626247-03-8P 626247-05-0P 626247-07-2P
 626247-09-4P 626247-11-8P 626247-13-0P
 626247-15-2P 626247-20-9P 626247-23-2P
 626247-25-4P 626247-27-6P 626247-30-1P
 626247-32-3P 626247-35-6P 626247-37-8P
 626247-40-3P 626247-43-6P 626247-45-8P
 626247-48-1P 626247-51-6P 626247-54-9P
 626247-57-2P 626247-58-3P 626247-60-7P
 626247-61-8P 626247-62-9P 626247-63-0P
 626247-64-1P 626247-65-2P 626247-66-3P
 626247-67-4P 626247-68-5P 626247-69-6P
 626247-70-9P 626247-71-0P 626247-72-1P
 626247-73-2P 626247-74-3P 626247-75-4P
 626247-76-5P 626247-77-6P 626247-78-7P
 626247-79-8P 626247-80-1P 626247-81-2P
 626247-82-3P 626247-83-4P 626247-84-5P
 626247-85-6P 626247-86-7P 626247-87-8P
 626247-88-9P 626247-89-0P 626247-90-3P
 626247-91-4P 626247-92-5P 626247-93-6P
 626247-94-7P 626247-95-8P 626247-96-9P
 626247-97-0P 626247-98-1P 626247-99-2P
 626248-00-8P 626248-01-9P 626248-02-0P
 626248-03-1P 626248-04-2P 626248-05-3P
 626248-06-4P 626248-07-5P 626248-08-6P
 626248-09-7P 626248-10-0P 626248-11-1P
 626248-12-2P 626248-13-3P 626248-14-4P
 626248-15-5P 626248-16-6P 626248-17-7P
 626248-18-8P 626248-19-9P 626248-20-2P
 626248-21-3P 626248-22-4P 626248-23-5P
 626248-24-6P 626248-25-7P 626248-26-8P
 626248-27-9P 626248-28-0P 626248-29-1P
 626248-30-4P 626248-31-5P 626248-32-6P
 626248-33-7P 626248-34-8P 626248-35-9P
 626248-36-0P 626248-37-1P 626248-38-2P
 626248-39-3P 626248-40-6P 626248-41-7P
 626248-42-8P 626248-43-9P 626248-46-2P
 626249-06-7P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prepn. of quinazolinylmethyl urea derivs. as fungal efflux pump
 inhibitors)
 RN 626245-51-0 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-
 oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-, monomethanesulfonate
 (9CI) (CA INDEX NAME)
 CH 1
 CRN 562835-78-3
 CMF C30 H33 Cl N6 O4

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626245-69-0 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-
 fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-ethyl-
 (9CI) (CA INDEX NAME)



RN 626245-70-3 CAPLUS
 CN Pyridinium, 1-[2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-
 fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-
 piperazinyl]-2-oxoethyl]-, chloride (9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2
 CRN 75-75-2
 CMF C H4 O3 S




RN 626245-67-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-
 fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, ethyl
 ester (9CI) (CA INDEX NAME)




RN 626245-68-9 CAPLUS
 CN 1-Piperazineacetamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-
 fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-(2-
 fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626245-74-7 CAPLUS
 CN 1-Piperazinebutanoic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-
 fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI)
 (CA INDEX NAME)




RN 626245-81-6 CAPLUS
 CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-
 fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-
 piperazinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626245-83-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 2-(4-oxo-1(4H)-pyridinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 626245-85-0 CAPLUS
 CN Morpholine, 4-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl- (9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626245-93-0 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 626245-96-3 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 626246-00-2 CAPLUS

Habte

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626245-88-3 CAPLUS
 CN Urea, N'-(6-chloro-3-pyridazinyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 626245-90-7 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Urea, N-(2,4-difluorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-04-6 CAPLUS
 CN Urea, N-(3,4-dimethoxyphenyl)-N-[1-[5-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-07-9 CAPLUS
 CN Urea, N-[1-[6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-10-4 CAPLUS
 CN Urea, N'-(4-chlorophenyl)-N-[1-[6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 626246-13-7 CAPLUS
 CN Urea, N-[1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-16-0 CAPLUS
 CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-[6-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-17-1 CAPLUS
 CN Urea, N-(2,4-difluorophenyl)-N-[1-[6-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-19-3 CAPLUS
 CN Urea, N'-(4-chlorophenyl)-N-[1-[3,4-dihydro-6-methyl-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 626246-22-8 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-6-methyl-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-25-1 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-6-methyl-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 626246-28-4 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-6-(1-oxopropoxy)-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626246-31-9 CAPLUS


CN Urea, N'-[1-[3,4-dihydro-6-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 626246-34-2 CAPLUS


CN Urea, N'-[1-(4-chlorophenyl)-N-[1-[3,4-dihydro-6-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626246-37-5 CAPLUS


CN Urea, N'-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)



RN 626246-40-0 CAPLUS


CN Urea, N'-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626246-43-3 CAPLUS


CN Urea, N'-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 626246-45-5 CAPLUS


CN Urea, N'-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626246-48-8 CAPLUS


CN Urea, N'-[1-[7-cyano-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-51-3 CAPLUS

CN 7-Quinazolinecarboxylic acid, 2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-54-6 CAPLUS
 CN Urea, N-(2,4-dimethoxyphenyl)-N'-[1-{7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl}ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-56-8 CAPLUS
 CN Urea, N'-[1-{3,4-dihydro-8-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl}ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-60-4 CAPLUS
 CN Urea, N'-(4-chlorophenyl)-N-[1-{3,4-dihydro-8-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl}ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 626246-64-8 CAPLUS
 CN Urea, N'-[1-{3,4-dihydro-6-hydroxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl}ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-67-1 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626246-69-3 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(3-chlorophenyl)amino]carbonyl](2,4-dimethoxyphenyl)amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 626246-71-7 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626246-72-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(phenylamino)carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 626246-74-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(3-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626246-75-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-difluorophenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 626246-84-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626246-89-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, ethyl ester (9CI) (CA INDEX NAME)




Habte

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 626246-76-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[6-chloro-2-[1-[(3-chlorophenyl)amino]carbonyl](2,4-dimethoxyphenyl)amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 626246-81-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

RN 626246-91-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-8-methoxy-4-oxo-3(4H)-quinazolinyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 626246-92-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(4-chlorophenyl)amino]carbonyl](2,4-dimethoxyphenyl)amino]ethyl]-8-methoxy-4-oxo-3(4H)-quinazolinyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 626246-93-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 2-(1H-imidazol-1-yl)ethyl ester (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 626246-94-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 2-(1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 626246-95-5 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 2-(3-hydroxy-1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 626247-01-6 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 2-(4-methyl-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 626247-03-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 2-(4-thiomorpholinyl)ethyl ester (9CI) (CA INDEX NAME)




Habe

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 626246-97-7 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 2-(1-piperidinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 626246-99-9 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

RN 626247-05-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 2-cyanoethyl ester (9CI) (CA INDEX NAME)




RN 626247-07-2 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 2-(1,3,4-thiadiazol-2-ylthio)ethyl ester (9CI) (CA INDEX NAME)




RN 626247-09-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 2-(1H-imidazol-2-ylthio)ethyl ester (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-11-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-[(1-methyl-1H-imidazol-2-yl)thio]ethyl ester (9CI) (CA INDEX NAME)




RN 626247-13-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-(2,5-dioxo-1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-23-2 CAPLUS
 CN Morpholine, 4-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 626247-25-4 CAPLUS
 CN Morpholine, 4-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-15-2 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-(1,3,4-thiadiazol-2-ylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 626247-20-9 CAPLUS
 CN 1-Piperazineacetamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-27-6 CAPLUS
 CN Morpholine, 4-[[4-[2-[1-[[[4-(4-fluorophenyl)amino]carbonyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 626247-30-1 CAPLUS
 CN Morpholine, 4-[[4-[2-[1-[[[3-(3-chlorophenyl)amino]carbonyl]-2,4-dimethoxyphenyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-32-3 CAPLUS
 CN Morpholine, 4-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(phenylamino)carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 626247-35-6 CAPLUS
 CN Pyrrolidine, 1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-43-6 CAPLUS
 CN Piperazine, 1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 626247-45-8 CAPLUS
 CN 1-Piperazineacetamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-37-8 CAPLUS
 CN Piperidine, 1-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 626247-40-3 CAPLUS
 CN Thiomorpholine, 4-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626247-48-1 CAPLUS
 CN Morpholine, 4-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 626247-51-6 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-[1-[3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 626247-54-9 CAPLUS

CN Piperazine, 1-[2-[1-[[[3-chlorophenyl]amino]carbonyl](2,4-dimethoxyphenyl)amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 626247-57-2 CAPLUS


CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 626247-58-3 CAPLUS


CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(phenylamino)carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-62-9 CAPLUS

CN Urea, N-[1-[3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl]ethyl]-N'-(2,4-dimethoxyphenyl)-N'-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626247-63-0 CAPLUS

CN Piperazine, 1-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626247-60-7 CAPLUS

CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-[6-fluoro-3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626247-61-8 CAPLUS

CN Urea, N-[1-[3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl]ethyl]-N'-(2,4-dimethoxyphenyl)-N'-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 626247-64-1 CAPLUS

CN Piperidine, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-(4-morpholinylacetyl)- (9CI) (CA INDEX NAME)



RN 626247-65-2 CAPLUS


CN Piperidine, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-[(4-methyl-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 626247-66-3 CAPLUS

CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-67-4 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,6-dimethoxy-3-pyridinyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 626247-68-5 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,6-dimethoxy-3-pyridinyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626247-71-0 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4-methyl-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 626247-72-1 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4-morpholinyl)acetyl]- (9CI) (CA INDEX NAME)




Habe

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-69-6 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 626247-70-9 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4-morpholinyl)acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 626247-73-2 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(1H-imidazol-1-yl)acetyl]- (9CI) (CA INDEX NAME)




RN 626247-74-3 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(1H-imidazol-1-yl)acetyl]- (9CI) (CA INDEX NAME)




RN 626247-75-4 CAPLUS
 CN Piperazine, 1-(cyanoacetyl)-4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-76-5 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(1-pyrrolidinylacetyl)- (9CI) (CA INDEX NAME)




RN 626247-77-6 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(3-hydroxy-1-pyrrolidinyl)acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-78-7 CAPLUS
CN Piperazine, 1-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(1-piperidinylacetyl)- (9CI) (CA INDEX NAME)




RN 626247-79-8 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(4-thiomorpholinylacetyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626247-80-1 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4-hydroxy-1-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 626247-81-2 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4-oxo-1(4H)-pyridinyl)acetyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 626247-82-3 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(1H-1,2,4-triazol-1-ylacetyl)- (9CI) (CA INDEX NAME)




RN 626247-83-4 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2,5-dioxo-1-pyrrolidinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 626247-84-5 CAPLUS
CN 1-Piperazinebutanamide, 4-[2-[1-[[[(4-chlorophenyl)amino]carbonyl](2,4-dimethoxyphenyl)amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-85-6 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2-methoxyethoxy)acetyl]- (9CI) (CA INDEX NAME)




RN 626247-86-7 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2-methoxyethoxy)ethoxy]acetyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626247-89-0 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 626247-90-3 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-87-8 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2-methoxyethoxy)acetyl]- (9CI) (CA INDEX NAME)




RN 626247-88-9 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(1H-imidazol-4-ylacetyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626247-91-4 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 626247-92-5 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2R)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-93-6 CAPLUS
 CN Piperidine, 4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 626247-94-7 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-4-[(1H-imidazol-4-yl)acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626247-97-0 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 626247-98-1 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-(hydroxymethyl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-95-8 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(1-methyl-1H-imidazol-4-yl)acetyl]- (9CI) (CA INDEX NAME)




RN 626247-96-9 CAPLUS
 CN Carbamic acid, [3-[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-99-2 CAPLUS
 CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626248-00-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[2-[4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-01-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626248-02-0 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626248-05-3 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 626248-06-4 CAPLUS
 CN Urea, N-[1-[3-[4-(4,5-dihydro-2-oxazolyl)-1-piperazinyl]-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626248-07-5 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-[1-[[[3-chlorophenyl]amino]carbonyl](2,4-dimethoxyphenyl)amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Habt

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-03-1 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 626248-04-2 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-08-6 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(ethenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 626248-09-7 CAPLUS
 CN Urea, N-[1-[3-[4-(4,5-dihydro-2-oxazolyl)-1-piperazinyl]-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-10-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626248-11-1 CAPLUS
CN Piperidine, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-[(2-methoxyethoxy)acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-14-4 CAPLUS
CN 1-Piperazinebutanamide, N-cyano-4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 626248-15-5 CAPLUS
CN 1-Piperazinebutanamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-12-2 CAPLUS
CN 1-Piperazinebutanamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 626248-13-3 CAPLUS
CN 1-Piperazinebutanamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626248-16-6 CAPLUS
CN Piperazine, 1-[2-[(1S)-1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 626248-17-7 CAPLUS
CN Piperazine, 1-[2-[(1R)-1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-18-8 CAPLUS
 CN Piperazine, 1-[(3-amino-1-oxopropyl)-4-[2-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 626248-19-9 CAPLUS
 CN Piperazine, 1-[(3-amino-1-oxopropyl)-4-[2-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-22-4 CAPLUS
 CN Piperazine, 1-[(2-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(methylamino)acetyl]- (9CI) (CA INDEX NAME)



RN 626248-23-5 CAPLUS
 CN Piperazine, 1-[(2-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylacetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626248-20-2 CAPLUS
 CN Piperazine, 1-[(2S)-2-amino-1-oxopropyl]-4-[2-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 626248-21-3 CAPLUS
 CN Piperazine, 1-[(2S)-2-amino-3-hydroxy-1-oxopropyl]-4-[2-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-24-6 CAPLUS
 CN Piperazine, 1-[(2-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4-formyl-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 626248-25-7 CAPLUS
 CN Carbamic acid, [2-[4-[2-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-2-oxoethyl]methyl-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-26-8 CAPLUS
 CN Carbamic acid, [(1S)-2-(4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl)-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 626248-27-9 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2-pyrrolidinyl)ethyl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-30-4 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(4-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 626248-31-5 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,6-dimethoxy-3-pyridinyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2R)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-28-0 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-4-oxo-3-(4-piperidinyl)-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626248-29-1 CAPLUS
 CN Pyrrolidine, 1-[2-[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-32-6 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626248-33-7 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(1-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-34-8 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(5-fluoro-2-pyridinyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(4-morpholinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 626248-35-9 CAPLUS
 CN Morpholine, 4-[[4-[2-[1-[(2,4-bis(cyclopropylmethoxy)phenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626248-37-1 CAPLUS
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[2-[1-[[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 626248-38-2 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-bis(cyclopropylmethoxy)phenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 626248-36-0 CAPLUS
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[2-[1-[[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-39-3 CAPLUS
 CN Piperazine, 1-[2-[1-[(5-acetyl-2-methoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(cyclopropylcarbonyl)- (9CI) (CA INDEX NAME)




RN 626248-40-6 CAPLUS
 CN Piperazine, 1-[2-[1-[[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-41-7 CAPLUS
 CN Urea, N-[1-[3-(4-(cyclopropylmethyl)-1-piperazinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626248-42-8 CAPLUS
 CN Piperazine, 1-[(3-amino-1-pyrrolidinyl)carbonyl]-4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626249-06-7 CAPLUS
 CN Morpholine, 4-[[4-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)




IT 562835-90-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of quinazolinylmethyl urea derivs. as fungal efflux pump inhibitors)
 RN 562835-90-9 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-43-9 CAPLUS
 CN Piperazine, 1-[(4-amino-1-piperidinyl)carbonyl]-4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 626248-46-2 CAPLUS
 CN Piperazine, 1-[(2S)-1-acetyl-2-pyrrolidinyl]carbonyl]-4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 562836-26-4P 626245-57-6P 626245-59-8P
 626245-61-2P 626245-63-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of quinazolinylmethyl urea derivs. as fungal efflux pump inhibitors)
 RN 562836-26-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 626245-57-6 CAPLUS
 CN 1-Piperazineacetic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 626245-59-8 CAPLUS

08/08/2006

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-[3-[4-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]-1-piperazinyl]-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626245-61-2 CAPLUS
 CN Piperazine, 1-(chloroacetyl)-4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 626245-63-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 33 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:867291 CAPLUS
 DOCUMENT NUMBER: 140:156722
 TITLE: Some new 2,3,6-trisubstituted quinazolinones as potent anti-inflammatory, analgesic and COX-II inhibitors
 AUTHOR(S): Kumar, Ashok; Sharma, Shalabh; Archana; Bajaj, Kiran; Sharma, Shipra; Panwar, Hemant; Singh, Tripti; Srivastava, V. K.
 CORPORATE SOURCE: Department of Pharmacology, Medicinal Chemistry Division, L.L.R.M Medical College, Meerut (U.P.), 250004, India
 SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(23), 5293-5299
 CODEN: BMECEP; ISSN: 0968-0896
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:156722
 GI




I

AB Various 2-(substitutedphenylmethyleneimino)aminoacetylmethylene-3-(2'-substitutedindol-3'-yl)-halosubstituted-4(3H)quinazolinones and 2-(substituted phenylaminomethyleneacetyl-4'-oxo-1'-thiazolidinyl-3-(2'-substitutedindol-3'-yl) 4(3H)-quinazolinones have been synthesized in the present studies. The structure of these compds. have been elucidated by elemental (C, H, N) and spectral (IR, 1H NMR and mass) anal. Furthermore, above said compds. were evaluated for their anti-inflammatory, analgesic, ulcerogenic activities and acute toxicity study. Compound I was found to be most potent. Compound I exhibiting less ulcerogenic liability and ALD50 >2000 mg/kg po.
 IT 655250-40-1P 655250-41-2P 655250-42-3P
 655250-43-4P 655250-44-5P 655250-45-6P
 655250-46-7P 655250-47-8P 655250-48-9P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (trisubstituted quinazolinones as anti-inflammatory and analgesic COX-II inhibitors)
 RN 655250-40-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-[[2-(2-methoxyphenyl)-4-oxo-3-thiazolidinyl]amino]-2-oxopropyl]-3-(2-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 33 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 655250-41-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-[[2-(4-methoxyphenyl)-4-oxo-3-thiazolidinyl]amino]-2-oxopropyl]-3-(2-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



RN 655250-42-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-[[2-(2-chlorophenyl)-4-oxo-3-thiazolidinyl]amino]-2-oxopropyl]-3-(2-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



RN 655250-43-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(1H-indol-3-yl)-6-iodo-2-[3-[[2-(2-methoxyphenyl)-4-oxo-3-thiazolidinyl]amino]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Habe

08/08/2006

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 phthalimidoethyl)-3,4-dihydroquinazolin-4-one (III). III (0.71 g) and 0.26 g 2,4-dimethoxyaniline were dissolved in 20 mL DMF, treated with freshly crushed K₂CO₃, and stirred at 80° for 16 h to give 2-[1-(3,4-dimethoxyphenyl)ethyl]-6-chloro-3-(2-phthalimidoethyl)-3,4-dihydroquinazolin-4-one which (0.46 g) was dissolved in 5 mL 1,2-dichloroethane, treated with 0.12 mL Ph isocyanate, and stirred at 40° for 16 h to give 668 N-[1-(6-chloro-3-(2-(1,3-dioxo-1,3-dihydroisindol-2-yl)ethyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-phenylurea (IV). IV showed MPC8 (concn. of efflux pump inhibitor necessary to reduce the fluconazole MIC 8-fold) of 50.03 µg/mL against *C. albicans* vs. MIC (concn. of fluconazole alone that causes a 80% inhibition the growth/proliferation of fungal cells) of 16 µg/mL.


IT 562835-78-3P, N'-(3-Chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562835-79-4P, Acetic acid 2-[4-(2-[1-(N'-(3-chlorophenyl)-N-(2,4-dimethoxyphenyl)ureido]ethyl)-4-oxo-4H-quinazolin-3-yl]piperazin-1-yl]ethyl ester 562835-80-7P, N'-(3-Chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-(3-(4-(2-hydroxyethyl)piperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562835-81-8P, N'-(3-Chlorophenyl)-N-(4-methoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562835-82-9P, N'-(3-Chlorophenyl)-N-(4-methoxy-2-methylphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562835-83-0P, N'-(2-Chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562835-84-1P, N'-(4-Chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562835-85-2P, N-(2,4-Dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N'-phenylurea 562835-86-3P, N-(2,4-Dimethoxyphenyl)-N'-(2-methoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562835-87-4P, 4-Chloro-N-(2,4-dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]benzenesulfonamide 562835-88-5P, (2,4-Dimethoxyphenyl)[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]carbamate 562835-89-6P, N'-(4-Chlorophenyl)-N-(4-methoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562835-90-9P, N-(2,4-Dimethoxyphenyl)-N'-(4-fluorophenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562835-91-0P, N-(2,4-Dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N'-p-tolylurea 562835-92-1P, N-(2,4-Dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562835-93-2P, 2-Chloro-N-(2,4-dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]benzenesulfonamide 562835-94-3P, (2,4-Dimethoxyphenyl)[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]carbamate 4-chlorophenyl ester 562835-96-5P, N-Benzo[1,3]dioxol-5-yl-N'-(3-chlorophenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562835-97-6P, (2,4-Dimethoxyphenyl)[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]carbamate p-tolyl ester 562835-98-7P, N-(2,4-Dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N'-m-tolylurea

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 562835-99-8P, N-(2,4-Dimethoxyphenyl)-N'-(3-fluorophenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562836-00-4P, N'-(3-Chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-(3-(1-methylpiperidin-4-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562836-01-5P, N-[1-(6-Chloro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N'-(3-chlorophenyl)-N-(2,4-dimethoxyphenyl)urea 562836-02-6P, N-[1-(6-Chloro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-phenylurea 562836-03-7P, N-[1-(6-Chloro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methoxyphenyl)urea 562836-04-8P, N-(2,4-Dimethoxyphenyl)-4-methyl-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]benzamide 562836-05-9P, 3-Chloro-N-(2,4-dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]benzamide 562836-06-0P, 4-Chloro-N-(2,4-dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]benzamide 562836-07-1P, 2-Chloro-N-(2,4-dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]benzamide 562836-08-2P, N-(2,4-Dimethoxyphenyl)-4-methoxy-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]benzamide 562836-09-3P, N-Benzo[1,3]dioxol-5-yl-N'-(4-chlorophenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562836-10-6P, N-[1-(6-Chloro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-isopropylurea 562836-11-7P, N'-(3-Chlorophenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N-(3,4,5-trimethoxyphenyl)urea 562836-12-8P, N-Benzo[1,3]dioxol-5-yl-N'-(4-methoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562836-13-9P, [1-(6-Chloro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl](2,4-dimethoxyphenyl)carbamate acid 4-chlorophenyl ester 562836-14-0P, (2,4-Dimethoxyphenyl)[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]carbamate acid 2-chlorophenyl ester 562836-15-1P, (2,4-Dimethoxyphenyl)[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]carbamate acid 4-methoxyphenyl ester 562836-16-2P, N'-(4-Chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-(6-fluoro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562836-18-4P, N-(2,4-Dimethoxyphenyl)-N'-(4-fluorophenyl)-N-[1-(3-(4-(2-hydroxyethyl)piperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562836-19-5P, N-[1-(3-(4-(2-Chlorophenyl)piperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)urea 562836-20-8P, N-(2,4-Dimethoxyphenyl)-N-[1-(6-fluoro-3-(4-(2-hydroxyethyl)piperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N'-(4-fluorophenyl)urea 562836-22-0P, N-(2,4-Dimethoxyphenyl)-N-[1-(6-methyl-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N'-p-tolylurea 562836-23-1P, N-(2,4-Dimethoxyphenyl)-N-[1-(6-methoxy-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N'-p-tolylurea


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 3,4-dihydroquinazolin-4-one derivs. as fungal efflux pump inhibitors and potentiators of antifungal agents for treating infections caused by fungi employing efflux pump resistance mechanism)

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 562835-78-3 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-[1-(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 562835-79-4 CAPLUS
 CN Urea, N-[1-(3-(4-(2-(acetyloxy)ethyl)-1-piperazinyl)-3,4-dihydro-4-oxo-2-quinazolinyl)ethyl]-N'-(3-chlorophenyl)-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-80-7 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-[1-(3,4-dihydro-3-(4-(2-hydroxyethyl)-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




Habte


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562835-81-8 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-[1-(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-82-9 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-[1-(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 562835-83-0 CAPLUS
 CN Urea, N'-(2-chlorophenyl)-N-[1-(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

08/08/2006


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562835-84-1 CAPLUS
CN Urea, N'-(4-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-85-2 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-phenyl- (9CI) (CA INDEX NAME)





L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 562835-86-3 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-87-4 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-88-5 CAPLUS
CN Carbamic acid, [1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl](2,4-dimethoxyphenyl)-, phenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562835-89-6 CAPLUS
CN Urea, N'-(4-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-90-9 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562835-91-0 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 562835-92-1 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-93-2 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562835-94-3 CAPLUS
CN Carbamic acid, [1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl] (2,4-dimethoxyphenyl)-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)




RN 562835-96-5 CAPLUS
CN Urea, N-1,3-benzodioxol-5-yl-N'-(3-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562835-99-8 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562836-00-4 CAPLUS
CN Urea, N'-(3-chlorophenyl)-N-[1-[3,4-dihydro-3-(1-methyl-4-piperidinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




Habe

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562835-97-6 CAPLUS
CN Carbamic acid, [1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl] (2,4-dimethoxyphenyl)-, 4-methylphenyl ester (9CI) (CA INDEX NAME)




RN 562835-98-7 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(3-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 562836-01-5 CAPLUS

CN Urea, N-[1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(3-chlorophenyl)-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562836-02-6 CAPLUS
CN Urea, N-[1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-phenyl- (9CI) (CA INDEX NAME)




RN 562836-03-7 CAPLUS
CN Urea, N-[1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562836-04-8 CAPLUS
 CN Benzamide, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 562836-05-9 CAPLUS
 CN Benzamide, 3-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzamide, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-4-methoxy- (9CI) (CA INDEX NAME)



RN 562836-09-3 CAPLUS
 CN Urea, N-1,3-benzodioxol-5-yl-N'-(4-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 562836-10-6 CAPLUS
 CN Urea, N-[1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




Habe


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562836-06-0 CAPLUS
 CN Benzamide, 4-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562836-07-1 CAPLUS
 CN Benzamide, 2-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562836-08-2 CAPLUS

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 562836-11-7 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562836-12-8 CAPLUS
 CN Urea, N-1,3-benzodioxol-5-yl-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562836-13-9 CAPLUS
 CN Carbamic acid, [1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl](2,4-dimethoxyphenyl)-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562836-14-0 CAPLUS
CN Carbamic acid, [1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl] (2,4-dimethoxyphenyl)-, 2-chlorophenyl ester (9CI) (CA INDEX NAME)




RN 562836-15-1 CAPLUS
CN Carbamic acid, [1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl] (2,4-dimethoxyphenyl)-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562836-16-2 CAPLUS
CN Urea, N'-(4-chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[6-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 562836-18-4 CAPLUS
CN Urea, N'-(4-chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[6-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562836-19-5 CAPLUS
CN Urea, N-[1-[3-(4-(2-chloroethyl)-1-piperazinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562836-20-8 CAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-[6-fluoro-3,4-dihydro-3-(4-(2-hydroxyethyl)-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562836-22-0 CAPLUS

Habte

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Urea, N-[1-[3,4-dihydro-6-methyl-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 562836-23-1 CAPLUS
CN Urea, N-[1-[3,4-dihydro-6-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



IT 562836-26-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3,4-dihydroquinazolin-4-one derivs. as fungal efflux pump inhibitors and potentiators of antifungal agents for treating infections caused by fungi employing efflux pump resistance mechanism)
RN 562836-26-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

08/08/2006

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:833514 CAPLUS
 DOCUMENT NUMBER: 137:337912
 TITLE: Preparation of purinylquinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
 INVENTOR(S): Sadhu, Chanchal; Dick, Ken; Treiberg, Jennifer; Sewell, C. Gregory; Kesicki, Edward A.; Oliver, Amy
 PATENT ASSIGNEE(S): ICOS Corp., USA
 SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of U.S. Ser. No. 841,341.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161014	A1	20021031	US 2001-27591	20011019
US 6667300	B2	20031223		
US 6518277	B1	20030211	US 2001-841341	20010424
CA 2463294	AA	20030501	CA 2002-2463294	20020827
WO 2003035075	A1	20030501	WO 2002-US27240	20020827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GW, GQ, GU, ML, MR, NE, SN, TD, TG				
EP 1438052	A1	20040721	EP 2002-757407	20020827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1606444	A	20050413	CN 2002-825687	20020827
JP 2005509635	T2	20050414	JP 2003-537642	20020827
ZA 2002008698	A	20031010	ZA 2002-8698	20021028
US 2003195211	A1	20031016	US 2003-337192	20030106
US 6800620	B2	20041005		
US 2004266780	A1	20041230	US 2003-697912	20031030
US 6949535	B2	20050927		
US 2005261317	A1	20051124	US 2005-110204	20050420
PRIORITY APPLN. INFO.:				
			US 2000-199655P	P 20000425
			US 2000-238057P	P 20001005
			US 2001-841341	A2 20010424
			US 2001-27591	A 20011019
			WO 2002-US27240	W 20020827
			US 2003-697912	A1 20031030
OTHER SOURCE(S): MARPAT 137:337912				
GI				

L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB A method of disrupting leukocyte function comprises administration of title compds. [I: X = C(Rb)2, CH2CHRB, CH:CRb; Rb = H, alkyl, heteroalkyl, aryl, heteroaryl, aralkyl, etc.; Y = null, S, SO, SO2, NH, O, CO, CO2, NHCOCH2S; R, R1 = H, alkyl, aryl, heteroaryl, halo, etc.; R2 = H, (substituted) alkyl, cycloalkyl, heterocycloalkyl, alkylencycloalkyl, alkenyl, alkylenearyl, aryl, heteroaryl, etc.; A = (substituted) mono- or bicyclic ring system containing ≥2 N atoms and in which ≥1 ring is aromatic]. Thus, dose-dependent decrease in histamine release from basophils

when stimulated with anti-IgE was 100% at 1,000 nM, with an EC50 of about 25 nM for I (Y = S, R = 5-Me, R1 = H, R2 = 2-ClC6H4, R3 = H; S connected to 6-position of purine ring; preparation given).

IT 371243-12-9P, 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- 371243-13-9P, 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- 371243-14-0P, 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino)methyl]-5-methyl-3-(2-methylphenyl)- 371243-15-1P, 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino)methyl]-3-(2-chlorophenyl)-5-fluoro- 371243-17-3P, 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino)methyl]-5-methyl-3-(2-methylphenyl)- 371243-22-0P, 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino)methyl]-5-methyl-3-(2-methylphenyl)- 371243-23-1P, 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- 474012-90-3P 474012-93-6P 474012-96-9P 474012-98-1P 474013-01-9P


RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of purinylquinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta)


RN 371243-12-9 CAPLUS

CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-13-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-14-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino)methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 371243-15-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-amino-1H-purin-6-yl)amino)methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-fluoro-1H-purin-6-yl)amino)methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 474012-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 474012-96-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474012-98-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 474013-01-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)





08/08/2006

L4 ANSWER 36 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:813938 CAPLUS
 DOCUMENT NUMBER: 137:337907
 TITLE: Preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions
 INVENTOR(S): Medina, Julio C.; Johnson, Michael G.; Li, An-Rong; Liu, Jiwen; Huang, Alan Xi; Zhu, Liusheng; Marcus, Andrew P.
 PATENT ASSIGNEE(S): Tularik Inc., USA
 SOURCE: PCT Int. Appl., 205 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083143	A1	20021024	WO 2001-US47850	20011211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2431553	AA	20021024	CA 2001-2431553	20011211
US 2002169159	A1	20021114	US 2001-15532	20011211
US 6964967	B2	20051115		
EP 1343505	A1	20030917	EP 2001-273533	20011211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004536796	T2	20041209	JP 2002-580947	20011211
CN 1575177	A	20050202	CN 2001-822596	20011211
BR 2001016096	A	20051018	BR 2001-16096	20011211
US 2003069234	A1	20030410	US 2002-164690	20020606
US 6794379	B2	20040921		
US 2003055054	A1	20030320	US 2002-231895	20020829
US 7053215	B2	20060530		
ZA 2003004342	A	20050509	ZA 2003-4342	20030603
NO 2003002612	A	20030805	NO 2003-2612	20030610
US 2005075333	A1	20050407	US 2004-946935	20040921
US 7067662	B2	20060627		
US 2006116388	A1	20060601	US 2006-332054	20060113
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S): MARPAT 137:337907				
GI				

L4 ANSWER 36 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title compds. I [wherein X = a bond, CO, CR5R6, CR5:, SO, SO2, or N: ; Z = a bond, N:, O, S, NR17, or CR7: ; with the proviso that X and Z are not both a bond; L = CO-alkylene or (hetero)alkylene; Q = (hetero)alkylene, CO, OCO, NR8CO, CH2CO, CH2SO, or CH2SO2; or NR4 = heterocyclyl; R1 and R2 = independently H, (hetero)alkyl, or (hetero)aryl; or CR1R2 = (hetero)cyclyl; or CR2R3 = heterocyclyl; R3 = OH, alkoxy, NH2, (di)alkylamino, heteroalkyl, heterocyclyl, acylaminoamidino, guanidino, urido, CN, heteroaryl, carbamoyl, or carboxy; R4 = (hetero)alkyl, (hetero)aryl, etc.; R5 and R6 = independently H, (hetero)alkyl, or (hetero)aryl; or CR5R6 = a ring; R7 and R8 = independently H, (hetero)alkyl, or (hetero)aryl; Y1 and Y2 = independently CR12: N:, O, S, or NR13; Y3 = N or C, wherein C shares a double bond with either Z or Y4; Y4 = NR14, CR14:, N:, NR14CR15R16; R12 = H, halo, OH, NH2, (di)alkylamino, (hetero)alkyl, or (hetero)aryl, with provisos: R13 = H, (hetero)alkyl, (hetero)aryl, etc.; R14 = (hetero)alkyl, (hetero)aryl, etc.; R15 and R16 = independently H or (hetero)alkyl; R17 = H, (hetero)alkyl, (hetero)aryl, etc.; with provisos] were prepared as chemokine receptor modulators, in particular CXCR3 antagonists. For example, anthranilic acid was acylated with propionyl chloride and the amide cyclized using acetic anhydride to give 2-ethylbenzo[d][1,3]oxazine-4-one. Treatment with 4-fluoroaniline, followed by ethylene glycol and NaOH afforded 2-ethyl-3-(4-fluorophenyl)-3H-quinazolin-4-one. Bromination and stepwise addition of 1-amino-2-methoxyethane and decanoyl chloride produced the decanoic acid (quinazolinylethyl)(methoxyethyl)amide II. Approx. one third of the 101 invention compds. tested in a CXCR3 binding assay displayed activity with IC50 values of < 1 μM. I are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis, and type I diabetes (no data).
 IT 473907-65-2P, T 0913409
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic)

L4 ANSWER 36 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (CXCR3 antagonist; prepn. of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions)
 RN 473907-65-2 CAPLUS
 CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-4-fluoro-N-(1-methyl-4-piperidinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 473719-99-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (CXCR3 antagonist; preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions)
 RN 473719-99-2 CAPLUS
 CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-4-fluoro-N-(1-methyl-4-piperidinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 473720-98-8P 473720-99-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions)
 RN 473720-98-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 36 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 473720-99-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

ACCESSION NUMBER: 2002:769983 CAPLUS
 DOCUMENT NUMBER: 137:302093
 TITLE: Photographic color coupler, silver halide photographic material, and azomethine dye
 INVENTOR(S): Takeuchi, Kiyoshi; Uehira, Shigeo
 PATENT ASSIGNEE(S): Fujii Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 54 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002296741	A2	20021009	JP 2001-102698	20010330
US 2003064332	A1	20030403	US 2002-106192	20020327
US 6677110	B2	20040113		
US 2004096787	A1	20040520	US 2003-679495	20031007
PRIORITY APPLN. INFO.:			JP 2001-102538	A 20010330
			JP 2001-102698	A 20010330
			US 2002-106192	A3 20020327

OTHER SOURCE(S): MARPAT 137:302093
 GI



L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB The invention relates to a photog. color coupler represented by I (Q = atoms for forming N-containing 6-membered ring, preferably 4-pyrimidinone ring; R1 = aryl, heterocyclyl; X = aryl; Y = H, group capable of leaving upon coupling reaction with oxidized developing agent) and a photog. material containing the color coupler. The invention also relates to an azomethine dye represented by II (Q = atoms for forming N-containing 6-membered ring, preferably 4-pyrimidinone ring; R1 = aryl, heterocyclyl; X = aryl; R5, R6, R7 = H, substituent; n = 0-4) formed by the above color coupler's coupling reaction. The photog. material shows excellent color hue, storage stability, color reproduction, and lightfastness.


IT 468730-22-5 468730-23-6 468730-24-7 468730-25-8

RL: PMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)

(azomethine dye; photog. color coupler forming azomethine dye for color photog. material showing improved color hue, storage stability, color reproduction, and lightfastness)

RN 468730-22-5 CAPLUS


CN Benzoic acid, 4-chloro-3-[[[3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl] [4-ethyl[2-[(methylsulfonyl)amino]ethyl]amino]-2-methylphenyl]imino]acetyl]amino]-, dodecyl ester (9CI) (CA INDEX NAME)



RN 468730-23-6 CAPLUS


CN Benzoic acid, 3-[[[3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl] [4-ethyl[2-[(methylsulfonyl)amino]ethyl]amino]-2-methylphenyl]imino]acetyl]amino]-4-methoxy-, tetradecyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 468730-24-7 CAPLUS


CN 2-Quinazolineacetamide, N-[5-[[2-(2,4-bis(1,1-dimethylpropyl)phenoxy)-1-oxobutyl]amino]-2-methoxyphenyl]-6,8-dichloro-α-[[4-ethyl[2-[(methylsulfonyl)amino]ethyl]amino]-2-methylphenyl]imino]-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)



RN 468730-25-8 CAPLUS

CN 2-Quinazolineacetamide, N-[2-chloro-5-[(diethylamino) sulfonyl]phenyl]-α-[[4-ethyl[2-[(methylsulfonyl)ethyl]amino]-2-methylphenyl]imino]-3,4-dihydro-4-oxo-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 468730-14-5P 468730-15-6P

RL: MOA (Modifier or additive use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (coupler preparation; photog. color coupler forming azomethine dye for color photog. material showing improved color hue, storage stability, color reproduction, and lightfastness)

RN 468730-14-5 CAPLUS


CN Benzoic acid, 4-chloro-3-[[[3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl]acetyl]amino]-, dodecyl ester (9CI) (CA INDEX NAME)




RN 468730-15-6 CAPLUS

CN Benzoic acid, 3-[[[3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl]acetyl]amino]-4-methoxy-, tetradecyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 468730-20-3P 468730-21-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (coupler preparation; photog. color coupler forming azomethine dye for
 color photog. material showing improved color hue, storage stability, color
 reproduction, and lightfastness)
 RN 468730-20-3 CAPLUS
 CN Benzoic acid, 3-[[bromo(3,4-dihydro-4-oxo-3-phenyl-2-
 quinazolinyl)acetyl]amino]-4-chloro-, dodecyl ester (9CI) (CA INDEX NAME)




RN 468730-21-4 CAPLUS
 CN Benzoic acid, 3-[[bromo(3,4-dihydro-4-oxo-3-phenyl-2-
 quinazolinyl)acetyl]amino]-4-methoxy-, tetradecyl ester (9CI) (CA INDEX
 NAME)

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468730-19-0 CAPLUS
 CN 2-Quinazolineacetamide, α-1H-benzotriazol-1-yl-3-(1,2-dihydro-2-oxo-
 4-pyridinyl)-N-[2-(hexadecyloxy)-5-[[[1-oxopropyl]amino]sulfonyl]phenyl]-
 3,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




IT 468730-12-3P 468730-13-4P
 RL: MOA (Modifier or additive use); SPN (Synthetic preparation); PREP
 (Preparation); USES (Uses)
 (coupler; photog. color coupler forming azomethine dye for color
 photog. material showing improved color hue, storage stability, color
 reproduction, and lightfastness)
 RN 468730-12-3 CAPLUS
 CN Benzoic acid, 4-chloro-3-[[[3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl] (5,5-
 dimethyl-2,4-dioxo-3-oxazolidinyl)acetyl]amino]-, dodecyl ester (9CI) (CA
 INDEX NAME)

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 468730-16-7 468730-17-8 468730-19-0
 RL: MOA (Modifier or additive use); USES (Uses)
 (coupler; photog. color coupler forming azomethine dye for color
 photog. material showing improved color hue, storage stability, color
 reproduction, and lightfastness)
 RN 468730-16-7 CAPLUS
 CN 2-Quinazolineacetamide, N-[5-[[2-(2,4-bis(1,1-dimethylpropyl)phenoxy)-1-
 oxobutyl]amino]-2-methoxyphenyl]-6,8-dichloro-α-[2,5-dioxo-3-
 (phenylmethyl)-1-imidazolidinyl]-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA
 INDEX NAME)




RN 468730-17-8 CAPLUS
 CN 2-Quinazolineacetamide, N-[2-chloro-5-[[diethylamino]sulfonyl]phenyl]-3,4-
 dihydro-4-oxo-3-(4-pyridinyl)-α-1H-1,2,4-triazol-1-yl- (9CI) (CA
 INDEX NAME)

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468730-13-4 CAPLUS
 CN Benzoic acid, 3-[[[3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl] (5,5-dimethyl-
 2,4-dioxo-3-oxazolidinyl)acetyl]amino]-4-methoxy-, tetradecyl ester (9CI)
 (CA INDEX NAME)



L4 ANSWER 38 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:291843 CAPLUS
 DOCUMENT NUMBER: 136:316838
 TITLE: Color photographic paper comprising azomethine dye forming coupler
 INVENTOR(S): Uehira, Shigeki; Ogasawara, Jun; Takeuchi, Kiyoshi; Shinada, Yasuhiro; Deguchi, Yasuaki
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 101 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1197799	A1	20020417	EP 2001-122626	20010927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002107880	A2	20020410	JP 2000-294964	20000927
JP 2002174884	A2	20020621	JP 2001-101419	20010330
PRIORITY APPL. INFO.:			JP 2000-294964	A 20000927
			JP 2000-297609	A 20000928
			JP 2001-101418	A 20010330

OTHER SOURCE(S): MARPAT 136:316838
 GI



AB Disclosed is a photog. dye-forming coupler of the formula I (E = aryl, heterocyclic, -C(=O)W group, in which W = nitrogen-containing heterocyclic group; Z = aryl, heterocyclic; X, Y = O, S, N-R, in which R is a substituent, with the proviso that when E = aryl or heterocyclic group, X and Y are O, and when E = -C(=O)W group, Z is aryl). Also disclosed are a silver halide photog. paper that contains at least one dye-forming coupler of the formula I and a method for producing an azomethine dye using a compound of the formula I.


IT 411241-90-2P
 RL: PNU (Preparation, unclassified); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (azomethine dye; silver halide photog. light-sensitive material comprising dye-forming coupler and method for producing azomethine dye)

RN 411241-90-2 CAPLUS
 CN Benzoic acid, 3-[[[(3-cyclohexyl-3,4-dihydro-4-oxo-2-quinazolinyl)[[4-ethyl[2-[(methylsulfonyl)amino]ethyl]amino]-2-methylphenyl]imino]acetyl]amino]-4-methoxy-, tetradecyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 39 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:79224 CAPLUS
 DOCUMENT NUMBER: 135:357937
 TITLE: Quinazolinone derivatives as inhibitors of human phosphatidylinositol 3-kinase delta
 INVENTOR(S): Sadhu, Chanchal; Dick, Ken; Treiberg, Jennifer; Sowell, C. Gregory; Kesicki, Edward A.; Oliver, Amy
 PATENT ASSIGNEE(S): Icos Corporation, USA
 SOURCE: PCT Int. Appl., 278 pp.
 CODEN: PIKX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081346	A2	20011101	WO 2001-US13315	20010424
WO 2001081346	A3	20020321		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2406278	AA	20011101	CA 2001-2406278	20010424
EP 1278748	A2	20030129	EP 2001-928855	20010424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010371	A	20030617	BR 2001-10371	20010424
JP 2003531209	T2	20031021	JP 2001-578436	20010424
NZ 522076	A	20050826	NZ 2001-522076	20010424
NO 2002005104	A	20021210	NO 2002-5104	20021024
ZA 2002008698	A	20031010	ZA 2002-8698	20021028
PRIORITY APPL. INFO.:			US 2000-199655P	P 20000425
			US 2000-238057P	P 20001005
			WO 2001-US13315	W 20010424

OTHER SOURCE(S): MARPAT 135:357937
 GI




L4 ANSWER 38 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AB Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are claimed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Comps. are provided that inhibit PI3Kδ activity, including comps. that selectively inhibit PI3Kδ activity. The comps. claimed are all quinazolin-4-one derivs., including I (Y = null, S, NH; R = H, halo, OH, OMe, Me, CF3; R1 = H, OMe, halo; R2 together with C-6 and C-7 of quinazoline ring define a 5- or 6-membered aromatic ring optionally containing ≥ 1 O, N or S; R2 = C1-6 alkyl, Ph, halophenyl, alkylphenyl, biphenyl, PhCH2, pyridinyl, 4-methylpiperazinyl, CO2Et, morpholinyl; R3 = NH2, halo, C1-3 alkyl, S(C1-3 alkyl), OH, NH(C1-3 alkyl), N(C1-3 alkyl)2, NH(C1-3 alkyl)enophenyl; q = 1, 2) and pharmaceutically acceptable salts and solvates thereof. Methods of using PI3Kδ inhibitory comps. to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory comps. to inhibit PI3Kδ-mediated processes in vitro and in vivo. Thus, in an example, dose-dependent decrease in histamine release from basophils when stimulated with anti-IgE was 100% at 1,000 nM, with an EC50 of about 25 nM for I (Y = S, R = 5-Me, R1 = H, R2 = 2-ClC6H4, R3 = H; S connected to 6-position of purine ring; preparation given).
 IT 371243-12-8P 371243-13-9P 371243-14-0P
 371243-15-1P 371243-17-3P 371243-22-0P
 371243-23-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and inhibition of human phosphatidylinositol kinase by)
 RN 371243-12-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-13-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-14-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-amino-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)]- (9CI) (CA INDEX NAME)




RN 371243-15-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[[[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)]- (9CI) (CA INDEX NAME)




RN 371243-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)]- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[[[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 40 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:290354 CAPLUS
 DOCUMENT NUMBER: 135:76844
 TITLE: Quinazolin-4-one α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonists: Structure-Activity Relationship of the C-2 Side Chain Tether
 AUTHOR(S): Chenard, Bertrand L.; Welch, Willard M.; Blake, James F.; Butler, Todd W.; Reinhold, Anthony; Ewing, Frank E.; Menniti, Frank S.; Pagnozzi, Martin J.
 CORPORATE SOURCE: Global Research and Development Groton Laboratories, Pfizer Inc., Groton, CT, 06340, USA
 SOURCE: Journal of Medicinal Chemistry (2001), 44(11), 1710-1717
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB A series of 6-fluoro-3-(2-chlorophenyl)quinazolin-4-ones has been prepared, which contains a 2-fluorophenyl ring attached to C-2 by a variety of two-atom tethers. These compds. were used to probe the structure-activity relationship (SAR) for AMPA receptor inhibition. The relative potencies of the new compds. ranged from 11 nM to greater than 10 μ M. The differential activity of the compds. was rationalized on the basis of alterations of the 2-fluorophenyl positioning (planar and radial) relative to the quinazolin-4-one ring based on computational methods. From this effort, new AMPA receptor antagonists 1 [R = 2-F, 2-CN, 3-CN, 3-pyrrolidinomethyl], containing the methylamino tether group, have been identified.

IT 217942-71-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation of 2-arylaminoethylquinazolinones as AMPA receptor antagonists)

RN 217942-71-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[[[(2-fluorophenyl)amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 40 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 217942-52-4P 217942-64-8P 217942-66-0P
221152-63-2P 346700-93-4P 346700-94-5P
346700-95-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 2-arylaminoethylquinazolinones as AMPA receptor antagonists)

RN 217942-52-4 CAPLUS
CN Benzonitrile, 3-[[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 217942-64-8 CAPLUS
CN Acetamide, N-[[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 40 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 346700-94-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[[[2-fluorophenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 346700-95-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[[[3-methylphenyl]amino]methyl]- (9CI) (CA INDEX NAME)




IT 346700-98-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-arylaminoethylquinazolinones as AMPA receptor antagonists)

Habe


L4 ANSWER 40 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 217942-66-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 221152-63-2 CAPLUS
CN Benzonitrile, 2-[[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 346700-93-4 CAPLUS
CN Acetamide, N-[[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 40 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 346700-98-9 CAPLUS
CN Formamide, N-[[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

08/08/2006

L4 ANSWER 41 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER:
DOCUMENT NUMBER:2001:284612 CAPLUS
135:76842TITLE:
AUTHOR(S):Double anion capture reactions of anthranilic esters with oxaldiimidoyl dichlorides - efficient synthesis of 2,2'-biquinazoline-4,4'-(3H,3'H)-diones
Langer, Peter; Wuckelt, Jorg; Doring, Manfred; Gorls, Helmar

CORPORATE SOURCE:

Institut für Organische Chemie der
Georg-August-Universität Göttingen, Göttingen, 37077,
Germany

SOURCE:

European Journal of Organic Chemistry (2001), (8),
1503-1509

PUBLISHER:

CODEN: EJOCFK; ISSN: 1434-193X

DOCUMENT TYPE:

Wiley-VCH Verlag GmbH

LANGUAGE:

Journal

OTHER SOURCE(S):

English
CASREACT 135:76842

AB The reaction of anthranilic acids with oxaldiimidoyl dichlorides offers a new and convenient synthesis of quinazolin-4-ones. Condensation of anthranilic esters with diimidoyl dichlorides affords 2,2'-biquinazoline-4,4'-(3H,3'H)-diones, which constitute a new class of dimeric heterocyclic compds. In contrast, condensation of the dianion of N-Me o-tolylamide with di(imidoyl) dichlorides affords seven- rather than six-membered ring products. Starting with 2-aminopyridine, 2,3-diimino-2,3-dihydroimidazo[1,2-a]pyridines could be efficiently prepared

IT


242479-75-OP
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(synthesis and crystal structure of biquinazolinones)

RN

242479-75-0 CAPLUS

CN

2-Quinazolinecarboxamide, 3,4-dihydro-6,7-dimethoxy-N,3-bis(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)



IT 242479-73-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(synthesis of biquinazolinones by reactions of anthranilic esters with oxaldiimidoyl dichlorides)

RN


242479-73-8 CAPLUS

CN

2-Quinazolinecarboxamide, 3,4-dihydro-N,3-bis(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 41 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN


(Continued)



RN 242479-78-3 CAPLUS

CN


2-Quinazolinecarboxamide, 3,4-dihydro-6,7-dimethoxy-N,3-bis(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 242479-79-4 CAPLUS

CN

2-Quinazolinecarboxamide, N,3-bis[4-(1,1-dimethylethyl)phenyl]-3,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 41 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN

(Continued)



IT 30689-31-7P 242479-74-9P 242479-77-2P

242479-78-3P 242479-79-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of biquinazolinones by reactions of anthranilic esters with oxaldiimidoyl dichlorides)

RN

30689-31-7 CAPLUS

CN


2-Quinazolinecarboxamide, 3,4-dihydro-4-oxo-N,3-diphenyl- (9CI) (CA INDEX NAME)



RN 242479-74-9 CAPLUS

CN

2-Quinazolinecarboxamide, 3,4-dihydro-8-methyl-N,3-bis(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 242479-77-2 CAPLUS

CN

2-Quinazolinecarboxamide, 3,4-dihydro-N,3-bis(4-methoxyphenyl)-8-methyl-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 42 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER:

1999:444655 CAPLUS

DOCUMENT NUMBER:

131:214256

TITLE:

Efficient synthesis of quinazolin-4-ones and axially chiral 2,2'-bis-quinazolin-4-ones by reaction of anthranilic acid derived nucleophiles with oxalic acid-bis(imidoyl)chlorides

AUTHOR(S):

Wuckelt, Jorg; Doring, Manfred; Beckert, Rainer;
Langer, Peter

CORPORATE SOURCE:

Institut Anorganische Analytische Chemie, Univ. Jena,
Jena, D-07743, Germany

SOURCE:

Synlett (1999), (7), 1100-1102

PUBLISHER:

CODEN: SYNLES; ISSN: 0936-5214

DOCUMENT TYPE:

Georg Thieme Verlag

LANGUAGE:

Journal

OTHER SOURCE(S):

English
CASREACT 131:214256

AB The reaction of anthranilic acid-derived nucleophiles with oxalic bis(imidoyl) chlorides provides a convenient synthesis of quinazolin-4-ones and 2,2'-bis(quinazolin-4-ones).

IT

30689-31-7P 242479-73-8P 242479-74-9P

242479-75-0P 242479-77-2P 242479-78-3P

242479-79-4P

RL:


SPN (Synthetic preparation); PREP (Preparation)
(preparation of quinazolinones and axially chiral biquinazolinones from anthranilates and oxalic imidoyl chlorides)

RN

30689-31-7 CAPLUS

CN


2-Quinazolinecarboxamide, 3,4-dihydro-4-oxo-N,3-diphenyl- (9CI) (CA INDEX NAME)



RN 242479-73-8 CAPLUS

CN

2-Quinazolinecarboxamide, 3,4-dihydro-N,3-bis(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 242479-74-9 CAPLUS


CN

2-Quinazolinecarboxamide, 3,4-dihydro-8-methyl-N,3-bis(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 42 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 242479-75-0 CAPLUS
CN 2-Quinazolinecarboxamide, 3,4-dihydro-6,7-dimethoxy-N,3-bis(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 242479-77-2 CAPLUS
CN 2-Quinazolinecarboxamide, 3,4-dihydro-N,3-bis(4-methoxyphenyl)-8-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 242479-78-3 CAPLUS
CN 2-Quinazolinecarboxamide, 3,4-dihydro-6,7-dimethoxy-N,3-bis(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:198895 CAPLUS
DOCUMENT NUMBER: 130:311760
TITLE: Synthesis and fungicidal activity of 3-aryl-2-(4'-aryl thiazol-2'-ylaminomethyl) quinazol-4 (3H)-ones
AUTHOR(S): Pattanaik, J. M.; Pattanaik, M.; Bhatta, D.
CORPORATE SOURCE: Department of Chemistry, Utkal University, Bhubaneswar, 751 004, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1998), 37B(12), 1304-1306
CODEN: IJSCDH; ISSN: 0376-4699
PUBLISHER: National Institute of Science Communication, CSIR
DOCUMENT TYPE: Journal
LANGUAGE: English


AB A series of 3-aryl-2-(4-aryl-2-thiazolylaminomethyl) quinazol-4(3H)-ones was prepared by condensing 3-aryl-2-chloromethylquinazol-4(3H)-ones with 2-amino-4-substituted phenylthiazoles. Another group of 3-aryl-6,8-dibromo-2-(4-aryl-2-thiazolylaminomethyl)quinazol-4(3H)-ones was also synthesized from 3-aryl-6,8-dibromo-2-chloromethylquinazol-4(3H)-ones and 2-amino-4-substituted phenylthiazoles in the same manner. Their antifungal activity was determined

IT 223590-48-5P 223590-49-6P 223590-50-9P
223590-51-0P 223590-52-1P 223590-53-2P
223590-54-3P 223590-55-4P 223590-56-5P
223590-57-6P 223590-58-7P 223590-59-8P
223590-60-1P 223590-61-2P 223590-62-3P
223590-63-4P 223590-64-5P 223590-65-6P
223590-66-7P 223590-67-8P 223590-68-9P
223590-69-0P 223590-70-3P 223590-71-4P
223590-72-5P 223590-73-6P 223590-74-7P
223590-75-8P 223590-76-9P 223590-77-0P
223590-78-1P 223590-79-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SYN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and fungicidal activity of [(arylthiazolyl)aminomethyl]quinazol-ones)


RN 223590-48-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-(4-methylphenyl)-2-thiazolyl]amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 223590-49-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 42 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 242479-79-4 CAPLUS
CN 2-Quinazolinecarboxamide, N,3-bis[4-(1,1-dimethylethyl)phenyl]-3,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 223590-50-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(2-methylphenyl)-2-[[[4-(4-methylphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 223590-51-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 223590-52-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(2-methoxyphenyl)-2-[[[4-(4-methoxyphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 223590-53-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 223590-54-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-2-[[[4-(4-methylphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 223590-55-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 223590-59-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[[[4-(4-methylphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 223590-60-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[[[4-(4-methoxyphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 223590-61-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 223590-62-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[[[4-(4-methylphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)

Habe


L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 223590-56-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methylphenyl)-2-[[[4-(4-methylphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 223590-57-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-(4-methoxyphenyl)-2-thiazolyl]amino]methyl]-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 223590-58-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 223590-63-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 223590-64-5 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-[[[4-(4-methylphenyl)-2-thiazolyl]amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 223590-65-6 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 223590-66-7 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(2-methylphenyl)-2-[[[4-(4-

08/08/2006


L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methylphenyl)-2-thiazolyl]amino]methyl)- (9CI) (CA INDEX NAME)



RN 223590-67-8 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-([(4-(4-methoxyphenyl)-2-thiazolyl]amino)methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 223590-68-9 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(2-methoxyphenyl)-2-([(4-(4-methoxyphenyl)-2-thiazolyl]amino)methyl)- (9CI) (CA INDEX NAME)




RN 223590-69-0 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-([(4-(4-chlorophenyl)-2-thiazolyl]amino)methyl]-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 223590-73-6 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-([(4-(4-methoxyphenyl)-2-thiazolyl]amino)methyl]-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 223590-74-7 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(4-methylphenyl)-2-([(4-(4-chlorophenyl)-2-thiazolyl]amino)methyl]- (9CI) (CA INDEX NAME)




RN 223590-75-8 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(4-chlorophenyl)-2-([(4-(4-methylphenyl)-2-thiazolyl]amino)methyl]- (9CI) (CA INDEX NAME)




RN 223590-76-9 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(4-chlorophenyl)-2-([(4-(4-methoxyphenyl)-2-thiazolyl]amino)methyl]- (9CI) (CA INDEX NAME)

Hahte


L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 223590-70-3 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(2-chlorophenyl)-2-([(4-(4-methoxyphenyl)-2-thiazolyl]amino)methyl]- (9CI) (CA INDEX NAME)




RN 223590-71-4 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(2-chlorophenyl)-2-([(4-(4-chlorophenyl)-2-thiazolyl]amino)methyl]- (9CI) (CA INDEX NAME)




RN 223590-72-5 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(4-methylphenyl)-2-([(4-(4-methylphenyl)-2-thiazolyl]amino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 223590-77-0 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(4-chlorophenyl)-2-([(4-(4-chlorophenyl)-2-thiazolyl]amino)methyl]- (9CI) (CA INDEX NAME)



RN 223590-78-1 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(4-methoxyphenyl)-2-([(4-(4-methoxyphenyl)-2-thiazolyl]amino)methyl]- (9CI) (CA INDEX NAME)



RN 223590-79-2 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-([(4-(4-chlorophenyl)-2-thiazolyl]amino)methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

08/08/2006


L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:175749 CAPLUS
 DOCUMENT NUMBER: 130:218317
 TITLE: AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
 INVENTOR(S): Chenard, Bertrand Leo; Menniti, Frank Samuel; Welch, Willard McKowan, Jr.
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 22 pp.
 DOCUMENT TYPE: CODEN: EPXKDW
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 900568	A2	19990310	EP 1998-307181	19980904
EP 900568	A3	20010502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 11158072	A2	19990615	JP 1998-245269	19980831
JP 2001316267	A2	20011113	JP 2001-134816	19980831
AU 9883120	A1	19990318	AU 1998-83120	19980904
AU 736254	B2	20010726		
NZ 331741	A	20000825	NZ 1998-331741	19980904
US 6136812	A	20001024	US 1998-148974	19980904
ZA 9808139	A	20000322	ZA 1998-8139	19980907
CA 2246839	AA	19990305	CA 1998-2246839	19980908
CA 2246839	C	20021112		
PRIORITY APPLN. INFO.:				
			US 1997-58098P	P 19970905
			JP 1998-245269	A3 19980831

OTHER SOURCE(S): MARPAT 130:218317
 AB The invention relates to a method of treating dyskinesias associated with dopamine agonist therapy in a mammal which comprises administering to said mammal a compound, as defined herein, which is an antagonist of the AMPA receptor. Dopamine agonist therapy, as referred to in the present invention, is generally used in the treatment of a central nervous system disorder such as Parkinson's disease. One example compound of the 212 claimed was (S)-3-(2-chlorophenyl)-2-[2-(5-diethylaminomethyl-2-fluorophenyl)vinyl]-6-fluoro-3H-quinazolin-4-one.
 IT 217942-51-3 217942-54-6 217942-55-7
 217942-57-9 217942-58-0 217942-60-4
 217942-62-6 217942-64-8 217942-66-0
 217942-68-2 217942-69-3 217942-71-7
 217942-72-8 217942-86-4 221152-54-1
 221152-55-2 221152-56-3 221152-57-4
 221152-58-5 221152-59-6 221152-60-9
 221152-61-0 221152-62-1 221152-63-2
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (AMPA antagonists for treatment of dyskinesias associated with dopamine agonist therapy)
 RN 217942-51-3 CAPLUS
 CN Benzonitrile, 2-[[[3-(2-chloro-3-pyridinyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 217942-54-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-2-[[[3-(diethylamino)methyl]phenyl]amino]methyl]-6-fluoro- (9CI) (CA INDEX NAME)



RN 217942-55-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-pyrimidinylamino)methyl]- (9CI) (CA INDEX NAME)




RN 217942-57-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chloro-3-pyridinyl)-6-fluoro-2-[[[3-(methylphenyl)amino]methyl]- (9CI) (CA INDEX NAME)




Habte

L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 217942-58-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chloro-3-pyridinyl)-6-fluoro-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 217942-60-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chloro-3-pyridinyl)-6-fluoro-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 217942-62-6 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-(2-methyl-3-pyridinyl)-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 217942-64-8 CAPLUS
 CN Acetamide, N-[3-[[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)

08/08/2006


L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 217942-66-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 217942-68-2 CAPLUS
CN 3-Pyridinecarbonitrile, 2-[[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 217942-69-3 CAPLUS


L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 221152-54-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 221152-55-2 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-3-(2-chlorophenyl)-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 221152-56-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-3-(2-chlorophenyl)-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 221152-57-4 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-3-(2-chloro-3-pyridinyl)-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 4(3H)-Quinazolinone, 3-(2-chloro-3-pyridinyl)-6-fluoro-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 217942-71-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 217942-72-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 217942-86-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 221152-58-5 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-2-[[[3-[(diethylamino)methyl]phenyl]amino]methyl]-3-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 221152-59-6 CAPLUS
CN Benzonitrile, 2-[[[3-(2-chloro-3-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 221152-60-9 CAPLUS
CN Benzonitrile, 2-[[[3-(2-methyl-3-pyridinyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 221152-61-0 CAPLUS
 CN 3-Pyridinecarbonitrile, 2-[[[6-fluoro-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 221152-62-1 CAPLUS
 CN 3-Pyridinecarbonitrile, 2-[[[3-(2-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 221152-63-2 CAPLUS
 CN Benzonitrile, 2-[[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:3410 CAPLUS
 DOCUMENT NUMBER: 130:66507
 TITLE: Quinazolin-4-one AMPA antagonists
 INVENTOR(S): Chenard, Bertrand Leo; Reinhold, Anthony Ronald;
 Welch, Willard McKowan
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXKDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 884310	A1	19981216	EP 1998-304319	19980601
EP 884310	B1	20050907		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6627755	B1	20030930	US 1998-79420	19980514
AT 303997	E	20050915	AT 1998-304319	19980601
ES 2245015	T3	20051216	ES 1998-304319	19980601
CA 2240138	AA	19981209	CA 1998-2240138	19980605
CA 2240138	C	20020820		
JP 11012255	A2	19990119	JP 1998-160821	19980609
JP 3415443	B2	20030609		
BR 9801808	A	20000321	BR 1998-1808	19980609
US 2004049039	A1	20040311	US 2003-640482	20030813
US 6921764	B2	20050726		
PRIORITY APPLN. INFO.:				
		US 1997-49082P	P	19970609
		US 1997-53274P	P	19970721
		US 1997-50110P	P	19970613
		US 1998-79420	A3	19980514


OTHER SOURCE(S): MARPAT 130:66507
 GI



AB Preparation of quinazolin-4-one deriva. I [A = benzo- or thieno-fused aromatic ring; B = Ph, pyridyl, pyrimidyl; X = N, CH; Y2 = CH2NH, NHCH2; R1 = H, (C1-C6)alkyl optionally substituted with from one to three fluorine atoms, cyano, halo, amino, nitro and (C1-C6)alkoxy optionally substituted with from one to three fluorine atoms; R2 = halo, cyano, (C1-C6)alkyl

Habe


L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 optionally substituted with from one to three fluorine atoms, nitro, amino, (C1-C6)alkylthio, (C1-C6)alkoxy optionally substituted with from one to three fluorine atoms, hydroxy, etc.; R3, R4 = H, (C1-C6)alkyl optionally substituted with from one to three fluorine atoms, halo, cyano, hydroxy (C1-C6)alkoxy optionally substituted with from one to three fluorine atoms, etc.] and the use of such compds. to treat neurodegenerative, psychotropic, and drug and alc. induced central and peripheral nervous system disorders (no data), are described. E.g., reaction of 3-(2-chloropyridin-3-yl)-6-fluoro-3,4-dihydroquinazolin-4-one-2-carboxaldehyde and anthranilonitrile gave an intermediate imine, which was reduced to give 2-[[[3-(2-chloropyridin-3-yl)-6-fluoro-4-oxo-3,4-dihydroquinazolin-2-ylmethyl]amino]benzonitrile.

IT 217962-95-3P 217962-96-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 217962-95-3 CAPLUS
 CN Benzonitrile, 2-[[[3-(2-chloro-3-pyridinyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]-, (3R)- (9CI) (CA INDEX NAME)




RN 217962-96-4 CAPLUS
 CN Benzonitrile, 2-[[[3-(2-chloro-3-pyridinyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]-, (3S)- (9CI) (CA INDEX NAME)




IT 217942-51-3P 217942-52-4P 217942-54-6P
 217942-55-7P 217942-57-9P 217942-58-0P
 217942-59-1P 217942-60-4P 217942-62-6P
 217942-64-8P 217942-66-0P 217942-68-2P
 217942-69-3P 217942-71-7P 217942-72-8P
 217942-86-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

08/08/2006

L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of quinazolinone as AMPA antagonists)
 RN 217942-51-3 CAPLUS
 CN Benzonitrile, 2-[[[3-(2-chloro-3-pyridinyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 217942-52-4 CAPLUS
 CN Benzonitrile, 3-[[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 217942-54-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-2-[[[3-(diethylamino)methyl]phenyl]amino]methyl]-6-fluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 217942-59-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[[[3-(pyridinylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RN 217942-60-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chloro-3-pyridinyl)-6-fluoro-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 217942-62-6 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-(2-methyl-3-pyridinyl)-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 217942-55-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[[[3-(pyrimidinylamino)methyl]- (9CI) (CA INDEX NAME)




RN 217942-57-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chloro-3-pyridinyl)-6-fluoro-2-[[[3-(methylphenyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 217942-58-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chloro-3-pyridinyl)-6-fluoro-2-[[[3-(methyl-2-pyridinyl)amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 217942-64-8 CAPLUS
 CN Acetamide, N-[3-[[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 217942-66-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 217942-68-2 CAPLUS
 CN 3-Pyridinecarbonitrile, 2-[[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 217942-69-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chloro-3-pyridinyl)-6-fluoro-2-[(2-fluorophenyl)amino]methyl- (9CI) (CA INDEX NAME)





RN 217942-71-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-fluorophenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 217942-72-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(6-methyl-2-pyridinyl)amino]methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 46 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1996:233063 CAPLUS
 DOCUMENT NUMBER: 125:10737
 TITLE: Synthesis and reactions of 2-chloromethyl-3,1-benzoxazin-4-ones with amines
 AUTHOR(S): Amin, M.A.; Osman, A.N.; Aziza, M.A.; El-Hakim, A.E.
 CORPORATE SOURCE: Faculty of Pharmacy, Al-Azhar University, Egypt
 SOURCE: Egyptian Journal of Chemistry (1995), 38(1), 113-23
 CODEN: EGJCA3; ISSN: 0367-0422
 PUBLISHER: National Information and Documentation Centre
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Benzoxazinones I (Y = H, Br) were prepared and reacted with amines. Thus, reaction with RNH₂ (R = 2-MeC₆H₄, 2-HOC₆H₄, 3-MeC₆H₄, etc.) gave quinazolinones II.
 IT 177167-23-6P 177167-24-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and reaction of benzoxazinones with amines)
 RN 177167-23-6 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-3-phenyl-2-[(phenylamino)methyl- (9CI) (CA INDEX NAME)




RN 177167-24-7 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-3-(4-methylphenyl)-2-[(4-methylphenyl)amino]methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 217942-86-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-pyridinylamino)methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4
 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 46 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:534062 CAPLUS
 DOCUMENT NUMBER: 121:134062
 TITLE:
 4-(3H)-Quinazolones: 2-N-aryl/alkylaminomethyl/ethyl-3-p-hydroxyphenyl/p-anisyl/p-arylaminoacyloxyphenyl/p-N-arylcabamoylmethoxyphenyl-4-(3H)-quinazolones
 AUTHOR(S): Arasbharya, P. M.; Soni, V. C.; Parikh, A. R.
 CORPORATE SOURCE: Chem. Dep., Saurashtra Univ., Rajkot, 360 005, India
 SOURCE: Journal of the Institution of Chemists (India) (1992), 64(6), 238-41
 CODEN: JOICA7; ISSN: 0020-3254
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI





AB Some new 4(3H)-quinazolinone derivs., I and II, having N-arylaminomethyl/N-alkylaminomethyl/N-arylaminoethyl group at C(2) and p-hydroxyphenyl/p-anisyl/p-arylaminoacyloxyphenyl/p-(N-arylcabamoylmethoxy)phenyl group at C(3) were prepared. I and II showed moderate antimicrobial activity (no data). Structures of I and II were confirmed by IR spectra and elemental anal.

IT 156672-31-0P 156672-32-1P 156672-33-2P
 156672-34-3P 156672-35-4P 156672-36-5P
 156672-37-6P 156672-38-7P 156672-39-8P
 156672-40-1P 156672-41-2P 156672-42-3P
 156672-43-4P 156672-44-5P 156672-45-6P
 156672-47-8P 156672-49-0P 156672-51-4P
 156672-53-6P 156672-54-7P 156672-55-8P
 156672-56-9P 156672-57-0P 156672-58-1P
 156672-59-2P 156672-60-5P 156672-61-6P
 156672-62-7P 156672-63-8P 156672-64-9P
 156672-65-0P 156672-66-1P 156672-70-7P
 156672-71-8P 156672-72-9P 156672-74-1P
 156672-76-3P 156672-77-4P 156703-84-3P
 156703-85-4P 156932-49-9P 156932-50-2P
 156932-52-4P 156932-53-5P 156932-54-6P
 156932-55-7P 156932-56-8P 156932-57-9P
 156932-58-0P 156932-59-1P 156932-60-4P
 156932-61-5P 156932-62-6P 156932-63-7P
 156932-64-8P 156932-65-9P 156932-66-0P
 156932-68-2P 156932-69-3P 156932-70-6P
 156932-73-9P 156932-74-0P 156932-75-1P
 156932-76-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (prepn. and antimicrobial activity of)
 RN 156672-31-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)



RN 156672-32-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-chlorophenyl)amino]methyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)





RN 156672-33-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(3-chlorophenyl)amino]methyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 156672-34-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(2-methylphenyl)amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 156672-35-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(3-methylphenyl)amino]methyl]- (9CI) (CA INDEX NAME)





RN 156672-36-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(4-methylphenyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 156672-37-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(2-methoxyphenyl)amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-38-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(3-methoxyphenyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 156672-39-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(4-methoxyphenyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 156672-40-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(3-nitrophenyl)amino]methyl]- (9CI) (CA INDEX NAME)





RN 156672-41-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(4-nitrophenyl)amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-42-3 CAPLUS
CN 4-((3H)-Quinazolinone, 3-((4-hydroxyphenyl)-2-[(2-hydroxyphenyl)amino]methyl)- (9CI) (CA INDEX NAME)




RN 156672-43-4 CAPLUS
CN 4-((3H)-Quinazolinone, 3-((4-hydroxyphenyl)-2-[(4-hydroxyphenyl)amino]methyl)- (9CI) (CA INDEX NAME)




RN 156672-44-5 CAPLUS
CN Benzoic acid, 4-[[[3,4-dihydro-3-((4-hydroxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino]- (9CI) (CA INDEX NAME)





L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-53-6 CAPLUS
CN 4-((3H)-Quinazolinone, 3-((4-methoxyphenyl)-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)



RN 156672-54-7 CAPLUS
CN 4-((3H)-Quinazolinone, 2-[[[(2-chlorophenyl)amino]methyl]-3-((4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 156672-55-8 CAPLUS
CN 4-((3H)-Quinazolinone, 2-[[[(3-chlorophenyl)amino]methyl]-3-((4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 156672-56-9 CAPLUS
CN 4-((3H)-Quinazolinone, 2-[[[(4-chlorophenyl)amino]methyl]-3-((4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Habe

L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 156672-45-6 CAPLUS
CN Benzoic acid, 4-[[[3,4-dihydro-3-((4-hydroxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 156672-47-8 CAPLUS
CN Benzoic acid, 3-[[[3,4-dihydro-3-((4-hydroxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 156672-49-0 CAPLUS
CN 4-((3H)-Quinazolinone, 3-((4-hydroxyphenyl)-2-[(1-naphthalenylamino)methyl]- (9CI) (CA INDEX NAME)





RN 156672-51-4 CAPLUS
CN 4-((3H)-Quinazolinone, 2-[(cyclohexylamino)methyl]-3-((4-hydroxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-57-0 CAPLUS
CN 4-((3H)-Quinazolinone, 3-((4-methoxyphenyl)-2-[(2-methylphenyl)amino]methyl)- (9CI) (CA INDEX NAME)



RN 156672-58-1 CAPLUS
CN 4-((3H)-Quinazolinone, 3-((4-methoxyphenyl)-2-[(3-methylphenyl)amino]methyl)- (9CI) (CA INDEX NAME)





RN 156672-59-2 CAPLUS
CN 4-((3H)-Quinazolinone, 3-((4-methoxyphenyl)-2-[(4-methylphenyl)amino]methyl)- (9CI) (CA INDEX NAME)




RN 156672-60-5 CAPLUS
CN 4-((3H)-Quinazolinone, 3-((4-methoxyphenyl)-2-[(2-methoxyphenyl)amino]methyl)- (9CI) (CA INDEX NAME)

08/08/2006


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 156672-61-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(3-methoxyphenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-62-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(4-methoxyphenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-63-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(3-nitrophenyl)amino]methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 156672-70-7 CAPLUS
CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 156672-71-8 CAPLUS
CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 156672-72-9 CAPLUS
CN Benzoic acid, 3-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 156672-74-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(1-naphthalenylamino)methyl]- (9CI) (CA INDEX NAME)




Habte



L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-64-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(4-nitrophenyl)amino]methyl- (9CI) (CA INDEX NAME)



RN 156672-65-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-hydroxyphenyl)amino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 156672-66-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-hydroxyphenyl)amino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 156672-76-3 CAPLUS
CN Benzamide, N-[[[5-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-1,3,4-thiadiazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 156672-77-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(cyclohexylamino)methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 156703-84-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-chlorophenyl)amino]methyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 156703-85-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(2-nitrophenyl)amino]methyl]- (9CI) (CA INDEX NAME)

08/08/2006


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156932-49-9 CAPLUS
 CN Sulfamic acid, 4-[[[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 156932-50-2 CAPLUS
 CN Benzamide, N-[[[5-[[[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-1,3,4-thiadiazol-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 156932-52-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-(phenylamino)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-[(4-methylphenyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 156932-58-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-[(2-methoxyphenyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 156932-59-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-[(3-methoxyphenyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 156932-60-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-[(4-methoxyphenyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 156932-61-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-[(2-nitrophenyl)amino]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 156932-53-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-[(3-chlorophenyl)amino]ethyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 156932-54-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-[(4-chlorophenyl)amino]ethyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 156932-55-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-[(2-methylphenyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 156932-56-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-[(3-methylphenyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 156932-57-9 CAPLUS


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156932-62-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-[(4-nitrophenyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 156932-63-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-[(2-hydroxyphenyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 156932-64-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-[(4-hydroxyphenyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 156932-65-9 CAPLUS
 CN Benzoic acid, 4-[[[2-[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]ethyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 156932-66-0 CAPLUS
 CN Benzoic acid, 4-[[2-[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]ethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 156932-68-2 CAPLUS
 CN Sulfamic acid, [4-[[2-[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 156932-69-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-(1-naphthalenylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 156932-75-1 CAPLUS
 CN Sulfamic acid, [4-[[[2-[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 156932-76-2 CAPLUS
 CN Carbamic acid, [4-[[[2-[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




Habte


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 156932-70-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-(cyclohexylamino)ethyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 156932-73-9 CAPLUS
 CN Benzoic acid, 2-[[2-[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 156932-74-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-[(4-bromophenyl)amino]ethyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:508675 CAPLUS
 DOCUMENT NUMBER: 121:108675
 TITLE: 4(3H)-Quinazolones. Part I: 2-Alkyl/arylaminoethyl-3-p-hydroxy/methoxyphenyl-4(3H)-quinazolones
 AUTHOR(S): Parasharya, P. M.; Parikh, A. R.
 CORPORATE SOURCE: Chem. Dep., Saurashtra Univ., Rajkot, 360 005, India
 SOURCE: Journal of the Institution of Chemists (India) (1992), 64(5), 184-5
 CODEN: JOICA7; ISSN: 0020-3254
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The title compds. I (X = OH, OMe; R = alkyl, aryl) were prepared by amination of the 2-(bromomethyl) derivs. and tested for antibacterial activity. Some I showed remarkable antibacterial activity.



IT 156672-31-0P 156672-32-1P 156672-33-2P
 156672-34-3P 156672-35-4P 156672-36-5P
 156672-37-6P 156672-38-7P 156672-39-8P
 156672-40-1P 156672-41-2P 156672-42-3P
 156672-43-4P 156672-44-5P 156672-45-6P
 156672-47-8P 156672-49-0P 156672-50-3P
 156672-51-4P 156672-53-6P 156672-54-7P
 156672-55-8P 156672-56-9P 156672-57-0P
 156672-58-1P 156672-59-2P 156672-60-5P
 156672-61-6P 156672-62-7P 156672-63-8P
 156672-64-9P 156672-65-0P 156672-66-1P
 156672-67-2P 156672-69-4P 156672-70-7P
 156672-71-8P 156672-72-9P 156672-73-0P
 156672-74-1P 156672-76-3P 156672-77-4P
 156703-84-3P 156703-85-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antibacterial activity of)
 RN 156672-31-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)




08/08/2006

L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 156672-32-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[[(2-chlorophenyl)amino]methyl]-3-(4-hydroxyphenyl)-
(9CI) (CA INDEX NAME)

RN 156672-33-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[[(3-chlorophenyl)amino]methyl]-3-(4-hydroxyphenyl)-
(9CI) (CA INDEX NAME)


RN 156672-34-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(2-methylphenyl)amino]methyl]-
(9CI) (CA INDEX NAME)


RN 156672-35-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(3-methylphenyl)amino]methyl]-


L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 156672-39-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(4-methoxyphenyl)amino]methyl]-
(9CI) (CA INDEX NAME)

RN 156672-40-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(3-nitrophenyl)amino]methyl]-
(9CI) (CA INDEX NAME)


RN 156672-41-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(4-nitrophenyl)amino]methyl]-
(9CI) (CA INDEX NAME)


RN 156672-42-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(2-hydroxyphenyl)amino]methyl]-
(9CI) (CA INDEX NAME)



L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 156672-36-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(4-methylphenyl)amino]methyl]-
(9CI) (CA INDEX NAME)



RN 156672-37-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(2-methoxyphenyl)amino]methyl]-
(9CI) (CA INDEX NAME)


RN 156672-38-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(3-methoxyphenyl)amino]methyl]-
(9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 156672-43-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[[(4-hydroxyphenyl)amino]methyl]-
(9CI) (CA INDEX NAME)

RN 156672-44-5 CAPLUS

CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-
(9CI) (CA INDEX NAME)


RN 156672-45-6 CAPLUS

CN Benzoic acid, 3-[[[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-,
ethyl ester (9CI) (CA INDEX NAME)


RN 156672-47-8 CAPLUS

CN Benzoic acid, 3-[[[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-2-hydroxy-
(9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 156672-49-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(1-naphthalenylamino)methyl]- (9CI) (CA INDEX NAME)




RN 156672-50-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(5-benzoyl-1,3,4-thiadiazol-2-yl)amino]methyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)





RN 156672-51-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(cyclohexylamino)methyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


RN 156672-56-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-chlorophenyl)amino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 156672-57-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(2-methylphenyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 156672-58-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(3-methylphenyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 156672-59-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(4-methylphenyl)amino]methyl]- (9CI) (CA INDEX NAME)




Habte



L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 156672-53-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)



RN 156672-54-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-chlorophenyl)amino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)





RN 156672-55-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(3-chlorophenyl)amino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


RN 156672-60-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(2-methoxyphenyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 156672-61-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(3-methoxyphenyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 156672-62-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(4-methoxyphenyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 156672-63-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(3-nitrophenyl)amino]methyl]- (9CI) (CA INDEX NAME)

08/08/2006


L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-64-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[[4-nitrophenyl]amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-65-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[2-hydroxyphenyl]amino]methyl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 156672-66-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[4-hydroxyphenyl]amino]methyl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-72-9 CAPLUS
CN Benzoic acid, 3-[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 156672-73-0 CAPLUS
CN Benzenesulfonic acid, 4-[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 156672-74-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(1-naphthalenylamino)methyl]- (9CI) (CA INDEX NAME)




RN 156672-76-3 CAPLUS
CN Benzanide, N-[[5-[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-1,3,4-thiadiazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



Habe

L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 156672-67-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[4-bromophenyl]amino]methyl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 156672-69-4 CAPLUS
CN Benzoic acid, 2-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 156672-70-7 CAPLUS
CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 156672-71-8 CAPLUS
CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 156672-77-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[cyclohexylamino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 156703-84-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[4-chlorophenyl]amino]methyl-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 156703-85-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[2-nitrophenyl]amino]methyl]- (9CI) (CA INDEX NAME)




08/08/2006



L4 ANSWER 49 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:298578 CAPLUS
 DOCUMENT NUMBER: 120:298578
 TITLE: Synthesis and some reactions of 4-oxo-3-phenyl-(1H,3H)-quinazoline-2-thione
 AUTHOR(S): El-Deen, I.M.; Mohamed, S.M.
 CORPORATE SOURCE: Fac. Educ., El-Arish, Suez Canal Univ., Egypt
 SOURCE: Indian Journal of Heterocyclic Chemistry (1993), 2(4), 233-6
 CODEN: IJCHEI; ISSN: 0971-1627
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Room temperature treatment of 2-(3-phenylthioureido)benzoic acid with concentrated sulfuric acid led to 4-oxo-3-phenyl(1H,3H)quinazoline-2-thione (I) in generally very good yield. Ammonolysis, hydrazinolysis, and alkylation of I yielded 2-substituted 3-phenyl-(1H,3H)quinazoline-4-one II (R = NH₂, R₁ = Ph, CH₂Ph, NH₂, NHPH), 3-phenyl-4-(1H,3H)quinazoline-2-thioglycolic acid II (R = SCH₂CO₂H) and ester II (R = SCH₂CO₂Et). II (R = SCH₂CO₂H) reacted with p-anisaldehyde to afford the β-(3-phenyl-4-(1H,3H)quinazolin-2-yl-thio)-4-methoxystyrene II (R = SCH₂CH(C₆H₄OMe)-4). Treatment of II (R = SCH₂CO₂Et) with anthranilic acid gave the corresponding 2-substituted 4H-3,1-benzoxazin-4-one. Hydrazinolysis and arylation of the latter under Friedel-Crafts conditions affords N-substituted anthranilic acid hydrazide III (R₁ = NHNH₂) and N-2-(substituted) benzophenone III (R₁ = Ar).
 IT 146849-71-OP
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 146849-71-0 CAPLUS
 CN 2,4-(1H,3H)-Quinazolin-2-one, 3-phenyl-, 2-(phenylhydrazono) (9CI) (CA INDEX NAME)




L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 147766-67-4 CAPLUS
 CN Benzenesulfonamide, 4-[2-[(3-methylphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-68-5 CAPLUS
 CN Benzenesulfonamide, 4-[2-[(2-methoxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-69-6 CAPLUS
 CN Benzenesulfonamide, 4-[2-[(3-methoxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1993:449324 CAPLUS
 DOCUMENT NUMBER: 119:49324
 TITLE: 4-(3H)-quinazolones. Part III: Alkyl or arylaminomethyl/substituted cinnamyl-3-p-sulfonamidophenyl-4-(3H)-quinazolones
 AUTHOR(S): Gaur, V. B.; Shah, V. H.; Parikh, A. R.
 CORPORATE SOURCE: Chem. Dep., Saurashtra Univ., Rajkot, 360 005, India
 SOURCE: Journal of the Institution of Chemists (India) (1991), 63(6), 219-20
 CODEN: JOICA7; ISSN: 0020-3254
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Title compds, including aminomethyl derivs. I (R = Ph, 2-MeC₆H₄, 3-MeC₆H₄, 4-MeC₆H₄, 2-MeOC₆H₄, 3-MeOC₆H₄, 4-MeOC₆H₄, 2-O₂NC₆H₄, 3-O₂NC₆H₄, 4-O₂NC₆H₄, 2-ClC₆H₄, 3-ClC₆H₄, 4-ClC₆H₄, 4-BrC₆H₄, PhCH₂, 1-naphthyl, Me, Bu, octadecyl) and styryl derivs. II (R₁ = 2-O₂NC₆H₄, 3-O₂NC₆H₄, 4-O₂NC₆H₄, 2-ClC₆H₄, 3-ClC₆H₄, 4-ClC₆H₄), were prepared from aminosulfonylphenylmethylquinazolinone III. Several aminomethyl derivs., e.g., I (2-O₂NC₆H₄, 3-O₂NC₆H₄, 4-O₂NC₆H₄, 2-ClC₆H₄, 3-ClC₆H₄, 4-ClC₆H₄, Bu, octadecyl) showed good bactericidal and fungicidal activity.
 IT 147766-66-3P 147766-67-4P 147766-68-5P
 147766-69-6P 147766-70-9P 147766-71-0P
 147766-72-1P 147766-73-2P 147766-74-3P
 147766-76-5P 147766-77-6P 147766-78-7P
 147766-79-8P 147766-80-1P 147766-81-2P
 147766-82-3P 147766-83-4P 147792-99-2P
 148472-79-1P 148472-80-4P 149411-85-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 147766-66-3 CAPLUS
 CN Benzenesulfonamide, 4-[2-[(2-methylphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 147766-70-9 CAPLUS
 CN Benzenesulfonamide, 4-[2-[(4-methoxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-71-0 CAPLUS
 CN Benzenesulfonamide, 4-[2-[(3-nitrophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-72-1 CAPLUS
 CN Benzenesulfonamide, 4-[2-[(4-nitrophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 147766-73-2 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[3-chlorophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-74-3 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[4-chlorophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-76-5 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[4-bromophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 147766-80-1 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[2-hydroxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-81-2 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[3-hydroxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-82-3 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[4-hydroxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 147766-77-6 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[1-naphthalenylamino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-78-7 CAPLUS
 CN Benzoic acid, 4-[[3-[[4-(aminosulfonyl)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 147766-79-8 CAPLUS
 CN Benzoic acid, 4-[[3-[[4-(aminosulfonyl)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 147766-83-4 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[cyclohexylamino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147792-99-2 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[2-nitrophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 148472-79-1 CAPLUS
 CN Benzenesulfonamide, 4-[4-oxo-2-[(phenylamino)methyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 148472-80-4 CAPLUS
CN Benzenesulfonamide, 4-[2-[[2-chlorophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 149411-85-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[[4-methylphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 51 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2,4(1H,3H)-Quinazolinone, 3-phenyl-, 2-(phenylhydrazine) (9CI) (CA INDEX NAME)




L4 ANSWER 51 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:254854 CAPLUS
DOCUMENT NUMBER: 118:254854
TITLE: Synthesis and some reactions of 3-phenyl-(1H,3H)-quinazoline-2-thione-4-one
AUTHOR(S): El-Deen, I. M.; El-Desuky, S.
CORPORATE SOURCE: Fac. Educ., Suez Canal Univ., Egypt
SOURCE: Journal of the Serbian Chemical Society (1992), 57(11), 719-23
CODEN: JSCSEN; ISSN: 0352-5139
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 118:254854
GI




AB Room temperature treatment of 2-(3-Ph thioureido)-benzoic acid with concentrated sulfuric acid lead to the formation of 3-phenyl(1H,3H)-quinazoline-2-thione-4-one (I) in generally very good yield. Ammonolysis, hydrazinolysis and alkylation of I yielded 2-substituted-3-phenyl(1H,3H)-quinazoline-4-one II (R = NHPh, NHCH2Ph, NHH2, NHC(=O)Ph), 3-phenyl-4(1H3H)-quinazoline-2-thioglycolic acid II; R = SCH2CO2H) and the ester II (R = SCH2CO2Et), resp. Compound II (R = SCH2CO2H) reacted with anisaldehyde to afford the 8-[3-phenyl-4(1H,3H)-quinazoline-2-yl-thio]-4-methoxystyrene. Treatment of compound II (R = SCH2CO2Et) with anthranilic acid gave the corresponding 2-substituted-4H-3,1-benzoxazine-4-one III. Hydrazinolysis and arylation, under Friedel-Crafts conditions, of III affords N-substituted anthranilic acid hydrazide IV (R1 = NHC(=O)H2 and N-2-(substituted)-benzophenone IV (R1 = C6H3Me2-2,4), resp.
IT 146849-71-0P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
RN 146849-71-0 CAPLUS

L4 ANSWER 52 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:656106 CAPLUS
DOCUMENT NUMBER: 115:256106
TITLE: 4-(3H)-quinazolones. Part II: 2-alkyl- or arylaminomethyl-substituted cinnamyl-3-p-(N-phenylthioureidosulfonylphenyl)-4-(3H)-quinazolones
AUTHOR(S): Gaur, V. B.; Shah, V. H.; Parikh, A. R.
CORPORATE SOURCE: Chem. Dep., Saurashtra Univ., Rajkot, 360 005, India
SOURCE: Journal of the Institution of Chemists (India) (1991), 63(2), 66-8
CODEN: JOICAT; ISSN: 0020-3254
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB Title compds. I (R = Ph, substituted Ph, furyl, naphthyl, octadecyl; R1 = CH2NHR, CHBrCHBrPh, CH:CHPh) were prepared from the sulfonamide II. I have bactericidal and fungicidal activity.
IT 137205-41-5P 137205-42-6P 137205-43-7P
137205-44-8P 137205-45-9P 137205-46-0P
137205-47-1P 137205-48-2P 137205-49-3P
137205-50-6P 137205-51-7P 137205-53-9P
137205-54-0P 137205-55-1P 137205-56-2P
137205-57-3P 137205-58-4P 137205-59-5P
137205-60-8P 137205-92-6P 137205-93-7P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
RN 137205-41-5 CAPLUS
CN Benzenesulfonamide, 4-[4-oxo-2-[(phenylamino)methyl]-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-42-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[[4-methylphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[[[(phenylamino)thioxomethyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 52 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 137205-43-7 CAPLUS
CN Benzenesulfonamide, 4-[2-[[2-methoxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-44-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[[3-methoxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)





RN 137205-45-9 CAPLUS
CN Benzenesulfonamide, 4-[2-[[4-methoxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 52 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 137205-49-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[[2-chlorophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-50-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[[3-chlorophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-51-7 CAPLUS
CN Benzenesulfonamide, 4-[2-[[4-chlorophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 52 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 137205-46-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[[2-nitrophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-47-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[[3-nitrophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-48-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[[4-nitrophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 52 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 137205-53-9 CAPLUS
CN Benzenesulfonamide, 4-[2-[[4-bromophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-54-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[[1-naphthalenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-55-1 CAPLUS
CN Benzoic acid, 4-[[[3,4-dihydro-4-oxo-3-[[[(phenylamino)thioxomethyl]amino]sulfonyl]phenyl]-2-quinazolinyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 52 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 137205-56-2 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-4-oxo-3-[[[(phenylamino)thioxomethyl]amino]sulfonyl]phenyl]-2-quinazoliny]methyl]amino]- (9CI) (CA INDEX NAME)





RN 137205-57-3 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[[2-hydroxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazoliny]l-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-58-4 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[[3-hydroxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazoliny]l-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 52 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 137205-93-7 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[[3-methylphenyl]amino]methyl]-4-oxo-3(4H)-quinazoliny]l-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 52 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 137205-59-5 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[[4-hydroxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazoliny]l-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-60-8 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[[cyclohexylamino]methyl]-4-oxo-3(4H)-quinazoliny]l-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-92-6 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[[2-methylphenyl]amino]methyl]-4-oxo-3(4H)-quinazoliny]l-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 53 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 1391:449604 CAPLUS
 DOCUMENT NUMBER: 115:49604
 TITLE: Synthesis and biological activity of some newer substituted 3-aryl-4(3H)-quinazolinones
 AUTHOR(S): Shukla, Jagdish S.; Fadayan, Manouchehr
 CORPORATE SOURCE: Dep. Chem., Lucknow Univ., Lucknow, 226 007, India
 SOURCE: Indian Journal of Pharmaceutical Sciences (1989), 51(1), 5-6
 CODEN: IJPSIU; ISSN: 0250-474X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A number of [(arylmethylene)dihydrophenyloximidazoly]phenylaminomethyl]quinazolinones I (R = H, iodo; R1 = NO2, H, Cl, MeO; R2 = H, 4-OH, 2-OH, 4-OMe, 4-Cl, 3-NO2) were prepared by reaction of phenyl(benzylidene)oxazolinones II with p-(H2N)2C6H4 and alkylation of the resulting (aminophenyl)arylimidazolinones III with aryl(chloromethyl)quinazolinones IV. I were screened for anthelmintic, virucidal, and bactericidal activity. All the compds. showed marked activity against Bacillus subtilis and Staphylococcus aureus.


IT 134989-51-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and bactericidal activity of)

RN 134989-51-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[4-[4,5-dihydro-4-[[[4-hydroxyphenyl]methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl]-3-phenyl]- (9CI) (CA INDEX NAME)




IT 134989-58-5P 134989-59-6P 134989-60-9P
 134989-61-0P 134989-62-1P 134989-63-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, anthelmintic and bactericidal activity of)
 RN 134989-58-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[4-[4,5-dihydro-4-[[[4-nitrophenyl]methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl]-6-iodo-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 53 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 134989-59-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[4,5-dihydro-4-[(4-hydroxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl]-6-iodo-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 134989-60-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[4,5-dihydro-4-[(2-hydroxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 134989-61-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[4,5-dihydro-5-oxo-2-phenyl-4-(phenylmethylene)-1H-imidazol-1-yl]phenyl]amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:449595 CAPLUS
DOCUMENT NUMBER: 115:49595
TITLE: Quinazolinylpyrazolines as antiinflammatory agents
AUTHOR(S): Kumar, Ashok; Verma, R. S.; Jaju, B. P.; Sinha, J. N.
CORPORATE SOURCE: Dep. Pharmacol. Pharm., LLRM Med. Coll., Meerut, 250 004, India
SOURCE: Journal of the Indian Chemical Society (1990), 67(11), 920-1
CODEN: JICSAH; ISSN: 0019-4522
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 115:49595
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB [(N-Acetylarylpyrazolinyl)phenylaminomethyl]tolylquinazolinones I (R = r1, Br, R1 = 2-F, 2-, 4-MeO, 4-Me2N, 2-Cl, H) were prepared from (bromomethyl)quinazolinones II (R2 = Br) and 2-AcCGH4NH2 via condensation of [(acetylphenyl)aminomethyl]quinazolinones II (R2 = 2-MeOCGH4NH) with R1CGH4CHO and cyclocondensation of the resulting cinnamoyl derivs. III with H2NHNH2. Evaluation of the inflammation inhibiting activity of I, II (R2 = 2-AcCGH4NH), and III in albino rats at 50 mg/kg orally showed varying degrees of protection (7.2-34%) against carrageenin induced edema.


IT 134951-72-7P 134951-84-1P 134951-85-2P
134951-86-3P 134951-87-4P 134951-88-5P
134951-89-6P 134951-90-9P 134951-91-0P
134951-92-1P 134951-93-2P 134981-63-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and inflammation inhibiting activity of)

RN 134951-72-7 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-[2-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-5-(2-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 134951-84-1 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-[2-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro-5-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 53 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 134989-62-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[[[4-[4,5-dihydro-4-[(3-nitrophenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 134989-63-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[4,5-dihydro-4-[(3-nitrophenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 134951-85-2 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-[2-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 134951-86-3 CAPLUS
CN 1H-Pyrazole, 1-acetyl-5-(2-chlorophenyl)-3-[2-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 134951-87-4 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-5-[4-(dimethylamino)phenyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 134951-88-5 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[6-bromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-5-(2-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 134951-89-6 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[6-bromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro-5-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 134951-92-1 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[6-bromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-5-[4-(dimethylamino)phenyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 134951-93-2 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[6-bromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 134981-63-8 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro-5-phenyl- (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 134951-90-9 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[6-bromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 134951-91-0 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[6-bromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-5-(2-chlorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)





L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 134951-70-5P 134951-73-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, antiinflammatory activity, and condensation of, with aromatic aldehydes)

RN 134951-70-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-acetylphenyl)amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 134951-73-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-acetylphenyl)amino]methyl]-6-bromo-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




IT 134951-71-6P 134951-74-9P 134951-75-0P
 134951-76-1P 134951-77-2P 134951-78-3P

08/08/2006


L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 134951-79-4P 134951-80-7P 134951-81-8P
 134951-82-9P 134951-83-0P 134981-62-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn., antiinflammatory activity, and cyclocondensation of, with hydrazine)
 RN 134951-71-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[2-[3-(2-fluorophenyl)-1-oxo-2-propenyl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 134951-74-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[2-[3-(2-methoxyphenyl)-1-oxo-2-propenyl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 134951-75-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[2-[3-(4-methoxyphenyl)-1-oxo-2-propenyl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 134951-78-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-methylphenyl)-2-[[[2-(1-oxo-3-phenyl-2-propenyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 134951-79-4 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[[[2-[3-(2-fluorophenyl)-1-oxo-2-propenyl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 134951-80-7 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[[[2-[3-(4-methoxyphenyl)-1-oxo-2-propenyl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




Habte


L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 134951-76-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[2-[3-[4-(dimethylamino)phenyl]-1-oxo-2-propenyl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 134951-77-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[2-[3-(2-chlorophenyl)-1-oxo-2-propenyl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 134951-81-8 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[[[2-[3-[4-(dimethylamino)phenyl]-1-oxo-2-propenyl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 134951-82-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[[[2-[3-(2-chlorophenyl)-1-oxo-2-propenyl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 134951-83-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-3-(2-methylphenyl)-2-[[[2-(1-oxo-3-phenyl-2-propenyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 134981-62-7 CAPLUS

08/08/2006

L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 6-bromo-2-[[[2-(3-(2-methoxyphenyl)-1-oxo-2-propenyl)phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 55 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1991:122242 CAPLUS
 DOCUMENT NUMBER: 114:122242
 TITLE: Non-steroidal antiinflammatory agents. III: Synthesis of pyrazole derivatives of 4(3H)-quinazolinones
 AUTHOR(S): Farhaly, Ahmed M.; Chaaban, Ibrahim; Khalil, Mounir A.; Bekhit, Adnan A.
 CORPORATE SOURCE: Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
 SOURCE: Alexandria Journal of Pharmaceutical Sciences (1990), 4(1), 52-6
 CODEN: AJPSES; ISSN: 1110-1792
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:122242
 GI



AB Several groups of compds. were synthesized having a pyrazole or pyrazoline moiety attached to 4(3H)-quinazolinone at the 2- or 3-position either directly or through different linkages. The linkages include methinamino, ethenyl, iminomethyl, aminomethyl or methinehydrazino grouping. Thus, acetantranil (I) was treated with aminoantipyrine II to give 4(3H)-quinazolinone III. The antiinflammatory activity of representative examples of the products is reported.


IT 132111-60-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antiinflammatory activity of)

RN 132111-60-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[[[2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




IT 132088-57-4P 132088-58-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)

L4 ANSWER 55 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (prepn. of)
 RN 132088-57-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl]amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 132088-58-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-bromophenyl)-2-[[[2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 56 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1990:216839 CAPLUS
 DOCUMENT NUMBER: 112:216839
 TITLE: 2,3-Disubstituted quinazolinones and their antiparkinsonian activity
 AUTHOR(S): Naithani, Pankaj K.; Palit, Gautam; Srivastava, V. K.; Shanker, K.
 CORPORATE SOURCE: Dep. Pharmacol. Therapeut., King George's Med. Coll., Lucknow, 226 003, India
 SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1989), 28B(9), 745-50
 CODEN: IJCSDB; ISSN: 0376-4699
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 112:216839
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Fifteen title compds., e.g. I and II, were prepared from arylmethylquinazolinones, e.g., III. Of the compds. prepared, I showed the greatest antiparkinson activity with no toxicity.


IT 126946-15-4P 126946-40-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antiparkinson activity of)

RN 126946-15-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1,2-bis[(4-chlorophenyl)amino]-2-(4-hydroxy-3-methoxyphenyl)ethyl]-6,8-dibromo-3-[4-[3-[(4-chlorophenyl)amino]-1-oxopropyl]phenyl]- (9CI) (CA INDEX NAME)



RN 126946-40-5 CAPLUS
 CN 4(3H)-Quinazolinone, 6,8-dibromo-3-[4-[3-[(4-chlorophenyl)amino]-1-oxopropyl]phenyl]-2-[2-(4-hydroxy-3-methoxyphenyl)-1,2-bis[(4-methylphenyl)amino]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 57 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1988:630930 CAPLUS

DOCUMENT NUMBER: 109:230930

TITLE: Thiazolidinones, azetidinones, and formazans of quinazolinones

AUTHOR(S): Gupta, D. P.; Shanker, K.

CORPORATE SOURCE: Dep. Pharmacol. Ther., K. G's Med. Coll., Lucknow, 226 003, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1987), 26B(12), 1197-9


CODEN: IJCSDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 109:230930

GI



AB Hydrazones I (R1 and R2 are H, iodo, Br; R3 = ClCH2, tolyl, ClCH2NH, PhNH; R4 = Ph, tolyl) were treated with ClCH2COCl and Et3N to give azetidine derivs. II. 3-[(Quinazolinylmethyl)amino]thiazolidin-4-ones were obtained from I and HSCH2CO2H. I and aromatic diazonium salts gave formazans.

IT 117664-03-6P 117664-04-7P 117664-05-8P

117664-06-9P 117664-07-0P 117664-08-1P

117664-21-8P 117664-22-9P 117664-23-0P

117664-24-1P 117664-25-2P 117664-26-3P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 117664-03-6 CAPLUS


CN 4(3H)-Quinazolinone, 2-[[[3-chloro-2-oxo-4-(2-phenyl-1H-indol-3-yl)-1-azetidinyl]amino]methyl]-6-iodo-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 57 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 117664-04-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[[3-chloro-2-oxo-4-(2-phenyl-1H-indol-3-yl)-4-oxo-1-azetidinyl]amino]methyl]-6-iodo-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 117664-05-8 CAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-2-[[[3-chloro-2-oxo-4-(2-phenyl-1H-indol-3-yl)-1-azetidinyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 117664-06-9 CAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-2-[[[3-chloro-2-oxo-4-(2-phenyl-1H-indol-3-yl)-4-oxo-1-azetidinyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 57 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 117664-07-0 CAPLUS

CN 4(3H)-Quinazolinone, 6,8-dibromo-2-[[[3-chloro-2-oxo-4-(2-phenyl-1H-indol-3-yl)-1-azetidinyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 117664-08-1 CAPLUS


CN 4(3H)-Quinazolinone, 6,8-dibromo-2-[[[3-chloro-2-oxo-4-(2-phenyl-1H-indol-3-yl)-4-oxo-1-azetidinyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 117664-21-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-iodo-3-(2-methylphenyl)-2-[[[4-oxo-2-(2-phenyl-1H-indol-3-yl)-3-thiazolidinyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 57 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 117664-22-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-iodo-3-(2-methylphenyl)-2-[[[2-(4-methylphenyl)-1H-indol-3-yl]-4-oxo-3-thiazolidinyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 117664-23-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-3-(2-methylphenyl)-2-[[[2-(4-methylphenyl)-1H-indol-3-yl]-3-thiazolidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 117664-24-1 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-3-(2-methylphenyl)-2-[[[2-(4-methylphenyl)-1H-indol-3-yl]-4-oxo-3-thiazolidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN


1988:528914 CAPLUS
 109:128914
 DOCUMENT NUMBER:
 TITLE: Synthesis and pharmacological evaluation of
 N1-[p-[[[3-aryl-4-oxoquinazolin-2-yl)methyl]amino]benzoyl]-N4-arylthiosemicarbazides and
 2-(aryl-amino)-5-[p-[[[3-aryl-4-oxoquinazolin-2-yl)methyl]amino]phenyl]-1,3,4-thiadiazoles/oxadiazoles
 as oral hypoglycemic agents
 AUTHOR(S): Husain, M. I.; Jamali, Mohd Raghib
 CORPORATE SOURCE: Dep. Chem., Lucknow Univ., Lucknow, 226 007, India
 SOURCE: Indian Journal of Chemistry, Section B: Organic
 Chemistry Including Medicinal Chemistry (1988),
 27B(1), 43-6
 CODEN: IJCSDB; ISSN: 0376-4699
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 109:128914
 GI




AB Thiosemicarbazides I (R1 = Me, OMe, O2N; R2 = H, Me, OMe, Cl Br) were treated with concentrated H2SO4 at room temperature to give thiadiazoles II (Z = S):

II (Z = O) were obtained by treatment of I with HgO in MeOH at reflux. A number of II exhibited hypoglycemic activity.
 IT 116270-54-3P 116270-55-4P 116270-56-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and addition reaction of, with aryl isothiocyanates)
 RN 116270-54-3 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, hydrazide (9CI) (CA INDEX NAME)


L4 ANSWER 57 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 117664-25-2 CAPLUS
 CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(2-methylphenyl)-2-[[[4-oxo-2-(2-phenyl-1H-indol-3-yl)-3-thiazolidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 117664-26-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(2-methylphenyl)-2-[[[2-(4-methylphenyl)-1H-indol-3-yl]-4-oxo-3-thiazolidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 116270-55-4 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, hydrazide (9CI) (CA INDEX NAME)



RN 116270-56-5 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-nitrophenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, hydrazide (9CI) (CA INDEX NAME)



IT 116270-57-6P 116270-58-7P 116270-59-8P
 116270-60-1P 116270-61-2P 116270-62-3P
 116270-63-4P 116270-64-5P 116270-65-6P
 116270-66-7P 116270-67-8P 116270-68-9P
 116285-50-8P 116285-51-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclization reactions of, thiadiazole and oxadiazole derivs. from)
 RN 116270-57-6 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(phenylamino)thioxomethyl]hydrazide (9CI) (CA INDEX NAME)




Habte


08/08/2006

L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 116270-58-7 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-nitrophenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(phenylamino)thioxomethyl]hydrazide (9CI) (CA INDEX NAME)



RN 116270-59-8 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(4-methylphenyl)amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)




RN 116270-60-1 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-nitrophenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(4-methylphenyl)amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)




RN 116270-61-2 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(4-methoxyphenyl)amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 116270-66-7 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-nitrophenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(4-chlorophenyl)amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)



RN 116270-67-8 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(4-bromophenyl)amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)




RN 116270-68-9 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(4-bromophenyl)amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)




RN 116285-50-8 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(phenylamino)thioxomethyl]hydrazide (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 116270-62-3 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(4-methoxyphenyl)amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)



RN 116270-63-4 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-nitrophenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(4-methoxyphenyl)amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)




RN 116270-64-5 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(4-chlorophenyl)amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)




RN 116270-65-6 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(4-chlorophenyl)amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 116285-51-9 CAPLUS
 CN Benzoic acid, 4-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, 2-[(4-methylphenyl)amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)



IT 116270-69-0P 116270-70-3P 116270-71-4P
 116270-72-5P 116270-73-6P 116270-74-7P
 116270-75-8P 116270-76-9P 116270-77-0P
 116270-78-1P 116270-79-2P 116270-80-5P
 116270-81-6P 116270-82-7P 116270-83-8P
 116270-84-9P 116270-85-0P 116270-86-1P
 116270-87-2P 116270-88-3P 116270-89-4P
 116270-90-7P 116270-91-8P 116270-92-9P
 116270-93-0P 116270-94-1P 116270-95-2P


RL: SPN (Synthetic preparation): PREP (Preparation)
 (preparation of, as hypoglycemic)

RN 116270-69-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-methylphenyl)-2-[[[4-[5-(phenylamino)-1,3,4-thiadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 116270-70-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[[[4-[5-(phenylamino)-1,3,4-thiadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 116270-71-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-((4-nitrophenyl)amino)methyl)-1,3,4-thiadiazol-2-yl]phenyl]amino)methyl]- (9CI) (CA INDEX NAME)




RN 116270-72-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-((2-methylphenyl)amino)methyl)-1,3,4-thiadiazol-2-yl]phenyl]amino)methyl]- (9CI) (CA INDEX NAME)




RN 116270-73-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-((4-methoxyphenyl)amino)methyl)-1,3,4-thiadiazol-2-yl]phenyl]amino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 116270-76-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-((4-methoxyphenyl)amino)methyl)-1,3,4-thiadiazol-2-yl]phenyl]amino)methyl]- (9CI) (CA INDEX NAME)




RN 116270-77-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-((4-methoxyphenyl)amino)methyl)-1,3,4-thiadiazol-2-yl]phenyl]amino)methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 116270-78-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[[5-((4-chlorophenyl)amino)-1,3,4-thiadiazol-2-yl]phenyl]amino)methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 116270-74-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[[5-((4-methylphenyl)amino)-1,3,4-thiadiazol-2-yl]phenyl]amino)methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 116270-75-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[[5-((4-methoxyphenyl)amino)-1,3,4-thiadiazol-2-yl]phenyl]amino)methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 116270-79-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[[5-((4-chlorophenyl)amino)-1,3,4-thiadiazol-2-yl]phenyl]amino)methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 116270-80-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[[5-((4-chlorophenyl)amino)-1,3,4-thiadiazol-2-yl]phenyl]amino)methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 116270-81-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[[5-((4-bromophenyl)amino)-1,3,4-thiadiazol-2-yl]phenyl]amino)methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 116270-82-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[5-[(4-bromophenyl)amino]-1,3,4-thiadiazol-2-yl]phenyl]amino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 116270-83-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-methylphenyl)-2-[[[4-[5-(phenylamino)-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 116270-84-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[[[4-[5-(phenylamino)-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 116270-88-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[5-[(4-methylphenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 116270-89-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[5-[(4-methoxyphenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 116270-90-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[[[4-[5-[(4-methoxyphenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Habe


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 116270-85-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-nitrophenyl)-2-[[[4-[5-(phenylamino)-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 116270-86-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-methylphenyl)-2-[[[4-[5-(phenylamino)-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 116270-87-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[[[4-[5-(4-methylphenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 116270-91-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[5-[(4-chlorophenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 116270-92-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[5-[(4-methoxyphenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 116270-93-0 CAPLUS

08/08/2006

L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 2-[[[4-[5-[(4-chlorophenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 116270-94-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[4-[5-[(4-bromophenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 116270-95-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[4-[5-[(4-bromophenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 116285-52-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[4-[5-[(4-methoxyphenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 59 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1987:575980 CAPLUS
 DOCUMENT NUMBER: 107:175980
 TITLE: Synthesis of some quinazolones
 AUTHOR(S): Srivastava, Vijal K.; Singh, I. P.; Singh, Shradha; Gupta, M. B.; Shanker, K.
 CORPORATE SOURCE: Dep. Pharmacol. Ther., King George's Med. Coll., Lucknow, 226 003, India
 SOURCE: Indian Journal of Pharmaceutical Sciences (1986), 48(5), 133-6
 CODEN: IJSDIW; ISSN: 0250-474X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 107:175980
 GI




AB 4(3H)-Quinazolones I (n = 1, 2; R1 = R2 = disubstituted amino, or R1 = Br and R2 = alkoxy; R3 = OMe, NMe2; R4 = Br, iodo; R5 = H, Br) were prepared, and they showed antiparkinsonian and antitachycardic activity. Methylquinazolones underwent a condensation reaction with the resp. 4-R3C6H4CHO, and the products were converted to I.
 IT 110818-25-2P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and antiparkinsonian activity of)
 RN 110818-25-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[1,2-bis(diphenylamino)-2-(4-methoxyphenyl)ethyl]-6,8-dibromo-3-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 60 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1987:207516 CAPLUS
 DOCUMENT NUMBER: 106:207516
 TITLE: Synthesis and anticonvulsant activity of some new 4(3H)-quinazolone derivatives
 AUTHOR(S): El-Nasser Osman, Abdel Rahman; El-Sayed Barakat, Saber
 CORPORATE SOURCE: Fac. Pharm., Al-Azhar Univ., Cairo, Egypt
 SOURCE: Archiv for Pharmacology and Chem., Scientific Edition (1986), 14(2), 37-43
 CODEN: AVPCCS; ISSN: 0302-248X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Some new 2,3-disubstituted-4(3H)-quinazolones (I, X and Y = H or Br, and R = H, Br, Cl or NO2) as potential anticonvulsants were prepared by the N-bromosuccinimide bromination of 2-methyl-3-phenyl-4(3H)-quinazolones followed by the reaction of the resulting bromomethyl derivs. (II) with sulfanilamide [63-74-1].
 IT 108282-55-9P 108282-56-0P 108282-57-1P
 108282-58-2P 108282-59-3P 108282-60-6P
 108282-61-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and anticonvulsant activity of)
 RN 108282-55-9 CAPLUS
 CN Benzenesulfonamide, 4-[[[3-(4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 108282-56-0 CAPLUS
 CN Benzenesulfonamide, 4-[[[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)methyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 60 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 108282-57-1 CAPLUS
 CN Benzenesulfonamide, 4-[[[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 108282-58-2 CAPLUS
 CN Benzenesulfonamide, 4-[[[3,4-dihydro-3-(4-nitrophenyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 108282-59-3 CAPLUS
 CN Benzenesulfonamide, 4-[[[6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 108282-60-6 CAPLUS
 CN Benzenesulfonamide, 4-[[[6-bromo-3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1986:472082 CAPLUS
 DOCUMENT NUMBER: 105:72082
 TITLE: Thiadiazolyl quinazolones as potential CNS active agents
 AUTHOR(S): Pandey, V. K.; Lohani, H. C.; Agarwal, Akhilesh K.
 CORPORATE SOURCE: Dep. Chem., Lucknow Univ., Lucknow, 226007, India
 SOURCE: Biological Memoirs (1985), 11(2), 197-200
 CODEN: BMEMDK; ISSN: 0379-8097
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Ten thiadiazolyl quinazolones (I; R = Ph, PhCH=CH etc.; R1 = (Me)2N, (Et)2N, morpholino, etc.) were evaluated for their central nervous system activities in mice. Some compds. had central stimulant activity. Compds. containing styryl groups at position 2 of the quinazolone nucleus showed central depressant activities. The compds. were nontoxic and their approx. LD50 values ranged from 316 mg/kg to <1000 mg/kg, i.p.
 IT 74796-95-5 103537-64-0
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (central nervous system response to)
 RN 74796-95-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-methylphenyl)amino]methyl]-3-[5-[[[(2-methylphenyl)amino]methyl]-1,3,4-thiadiazol-2-yl]]- (9CI) (CA INDEX NAME)




RN 103537-64-0 CAPLUS

Habte

L4 ANSWER 60 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 108282-61-7 CAPLUS
 CN Benzenesulfonamide, 4-[[[6-bromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 61 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN 4(3H)-Quinazolinone, 2-[[[(2-methoxyphenyl)amino]methyl]-3-[5-[[[(2-methoxyphenyl)amino]methyl]-1,3,4-thiadiazol-2-yl]]- (9CI) (CA INDEX NAME)




08/08/2006

L4 ANSWER 62 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1983:405584 CAPLUS
 DOCUMENT NUMBER: 99:5584
 TITLE: Synthesis and biological activities of certain derivatives of 3-aryl-4(3H)-quinazolinones. Part I
 AUTHOR(S): Shankar, C. Ravi; Rao, A. Devendar; Reddy, B. Jayasena; Reddy, V. Malla
 CORPORATE SOURCE: Univ. Coll. Pharm. Sci., Kakatiya Univ., Warangal, 506 009, India
 SOURCE: Journal of the Indian Chemical Society (1983), 60(1), 61-3
 CODEN: JICSAH; ISSN: 0019-4522
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 99:5584
 GI




AB Nine different 3-aryl-2-(N',N'-substituted aminomethyl)-4(3H)-quinazolinones have been synthesized by condensing 3-aryl-2-chloromethyl-4(3H)-quinazolinones with different secondary bases. Similarly, seven different 3-aryl-2-(N4-arylsulfonamidomethyl)-4(3H)-quinazolinones, e.g. I, have been obtained on reacting 3-aryl-2-chloromethyl-4(3H)-quinazolinones with various aryl sulfonamides. The antibacterial and antifungal activities of the compds. have been determined and the structure-activity relationships is discussed.
 IT 86109-99-1P 86110-00-1P 86110-01-2P
 86110-02-3P 86110-03-4P 86110-04-5P
 86110-05-6P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation, bactericidal, and fungicidal activity of)
 RN 86109-99-1 CAPLUS
 CN Benzenesulfonamide, 4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 86110-00-1 CAPLUS
 CN Benzenesulfonamide, 4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-


L4 ANSWER 62 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzenesulfonamide, 4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-N-(2,6-dimethyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 86110-05-6 CAPLUS
 CN Benzenesulfonamide, N-(aminoiminomethyl)-4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 62 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 quinazolinyl]methyl]amino]-N-(2,6-dimethoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 86110-01-2 CAPLUS
 CN Benzenesulfonamide, 4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-N-(5-methyl-1,3,4-thiadiazol-2-yl)- (9CI) (CA INDEX NAME)



RN 86110-02-3 CAPLUS
 CN Benzenesulfonamide, 4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 86110-03-4 CAPLUS
 CN Acetamide, N-[[4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 86110-04-5 CAPLUS

L4 ANSWER 63 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1982:533440 CAPLUS
 DOCUMENT NUMBER: 97:133440
 TITLE: Physicochemical properties and stabilities of afloqualone (HQ-495)
 AUTHOR(S): Shimizu, Reiji; Nakamura, Kouji; Yaku, Kouji; Shimaoka, Yukio; Matsuo, Masaaki
 CORPORATE SOURCE: Anal. Chem. Res. Lab., Tanabe Seiyaku Co., Ltd., Osaka, 532, Japan
 SOURCE: Iyakuhin Kenkyu (1982), 13(3), 688-701
 CODEN: IYKEDH; ISSN: 0287-0894
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese
 GI




AB The solubility, stability, partition coefficient, powder x-ray diffraction pattern, UV, IR, NMR and mass spectra, etc. of HQ-495 (I) [56287-74-2] were determined
 I in solid state was stable to heat and moisture in the shade, but unstable to light. Decomposition of I by light was examined, the decomposition could be avoided by keeping the material in an amber container. In aqueous solution, I was unstable to light and heat. Impurities derived from synthetic process and decomposed products were determined by high-performance liquid chromatog. and TLC. Formation pathways of the decomposition products were proposed from the chromatog. results.
 IT 83038-91-9
 RL: ANT (Analyte); ANST (Analytical study) (chromatog. of, afloqualone stability in relation to)
 RN 83038-91-9 CAPLUS
 CN Benzamide, 5-[[[6-amino-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-2-[(fluoroacetyl)amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 64 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1980:514437 CAPLUS
 DOCUMENT NUMBER: 93:114437
 TITLE: Synthesis of possible antiparkinsonian compounds: Part I. Synthesis of 2-aryl/alkyl-3-(2-aminomethyl-1,3,4-thiadiazol-5-yl)quinazolin-4(3H)-ones
 AUTHOR(S): Pandey, V. K.; Lohani, H. C.
 CORPORATE SOURCE: Dep. Chem., Lucknow Univ., Lucknow, India
 SOURCE: Journal of the Indian Chemical Society (1979), 56(9), 915-16
 CODEN: JICSAH; ISSN: 0019-4522
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 93:114437
 GI




AB The thiadiazolylquinazolinone I (R = Ph, PhCH₂CH₂, o-MeC₆H₄NHCH₂, p-MeOC₆H₄NHCH₂; R₁ = R₂ = Et, Ph; R₁ = o-MeC₆H₄, p-MeOC₆H₄, R₂ = H, R₁R₂N = morpholino, piperazino) were prepared by reaction of the benzoxazines II (R₃ = Me, Ph, PhCH₂CH₂) with 2-amino-5-methyl-1,3,4-thiadiazole followed by bromination and reaction with amines.
 IT 74796-95-5P 74796-96-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 74796-95-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-methylphenyl)amino]methyl]-3-[5-[[[(2-methylphenyl)amino]methyl]-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 64 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 74796-96-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(4-methoxyphenyl)amino]methyl]-3-[5-[[[(4-methoxyphenyl)amino]methyl]-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 65 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 1980:446577 CAPLUS
 DOCUMENT NUMBER: 93:46577
 TITLE: Synthesis of some quinazolinone derivatives structurally related to certain sedatives, hypnotics and anticonvulsant agents
 AUTHOR(S): El-Ansary, A. K.; Botros, S.; Khalifa, M.
 CORPORATE SOURCE: Fac. Pharm., Univ. Cairo, Cairo, Egypt
 SOURCE: Pharmazie (1979), 34(11), 753-4
 CODEN: PHARAT; ISSN: 0031-7144
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Quinazolinones I (R = Br, Me, OEt; R₁ = 4-OMe, 3,4-(OMe)₂, 4-NMe₂, 4-OH, 2-OH, H) were obtained in 50-69% yield by treating 2-methyl-3-arylquinazolinones with benzaldehydes. II (R₂ = NHPH, NHC₆H₄Me-4, NHC₆H₄Me-2, NHC₆H₄Br-4, NHC₆H₄Cl-4, succinimido, phthalimido, saccharino) were obtained in 65-80% yield by aminating II (R₂ = Br).
 IT 72235-16-6P 72235-19-9P 74116-00-0P
 74116-01-1P 74116-02-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 72235-16-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)




RN 72235-19-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-methylphenyl)amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 65 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 74116-00-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(4-methylphenyl)amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 74116-01-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(4-bromophenyl)amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 74116-02-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(4-chlorophenyl)amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 66 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 72235-18-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(4-ethoxyphenyl)amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 72235-19-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-methylphenyl)amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 72235-20-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(cyclohexylamino)methyl]-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 66 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1980:22449 CAPLUS
 DOCUMENT NUMBER: 92:22449
 TITLE: Some reactions of nitrogen nucleophiles with 2-(bromomethyl)-3-phenyl-4(3H)-quinazolinone
 AUTHOR(S): Kirmani, M. Z.; Ahmed, Mrs. S. R.
 CORPORATE SOURCE: Dep. Chem., Indian Inst. Technol., New Delhi, 110029, India
 SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1979), 18B(1), 22-4
 CODEN: IJSCDB; ISSN: 0376-4699
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 92:22449
 GI




AB Treating quinazolinone I (R = CH2Br), which does not undergo ring expansion, with pyridine, quinoline, or Et3N gave the corresponding quaternary bromides, whereas using primary and secondary amines gave I [R = CH2R1 (R1 = NHPh, NHC6H4OMe-4, cyclohexylamino, piperidino, morpholino, NHC6H4OEt-4, NHC6H4Me-2)]. Also prepared were I (R = CH:NOH, CH:NNHPh).
 IT 72235-16-6P 72235-17-7P 72235-18-8P
 72235-19-9P 72235-20-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 72235-16-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)




RN 72235-17-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(4-methoxyphenyl)amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 67 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1976:523860 CAPLUS
 DOCUMENT NUMBER: 85:123860
 TITLE: Studies of 4-quinazolones. VII. Synthesis and properties of 2-[β-(arylamido)propionyl]-3-phenyl-4-quinazolones
 AUTHOR(S): Kozhevnikov, Yu. V.
 CORPORATE SOURCE: USSR
 SOURCE: Nauch. Tr. Perm. Farmats. In-t (1975), (8), 37-40
 From: Ref. Zh., Khim. 1976, Abstr. No. 11zh313
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 85:123860
 AB Title only translated.
 IT 55557-79-4P 55557-80-7P 55557-81-8P
 55557-82-9P 55557-84-1P 55557-85-2P
 55557-86-3P 55557-87-4P 55557-88-5P
 55557-90-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 55557-79-4 CAPLUS
 CN 2-Quinazolinopropanamide, 3,4-dihydro-4-oxo-N,3-diphenyl- (9CI) (CA INDEX NAME)




RN 55557-80-7 CAPLUS
 CN 2-Quinazolinopropanamide, 3,4-dihydro-N-(2-methylphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-81-8 CAPLUS
 CN 2-Quinazolinopropanamide, 3,4-dihydro-N-(3-methylphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 67 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 55557-82-9 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(4-methylphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)



RN 55557-84-1 CAPLUS
CN 2-Quinazolinepropanamide, N-(2-chlorophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-85-2 CAPLUS
CN 2-Quinazolinepropanamide, N-(4-chlorophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-86-3 CAPLUS
CN 2-Quinazolinepropanamide, N-(2-bromophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 68 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:140064 CAPLUS
DOCUMENT NUMBER: 82:140064
TITLE: 4(3H)-quinazolinone. 7. Synthesis and properties of 3-phenyl-4(3H)-quinazolinone-2-arylamides of β -propionic acid
AUTHOR(S): Kozhevnikov, Yu. V.
CORPORATE SOURCE: Perm. Farm. Inst., Perm, USSR
SOURCE: Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i Khimicheskaya Tekhnologiya (1974), 17(12), 1877-8
CODEN: IVUKAR; ISSN: 0579-2991
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB The quinazolinepropanamides I (R = Ph, MeCGH₄, PhCH₂, ClCGH₄, BrCGH₄, MeOCGH₄, Et₂NCH₂CH₂, cyclohexyl) were prepared by reaction of RN(MgX)₂ (X = halo) with the quinazolinepropanate II and subsequent hydrolysis.
IT 55557-79-4P 55557-80-7P 55557-81-8P
55557-82-9P 55557-84-1P 55557-85-2P
55557-86-3P 55557-87-4P 55557-88-5P
55557-90-9P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
RN 55557-79-4 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-4-oxo-N,3-diphenyl- (9CI) (CA INDEX NAME)




RN 55557-80-7 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(2-methylphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-81-8 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(3-methylphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 67 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 55557-87-4 CAPLUS
CN 2-Quinazolinepropanamide, N-(4-bromophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-88-5 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(4-methoxyphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-90-9 CAPLUS
CN 2-Quinazolinepropanamide, N-cyclohexyl-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 68 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 55557-82-9 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(4-methylphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)



RN 55557-84-1 CAPLUS
CN 2-Quinazolinepropanamide, N-(2-chlorophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-85-2 CAPLUS
CN 2-Quinazolinepropanamide, N-(4-chlorophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-86-3 CAPLUS
CN 2-Quinazolinepropanamide, N-(2-bromophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 68 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 55557-87-4 CAPLUS
CN 2-Quinazolinepropanamide, N-(4-bromophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-88-5 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(4-methoxyphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-90-9 CAPLUS
CN 2-Quinazolinepropanamide, N-cyclohexyl-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 70 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1971:76386 CAPLUS
DOCUMENT NUMBER: 74:76386
TITLE: Heterocyclic chemistry. LI. Reaction of ethoxalylanthranil with amines
AUTHOR(S): Petyunin, P. A.; Chernykh, V. P.; Petyunin, G. P.; Kozhevnikov, Yu. V.
CORPORATE SOURCE: Khar'k. Farm. Inst., Kharkov, USSR
SOURCE: Khimiya Geterotsiklicheskih Soedinenii (1970), (11), 1575-8
CODEN: KGS5AQ; ISSN: 0132-6244
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB The title compound (I, Z = O) reacted with 28 aromatic amines (RNH2) in DMF, yielding the corresponding I (Z = NR). The latter underwent amidation with NH3, WZH4, and R1C6H4NH2 (R1 = H, 3-, 4-Br, 3-Me, 4-MeO), and saponification in the usual manner.
IT 30689-31-7P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
RN 30689-31-7 CAPLUS
CN 2-Quinazolinecarboxamide, 3,4-dihydro-4-oxo-N,3-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 69 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:515526 CAPLUS
DOCUMENT NUMBER: 79:115526
TITLE: Vilsmeier-Haack reaction. V. Reaction of 2-methyl-4-quinazolinone derivatives and a new synthesis of pyrazolo[5,1-b]quinazolones
AUTHOR(S): Pandit, R. S.; Seshadri, S.
CORPORATE SOURCE: Dep. Chem. Technol., Univ. Bombay, Bombay, India
SOURCE: Indian Journal of Chemistry (1973), 11(6), 532-7
CODEN: IJOCAP; ISSN: 0019-5103
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB 2-Methyl-3-phenyl-4-quinazolinone underwent diformylation by the Vilsmeier reagent to give the dialdehyde I. I with HONH2, H2NNH2, PhNHNH2 gave the related 3-phenyl-4-quinazolinone derivs. with different heterocyclic systems in the 2-position. On treatment with polyphosphoric acid, I cyclized to give 12-oxoquino[2,1-b]quinazoline-6-carboxaldehyde (III). Vilsmeier-Haack reaction of 2-methyl-3-amino-4-quinazolinone gave 3-formylpyrazolo[5,1-b]quinazolinone (III). Various derivs. of III were prepared to investigate the fluorescence properties. Vilsmeier-Haack reaction on 2-methyl-3-acylamido-4-quinazolinone also gave III with the loss of acyl residues. 2-Methyl-3-anilino-4-quinazolinone reacts with the Vilsmeier reagent to give 1-phenylpyrazolo[5,1-b]quinazolinone.
IT 49552-40-1P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
RN 49552-40-1 CAPLUS
CN 2-Quinazolineacetaldehyde, 3,4-dihydro-4-oxo-3-phenyl-2-[(phenylamino)methylene]- (9CI) (CA INDEX NAME)



L4 ANSWER 71 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1968:427405 CAPLUS
DOCUMENT NUMBER: 69:27405
TITLE: Drugs acting on the central nervous system. Syntheses of substituted quinazolinones and quinazolines and triazepino- and triazocinoquinazolinones
AUTHOR(S): Gupta, C. M.; Bhaduri, A. P.; Khanna, N. M.
CORPORATE SOURCE: Div. Med. Chem., Cent. Drug Res. Inst., Lucknow, India
SOURCE: Journal of Medicinal Chemistry (1968), 11(2), 392-5
CODEN: JMCHAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB 2,3-Disubstituted 4-quinazolinones, 2,4-disubstituted quinazolines, and 5H-2,3-disubstituted triazepino[1,4,5] [2,1-b]quinazolin-11-ones (I) (R = 2-furyl, Ph, Me, and p-MeOC6H4) are prepared and tested for toxicity and anticonvulsant activity in mice. Of the 48 compds. prepared and tested, only 2-ethylthio-4-quinazolinone and 2,4-bis(dibenzylamino)quinazolinone gave protection against maximum electroshock, 3 other compds. showed slight activity, and the remainder were inactive.
IT 19062-62-5P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
RN 19062-62-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(6-methyl-2-pyridyl)amino]methyl-3-phenyl- (8CI) (CA INDEX NAME)



L4 ANSWER 72 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1939:4026 CAPLUS

DOCUMENT NUMBER: 33:4026

ORIGINAL REFERENCE NO.: 33:624b-d

TITLE: Attempts to synthesize methylenediquinazoline

derivatives

AUTHOR(S): Kassut, A.; Weil, S.

SOURCE: Roczniki Chemii (1938), 18, 163-9 (in French 168-9)

CODEN: ROCHAC; ISSN: 0035-7677

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB The authors tried to obtain a few derivs. of methylenediketoquinazoline by fusing anthranilic acid with aromatic amides of malonic acid, but they did not succeed. By fusion of the diamide or monophenyldiamide of malonic acid with anthranilic acid, $\text{CH}_2(\text{CONHPh})_2$ was obtained. From $p\text{-MeOC}_6\text{H}_4\text{NHCOCH}_2\text{CO}_2\text{Et}$ and anthranilic acid, $\text{CH}_2(\text{CONHC}_6\text{H}_4\text{OMe})_2$ is formed. Condensation of $o\text{-MeC}_6\text{H}_4\text{NHCOCH}_2\text{CO}_2\text{Et}$ with anthranilic acid gives the derivative of monoketoquinazoline. Condensations of antifebrin and

phenacetin with anthranilic acid by the aid of POCl_3 give the derivs. of monoketoquinazoline. By condensation of BzH with $\text{CH}_2(\text{CONHPh})_2$ the product containing 2 mols. of BzH and one of dianilide was obtained. $o\text{-HOC}_6\text{H}_4\text{CHO}$ condensed with $p\text{-MeOC}_6\text{H}_4\text{NHCOCH}_2\text{CO}_2\text{Et}$ and with $p\text{-MeC}_6\text{H}_4\text{NHCOCH}_2\text{CO}_2\text{Et}$ yields derivs. of coumarin.

IT 858277-01-7, 2-Quinazolineaceto-o-toluide, 3-(o-carboxyphenyl)-3,4-dihydro-4-oxo-

(preparation of)

RN 858277-01-7 CAPLUS

CN 2-Quinazolineaceto-o-toluide, 3-(o-carboxyphenyl)-3,4-dihydro-4-oxo- (4CI)
(CA INDEX NAME)

